# Famicord Group > A WordPress-powered website. Language: en URL: https://www.famicord.com/ All pages on this site are available as clean Markdown by adding the header `Accept: text/markdown` to any HTTP request. REST API: https://www.famicord.com/wp-json/mescio-for-agents/v1/markdown?url={page_url} ## Pages - [Landing page](https://www.famicord.com/landing-page): Join our educational program dedicated to midwives and discover the latest knowledge on cord blood and its role in modern medicine. By registering, you will gain access to exclusive resources, training opportunities, and a supportive community. Together, we can shape - [Eliane Gluckman Award Dinner – LP](https://www.famicord.com/eliane-gluckman-award-dinner): We’re full! Thank you so much for the huge interest in the Eliane Gluckman Award Dinner. We’re sorry to say that we’ve already reached our maximum capacity and registration is now closed We hope to see you at one of - [Eliane Gluckman Award Dinner – thank you page](https://www.famicord.com/eliane-gluckman-award-dinner-typ): Thank You for Registering Thank you for confirming your attendance at the Eliane Gluckman Award Dinner. A confirmation email has been sent to your email address, including a map with details of the meeting point from which you will be - [Expanded Access Programme](https://www.famicord.com/services-for-families/expanded-access-programme-famicord) - [Blog](https://www.famicord.com/blog) - [Stem Cell Applications Stories](https://www.famicord.com/services-for-families/stem-cell-applications-stories) - [Expanded Access Programme](https://www.famicord.com/services-for-families/expanded-access-programme) - [Stem Cells Banking](https://www.famicord.com/services-for-families/stem-cells-banking) - [CSR](https://www.famicord.com/services-for-families/csr) - [Services for business partner](https://www.famicord.com/services-for-business-partner) - [Our Services](https://www.famicord.com/services-for-business-partner/our-services) - [Our Quality](https://www.famicord.com/services-for-business-partner/our-quality) - [Our People](https://www.famicord.com/services-for-business-partner/our-people) - [Stem Cell Applications List](https://www.famicord.com/services-for-families/stem-cell-applications-list) - [FamiCord Contribution](https://www.famicord.com/services-for-families/famicord-contribution) - [Scientific Proof](https://www.famicord.com/services-for-families/scientific-proof) - [Przykładowa strona](https://www.famicord.com/przykladowa-strona): Przykładowa strona. Strony są inne niż wpisy na blogu, ponieważ nie tylko znajdują się zawsze w jednym miejscu, ale także pojawiają się w menu witryny (w większości motywów). Większość użytkowników zaczyna od strony z informacjami o sobie, która zapozna ich - [Homepage](https://www.famicord.com/) - [About us](https://www.famicord.com/about-us) - [FamiCord Story](https://www.famicord.com/about-us/famicord-story) - [FamiCord Group](https://www.famicord.com/about-us/famicord-group): CountryBrandWebsiteAustriaVita 34vita34.atCzech RepublicNárodní centrum pupečníkové krvepupecnikovakrev.czDenmarkVita 34vita34.dkGermanyVita 34vita34.deGermanyeticureticur.deHong-KongSmart Cellssmartcells.comHungaryKRIO Intezetkrio.huItalySorgentesorgente.comLatviaCilmes Šūnu Bankacilmessunubanka.lvLuxemburgFamiCord Suissefamicord.luPolandDiagnostica Bank Komórek Macierzystychdbkm.plPolandPolski Bank Komórek Macierzystychpbkm.plPortugalCrioestaminalcrioestaminal.ptPortugalBebéCordbebecord.ptRomaniaBiogenisbiogenis.roSlovakiaRodinná banka Slovakiacakam-babatko.skSpainVita 34secuvita.esSpainIvidabancodecordonivida.comSpainSevibesevibe.esSwitzerlandVita 34vita34.chSwitzerlandFamiCord Suissefamicord.chTurkeyFamicord-Acibadem Kordon Kanı Sağlık Hizmetlerifamicordturkiye.comTurkeyYaşam Bankası Sağlık Hizmetleri İç ve Dış Tıcaretkordonkanibankasi.comUnited Arab EmiratesSmart Cellssmartcells.aeUnited KingdomSmart Cellssmartcells.com - [Services for families](https://www.famicord.com/services-for-families) - [Stem Cells](https://www.famicord.com/services-for-families/stem-cells): Type of stem cellsCharacteristicsExamplesTotipotent cellsEach cell can develop into a new individualCells of embryo of 1-3 daysPluripotent cellsEach cell can form any cell type (over 200)Cells of blastocyst 5-14 days Multipotent cellsCell differentiate and can form a number of tissue - [Scientific Publications](https://www.famicord.com/services-for-business-partner/scientific-publications) - [Our Facilities](https://www.famicord.com/services-for-business-partner/our-facilities) - [Sustainability (ESG)](https://www.famicord.com/company/sustainability-esg) - [News](https://www.famicord.com/news) - [Contact](https://www.famicord.com/contact) - [Stellenangebote](https://www.famicord.com/career/career-with-famicord-germany/job-postings) - [Other Options for Cord Blood Banking](https://www.famicord.com/services-for-families/other-options-for-cord-blood-banking) - [Imprint](https://www.famicord.com/imprint) - [Data Privacy](https://www.famicord.com/data-privacy-statement) - [Whistleblowing](https://www.famicord.com/whistleblowing) - [Supervisory Board](https://www.famicord.com/company/supervisory-board-2) - [Supervisory Board](https://www.famicord.com/company/supervisory-board) - [Management Board](https://www.famicord.com/company/management-board) - [Certificates and Accreditations](https://www.famicord.com/services-for-business-partner/certificates-and-accreditations) - [Our Experience](https://www.famicord.com/services-for-business-partner/our-experience) - [Career](https://www.famicord.com/career) - [FamiCord Employees](https://www.famicord.com/career/famicord-employees) - [Career within the FamiCord Group](https://www.famicord.com/career/career-within-the-famicord-group) - [Career with FamiCord Germany](https://www.famicord.com/career/career-with-famicord-germany) - [Company](https://www.famicord.com/company) - [Financial Data](https://www.famicord.com/company/financial-data) ## Blog Posts - [FamiCord Advances Scientific Dialogue on Cell Therapies at EACD 2026](https://www.famicord.com/famicord-advances-scientific-dialogue-on-cell-therapies-at-eacd-2026) (2026-06-30): FamiCord Group participated in the 38th Annual Meeting of the European Academy of Childhood-onset Disability (EACD), held on 3–6 June 2026 in Galway, Ireland, reaffirming its commitment to advancing evidence-based regenerative medicine and supporting scientific collaboration in the field of - [Cell Therapies – From Experiment to Standard of Care](https://www.famicord.com/cell-therapies-from-experiment-to-standard-of-care) (2026-05-06): On May 1, we marked World Fanconi Anemia Day, and tomorrow the 3rd Fanconi Anemia Europe Scientific Meeting will take place in Gdańsk. Fanconi anemia is a rare genetic disorder in which impaired DNA repair leads to bone marrow failure. - [Autism Awareness Day: First FamiCord EAP Therapies Launched for ASD Patients](https://www.famicord.com/autism-awareness-day-first-famicord-eap-therapies-launched-for-asd-patients) (2026-04-02): On the occasion of World Autism Awareness Day, FamiCord Group marks an important milestone in expanding access to innovative therapies. Today, the first clients of Crioestaminal – part of the FamiCord Group – had the opportunity to participate in stem - [FamiCord Group Recognized as Europe’s Leading Stem Cell Bank](https://www.famicord.com/famicord-group-recognized-as-europes-leading-stem-cell-bank) (2025-11-17): FamiCord is the largest stem cell bank in Europe and the third largest in the world. The quality of its services is validated by international certifications, and the company has now been recognized as Europe’s Leading Stem Cell Bank by Life Sciences Review, highlighting its commitment to excellence, clinical reliability, and innovation in stem cell banking.FamiCord Group have been awarded as “The Europe’s Leading Stem Cell Bank” , independent experts jury underlined FamiCord has established itself as a leading provider in the field, guiding families through the collection, processing, and long-term preservation of cord blood and perinatal tissues. - [Infantile cerebral palsy – Convincing evidence for the use of perinatal stem cells](https://www.famicord.com/infantile-cerebral-palsy-convincing-evidence-for-the-use-of-perinatal-stem-cells) (2025-08-27): Leipzig, July 15, 2025 - Cerebral palsy (CP) continues to be one of the most common motor disabilities in childhood and is associated with permanent movement restrictions and spasticity. The therapeutic potential of stem cells from umbilical cord blood and tissue was discussed at the 37th Annual Meeting of the European Academy Of Childhood-onset Disabilities (EACD) and the 4th Meeting of the International Alliance of Academies of C hildhood Disability (IAACD) from June 24 - 28, 2025 in Heidelberg. As part of a symposium supported by FamiCord AG, international experts presented the current state of research and reported on the results from clinical practice. - [FamiCord Group’s Dubai Laboratory Earns Prestigious AABB Accreditation](https://www.famicord.com/famicord-groups-dubai-laboratory-earns-prestigious-aabb-accreditation) (2025-06-03): Dubai, UAE – – FamiCord Group, the largest cord blood bank in Europe, proudly announces that its state-of-the-art laboratory in Dubai has received the prestigious accreditation from the Association for the Advancement of Blood & Biotherapies (AABB) – a globally recognized standard of excellence in the field of cellular and blood banking services. - [Dr Tomasz Baran – FamiCord Vicepresident – speaks on cord blood banking at world’s largest cord blood conference](https://www.famicord.com/dr-tomasz-baran-famicord-vicepresident-speaks-on-cord-blood-banking-at-worlds-largest-cord-blood-conference) (2024-09-06): Tomasz Baran, MD, MBA, Vice President of FamiCord Group, recently shared his expertise on cord blood banking at the world’s largest cord blood conference... - [Expanison of cord blood stem cells as a chance for cancer patients](https://www.famicord.com/expanison-of-cord-blood-stem-cells-as-a-chance-for-cancer-patients) (2024-07-15): Cord blood stem cells are used in medicine for treatment of over 80 different  diseases such as leukemias, lymphomas and sickle cell anaemia for over 30 years. It has also been proven that... - [New service available – Placenta banking](https://www.famicord.com/new-service-available-placenta-banking) (2024-04-01): FamiCord Group is excited to announce the international roll-out of this innovative service to new markets. In 2024, placenta banking... - [Autologus cord blood in autism treatment – new clinical trial in Romania](https://www.famicord.com/autologus-cord-blood-in-autism-treatment-new-clinical-trial-in-romania) (2024-03-27): Researchers at Bioforum Foundation have been studying whether intravenous infusions of cord blood stem cells can help young children with autism spectrum disorder (ASD). - [FamiCord and Vita 34 Vice president speaks on cord blood banking at Advanced Therapies conference in London](https://www.famicord.com/famicord-and-vita-34-vice-president-speaks-on-cord-blood-banking-at-advanced-therapies-conference-in-london) (2024-03-20): Tomasz Baran, MD, MBA, Vice President of FamiCord Group and Vita 34, shared his expertise on the evolving field of cord blood... - [FamiCord Group Central Laboratory with prestigous AABB accrediation](https://www.famicord.com/famicord-group-central-laboratory-with-prestigous-aabb-accrediation) (2024-03-05): The Central Laboratory of the FamiCord Group has achieved prestigious AABB accreditation for Cellular Starting Material (CSM), underscoring FamiCord's commitment to upholding the highest standards of quality and safety, as well as continuous improvement of procedures related to the preparation of co... - [Smart Cells International [Famicord Group] chooses Dubai as GCC hub for stem cell banking, expanding global presence](https://www.famicord.com/smart-cells-international-famicord-group-chooses-dubai-as-gcc-hub-for-stem-cell-banking-expanding-global-presence) (2024-02-14): Dubai, Feb. 8, 2024— Smart Cells International (SCI), aleading member of FamiCord Group, proudly declares Dubai as its GCC hub for stem cell banking, solidifying its commitment to advancing healthcare solutions in the Middle East. SCI's decision to establish its state-of-the-art laboratory in Dubai... - [Yesterday, today and tomorrow: Umbilical cord blood can save lives World Cord Blood Day 2023](https://www.famicord.com/yesterday-today-and-tomorrow-umbilical-cord-blood-can-save-lives-world-cord-blood-day-2023) (2023-11-14): 15th November 2023, Berlin, Germany: As every year in mid-November global science community celebrates World Cord Blood Day. During that day many events, conferences and workshops take place around the world. - [FamiCordTx launches first in human application of CAR-T drug candidates](https://www.famicord.com/famicordtx-launches-first-in-human-application-of-car-t-drug-candidates) (2023-07-17): FamiCord Group, a leading cell bank in Europe and one of the largest globally, has begun enrollment in Phase I of... - [Groundbreaking: NO MORE LIMITATIONS FOR CORD BLOOD USE](https://www.famicord.com/groundbreaking-no-more-limitations-for-cord-blood-use) (2023-04-21): On 17 April 2023, the FDA gave approval to the Gamida Cell product “Omisirge” (known also as omidubicel or NiCord)... - [FamiCord enters United Kingdom and expands outside Europe](https://www.famicord.com/famicord-enters-united-kingdom-and-expands-outside-europe) (2021-09-02): Polski Bank Komórek Macierzystych S.A. (PBKM), which leads the international FamiCord Group, Europe's largest stem cell bank, signed a transaction agreement with... - [Completion of the 1st phase inventory check of biological material samples stored originally by former service provider](https://www.famicord.com/completion-of-the-1st-phase-inventory-check-of-biological-material-samples-stored-originally-by-former-service-provider) (2020-09-08): This information is addressed to the customers of former service provider in connection with which we have been authorized as a contact point for the customers of former service provider... - [The FamiCord Group strengthens its position in Turkey](https://www.famicord.com/the-famicord-group-strengthens-its-position-in-turkey) (2020-03-19): The FamiCord Group strengthens its position in Turkey by investing in a stem cell bank belonging to the Acıbadem Healthcare Group... - [Letter of intent between Medical University of Warsaw (WUM) and FamiCordTx signed](https://www.famicord.com/letter-of-intent-between-medical-university-of-warsaw-wum-and-famicordtx-signed) (2020-02-06): Rector of the Medical University of Warsaw prof. Mirosław Wielgoś and representatives of the FamiCordTx company: Dr Tomasz Baran - President of the Management Board and Dr Tomasz Ołdak - Member of the Management Board - signed aletter of intent regarding cooperation in the field of development and i... - [FamiCord is number 1 in Europe and number 5 in the World](https://www.famicord.com/famicord-is-number-1-in-europe-and-number-5-in-the-world) (2018-10-07): According to recent publication by Parents Guide Cord Blood Foundation - FamiCord Group, founded by Polski Bank Komórek Macierzystych (PBKM), proudly stands as... - [Acquisition of BioCell Lugano, Switzerland](https://www.famicord.com/acquisition-of-biocell-lugano-switzerland) (2018-05-16): FamiCord Group acquired BioCell Lugano, which includes a modern laboratory in Switzerland. This is another important step... - [Expansion of FamiCord activity to Balkans](https://www.famicord.com/expansion-of-famicord-activity-to-balkans) (2018-02-02): Recently FamiCord established new partnership with leading company from the sector in Balkan countries - BioSave Group. Based on... - [PBKM granted 13.7 mln PLN funds from NCBiR to develop stem cell therapy for ALS](https://www.famicord.com/pbkm-granted-13-7-mln-pln-funds-from-ncbir-to-develop-stem-cell-therapy-for-als) (2017-06-06): The National Center for Research and Development (NCBiR) in Poland has approved the request of PBKM (Polski Bank Komórek Macierzystych) for co-financing the project titled "Development of... - [Vita 34 AG: Vita 34 concludes purchase agreement for the entire acquisition of its competitor Seracell Pharma AG](https://www.famicord.com/vita-34-ag-vita-34-concludes-purchase-agreement-for-the-entire-acquisition-of-its-competitor-seracell-pharma-ag) (2017-04-20): Vita 34 AG intends to fully acquire all shares of Seracell Pharma AG, the second largest supplier of... - [PBKM becomes a member of EBMT](https://www.famicord.com/pbkm-becomes-a-member-of-ebmt) (2016-10-08): We are very proud to report that Polski Bank Komórek Macierzystych has become a member of EBMT – European Society for Blood and Marrow Transplantation. It is the biggest... - [Sevibe Cells – the only bank in Spain accredited with AABB](https://www.famicord.com/sevibe-cells-the-only-bank-in-spain-accredited-with-aabb) (2015-10-15): In October 2015 Sevibe Cells became the first bank in Spain accredited by the American Association of Blood Banks (AABB) - internationally recognized symbol of quality of products and services in the filed of cord blood banking. Being accredited by AABB means that all Clients ofSevibe Cells can be s... - [Vita 34 Takes Over Danish StemCare Group](https://www.famicord.com/vita-34-takes-over-danish-stemcare-group) (2015-09-08): Vita 34 AG, one of Europe’s leading stem cell banks, has successfully completed the acquisition of the Danish StemCare Group, a prominent player in the field... - [FamiCord Group continues international expansion](https://www.famicord.com/famicord-group-continues-international-expansion) (2014-02-10): Yasam is the oldest Turkish stem cell bank and has been operating for over 10 years. Yasam, like all FamiCord Group banks, has the highest quality standards. By 2013, it had provided on 4 occasions deposited umbilical cord blood to treat children. Yasam has its own specialized laboratory, providing... - [FamiCord Group opened a new laboratory in Budapest](https://www.famicord.com/famicord-group-opened-a-new-laboratory-in-budapest) (2013-01-23): KRIO Institute in Hungary opened anew laboratory to enable the stem cell bank to process samples manually. Manual technology allows for the correction of errors that may occur during collection and separation of blood, thus samples made available for afuture therapy are especially rich in cells. Ma... ## Job offers - [DIRECT SALES, EVENT & HCP CONSULTANT / PHARMAREFERENT (M/W/D)](https://www.famicord.com/career/employment-in-germany/job-postings/direct-sales-event-hcp-consultant-pharmareferent-m-w-d): EINSATZGEBIETE:METROPOLREGION MÜNCHEN MIT HOHER REISEBEREITSCHAFT FÜR NATIONALE EINSÄTZEMETROPOLREGION LEIPZIG MIT HOHER REISEBEREITSCHAFT FÜR NATIONALE EINSÄTZE Die FamiCord Gruppe ist der Pionier und Marktführer im Zellbanking in Europa. Wir nutzen das therapeutische Potenzial von Stammzellen und Immunzellen um die Gesundheit von - [DIRECT SALES & EVENT CONSULTANT UND HEBAMMEN COMMUNITY MANAGER (M/W/D)](https://www.famicord.com/career/employment-in-germany/job-postings/direct-sales-event-consultant-und-hebammen-community-manager-m-w-d-2): EINSATZGEBIETE:METROPOLREGION MÜNCHEN MIT HOHER REISEBEREITSCHAFT FÜR NATIONALE EINSÄTZEMETROPOLREGION LEIPZIG MIT HOHER REISEBEREITSCHAFT FÜR NATIONALE EINSÄTZE Die FamiCord Gruppe ist der Pionier und Marktführer im Zellbanking in Europa. Wir nutzen das therapeutische Potenzial von Stammzellen und Immunzellen um die Gesundheit von --- # Full Content --- title: "FamiCord Advances Scientific Dialogue on Cell Therapies at EACD 2026" url: "https://www.famicord.com/famicord-advances-scientific-dialogue-on-cell-therapies-at-eacd-2026" lang: "en" type: "post" description: "FamiCord Group participated in the 38th Annual Meeting of the European Academy of Childhood-onset Disability (EACD), held on 3–6 June 2026 in Galway, Ireland, reaffirming its commitment to advancing evidence-based regenerative medicine and supporting scientific collaboration in the field of" last_modified: "2026-08-04T12:35:01+00:00" categories: [2026] translations: de: "https://www.famicord.com/famicord-advances-scientific-dialogue-on-cell-therapies-at-eacd-2026" --- # FamiCord Advances Scientific Dialogue on Cell Therapies at EACD 2026 **FamiCord Group participated in the 38th Annual Meeting of the European Academy of Childhood-onset Disability (EACD), held on 3–6 June 2026 in Galway, Ireland, reaffirming its commitment to advancing evidence-based regenerative medicine and supporting scientific collaboration in the field of pediatric neurology.** As Europe’s leading scientific congress dedicated to childhood-onset disabilities, EACD 2026 brought together clinicians, researchers and healthcare professionals from around the world to discuss the latest developments in the diagnosis and treatment of neurological disorders in children. This year’s scientific programme reflected the growing international interest in regenerative medicine, with dedicated sessions focusing on the role of umbilical cord blood and perinatal tissue-derived cell therapies in cerebral palsy. ## FamiCord Industry Symposium As part of the congress, FamiCord organized an Industry Symposium entitled **“Status of Perinatal Tissue-Derived Stem Cells in Cerebral Palsy: Challenges and Opportunities”**, moderated by **Professor Marcin Bonikowski**. The symposium featured internationally recognized experts **Professor Iona Novak** (Cerebral Palsy Alliance, Australia) and **Professor Jeroen Vermeulen** (Maastricht University Medical Center, the Netherlands), who reviewed the current clinical evidence supporting the use of umbilical cord blood and mesenchymal stromal cells (MSCs) in cerebral palsy. Both speakers emphasized the encouraging safety profile of cell-based therapies while highlighting the importance of further high-quality clinical research to strengthen the evidence base and support broader clinical implementation. ## Presenting New Clinical Data During the congress, FamiCord also co-authored and presented a scientific poster together with the University Children’s Hospital in Lublin entitled **“Mesenchymal Stem Cell Therapy Improves Motor Function in Children with Cerebral Palsy: Preliminary Independent Observations.”** The study presented preliminary clinical observations from children treated with GMP-manufactured mesenchymal stromal cells produced as an ATMP under the Hospital Exemption pathway. Importantly, treatment outcomes were assessed independently by a clinical centre different from the treating institution, providing additional scientific value to the presented data. Preliminary findings demonstrated improvements in motor function in the majority of evaluated patients using standardized neurological assessment scales. ## Advancing Evidence-Based Regenerative Medicine EACD 2026 confirmed the growing scientific interest in regenerative medicine for neurological disorders. Throughout the congress, experts discussed the biological rationale for cell therapies, the role of neuroinflammation in cerebral palsy, encouraging clinical safety data and the need for further Phase III clinical trials to establish future standards of care. _“Scientific progress is driven by collaboration, high-quality clinical evidence and open dialogue. EACD provides a unique platform to exchange knowledge with leading experts in pediatric neurology and regenerative medicine. At FamiCord, we are proud to contribute not only through scientific research and clinical collaborations, but also by creating opportunities for meaningful discussion that helps translate promising science into future therapeutic solutions for patients,”_ said **Tomasz Baran, Chief Medical Officer of FamiCord Group**. ## More Than a Stem Cell Bank FamiCord’s presence at EACD 2026 reflects the Group’s long-term strategy of supporting the development of advanced cell therapies through scientific partnerships, translational research and GMP manufacturing capabilities. By organizing an international scientific symposium, presenting original clinical data and actively contributing to discussions on the future of regenerative medicine, FamiCord continues to strengthen its position as **more than a stem cell bank**—a trusted partner in the development of advanced therapy medicinal products (ATMPs) and innovative cell-based therapies. --- --- title: "Cell Therapies – From Experiment to Standard of Care" url: "https://www.famicord.com/cell-therapies-from-experiment-to-standard-of-care" lang: "en" type: "post" description: "On May 1, we marked World Fanconi Anemia Day, and tomorrow the 3rd Fanconi Anemia Europe Scientific Meeting will take place in Gdańsk. Fanconi anemia is a rare genetic disorder in which impaired DNA repair leads to bone marrow failure." last_modified: "2026-05-07T11:11:52+00:00" categories: [2026] --- # Cell Therapies – From Experiment to Standard of Care On May 1, we marked World Fanconi Anemia Day, and tomorrow the 3rd Fanconi Anemia Europe Scientific Meeting will take place in Gdańsk. Fanconi anemia is a rare genetic disorder in which impaired DNA repair leads to bone marrow failure. There are several treatment methods for this disease—blood and platelet transfusions, stimulation of blood cell production—but the cornerstone of treatment is bone marrow transplantation. In 1988, stem cells from umbilical cord blood were used for the first time in the world to treat this disease. This proved that cord blood can be an effective alternative to bone marrow or peripheral hematopoietic stem cells in the treatment of blood disorders. Forty years ago, this was a medical experiment; today, it is not, and umbilical cord blood stem cells are used worldwide in medicine, especially in hematology. Cell therapies using cord blood are not merely a promise of the future. Their history began with basic research conducted in the 1980s. In 1988, a breakthrough occurred—the first clinical application in a patient. In Europe, then a cradle of pioneering and innovative medical solutions, Prof. Eliane Gluckman decided to perform the first cord blood transplant, saving the life of Matthew Farrow. Matthew was 5 years old at the time and suffered from Fanconi anemia. The transplant was made possible by collecting stem cells from the umbilical cord blood of his younger sister, who had been born four months earlier. This was the world’s first successful cord blood transplant, performed in 1988—over 35 years ago—and at the time an innovative and experimental medical procedure that initiated a new era in the use of stem cells in therapy. Today, hematopoietic stem cell transplantation is a recognized and widely used treatment for hematological diseases. Since 2006, European guidelines have placed cord blood stem cells on par with those derived from bone marrow or peripheral blood—meaning they are an equivalent source of transplant material. “Many people are still unaware of how important cord blood stem cell transplants are. My younger sister’s cord blood saved my life when I was five and allowed me to grow up, have my own family, and live a normal life. I was very lucky, because I know many people who unfortunately could not be saved. There is still too little awareness about the importance of cord blood stem cells. I am living proof that this method works,” says Matthew Farrow, the first patient in the world to receive a cord blood transplant. Stem cells from cord blood have unique properties that translate into specific therapeutic benefits. After transplantation, they engraft in the recipient’s bone marrow and begin producing healthy blood and immune cells, allowing restoration of functions impaired by disease. “Cord blood cells offer hope in the treatment of cancer, particularly acute myeloid leukemia, as well as many non-cancerous diseases. Importantly, in cord blood stem cell transplantation, full HLA matching is not required, unlike with bone marrow or peripheral blood cells. This means that some degree of mismatch is acceptable, while the chances of a successful transplant remain very high. The risk of immunological complications is also lower,” emphasizes Prof. Krzysztof Kałwak, Head of the Department of Bone Marrow Transplantation, Oncology and Pediatric Hematology at the Medical University of Wrocław and Chair of the EBMT Pediatric Diseases Working Party. In recent years, the conditions surrounding cord blood transplantation have changed significantly. The development of cord blood banks, improved storage techniques, and advances in donor matching have greatly increased the availability of this therapy. Until recently, one of the concerns and arguments against cord blood banking was the belief that the collected volume was too small and did not contain enough stem cells for treatment, especially in older children or adults. Currently, two technologies for the expansion of hematopoietic stem cells from cord blood are registered, significantly broadening the clinical applications of this unique biological material. The development of transplantology and increasing availability of cord blood mean that more and more patients—including those with Fanconi anemia—can benefit from a therapy that was once considered a breakthrough innovation and is now a foundation of modern hematology and transplantation medicine. “In light of current medical knowledge, transplantation of stem cells from cord blood is no longer an experimental method but a proven, life-saving procedure that offers a real chance for cure or long-term remission. This method should be treated as one of the equivalent therapeutic options, selected by the physician depending on the patient’s clinical indications,” adds Prof. Krzysztof Kałwak. **Graft-versus-Host Disease** One of the key issues related to stem cell transplantation, including cord blood transplantation, is graft-versus-host disease (GvHD). This is a complication in which donor immune cells recognize the recipient’s tissues as foreign and begin to attack them. GvHD can be treated; however, in some cases, available therapies are ineffective. In such situations, mesenchymal stem cells (MSCs), isolated for example from the umbilical cord, may serve as an alternative. They form the basis for so-called advanced therapy medicinal products (ATMPs). “Prevention and treatment of graft-versus-host disease (GvHD) is a key element of the transplantation process, significantly affecting its success. In some cases, available prophylactic and therapeutic methods are insufficient, which may lead to serious complications, prolonged hospitalization, or even life-threatening situations. Therefore, it is crucial to ensure patients have access not only to the transplant itself but also to comprehensive peri-transplant care, including modern methods for preventing and treating GvHD, which significantly increases the chances of successful therapy and recovery,” emphasizes Prof. Krzysztof Czyżewski from the Department of Pediatrics, Hematology, Oncology, Immunology and Transplantology at Nicolaus Copernicus University in Toruń. Hematopoietic stem cell transplantation, including from cord blood, has for years been a recognized and widely used standard treatment for many hematological diseases, while therapies using mesenchymal stem cells (MSCs) remain in clinical development and are sometimes described as “experimental.” However, this does not mean they are unproven—on the contrary, they are based on solid scientific foundations and are subject to rigorous regulations, institutional oversight, and bioethical review. Unfortunately, the complexity of issues related to cell therapies means that the term “experimental therapy” is often misunderstood and unjustly perceived negatively. It is worth remembering that every breakthrough treatment—from antibiotics to transplantation—was once an innovation at the research stage, and medical progress has always relied on the courage to introduce new, responsibly tested solutions that eventually become standards of care. **FamiCord Group** is one of the leading stem cell banking groups in Europe and worldwide. The organization operates across multiple international markets, offering comprehensive services related to the collection, processing, and storage of stem cells. Guided by the mission of protecting health and life, FamiCord enables the preservation of biological material derived from umbilical cord blood and other perinatal tissues. As a provider of integrated medical services, the Group ensures the highest standards of quality and safety at every stage of cooperation. With many years of experience and strong scientific and expert background, FamiCord supports the development of modern stem cell-based therapies. --- --- title: "Autism Awareness Day: First FamiCord EAP Therapies Launched for ASD Patients" url: "https://www.famicord.com/autism-awareness-day-first-famicord-eap-therapies-launched-for-asd-patients" lang: "en" type: "post" description: "On the occasion of World Autism Awareness Day, FamiCord Group marks an important milestone in expanding access to innovative therapies. Today, the first clients of Crioestaminal – part of the FamiCord Group – had the opportunity to participate in stem" last_modified: "2026-04-01T13:10:43+00:00" categories: [2026] --- # Autism Awareness Day: First FamiCord EAP Therapies Launched for ASD Patients On the occasion of World Autism Awareness Day, FamiCord Group marks an important milestone in expanding access to innovative therapies. Today, the first clients of Crioestaminal – part of the FamiCord Group – had the opportunity to participate in stem cell therapy for autism spectrum disorder (ASD) under the Expanded Access Programme (EAP). The EAP, launched by FamiCord Group, is dedicated to clients who have stored their own umbilical cord blood within the Group’s laboratories and meet defined medical and qualification criteria for participation. The program enables access to emerging therapeutic options in areas where conventional medicine still faces limitations, with two main indications: autism spectrum disorder (ASD) and cerebral palsy (CP). Umbilical cord blood has been successfully used for over 35 years in the treatment of more than 80 oncological and hematological diseases. Over time, its application has expanded into metabolic disorders, immunodeficiencies, and neurological conditions. Today, increasing attention is being given to its potential role in supporting children with autism spectrum disorder. ASD is a complex neurodevelopmental condition characterized by challenges in social communication, restricted interests, and repetitive behaviors. It is estimated to affect approximately 1 in 54 children in developed countries, with around 75 million individuals impacted globally. While stem cell therapy for autism remains experimental, growing scientific interest is supported by ongoing clinical research. Early studies, including those conducted at Duke University, have explored the use of autologous cord blood in children with neurodevelopmental disorders. Although results have been mixed, subgroup analyses suggest potential benefits in communication, attention, and neurological function in selected patient populations. Building on the experience and scientific insights from the Duke Center for Autism and Brain Development, FamiCord Group – in collaboration with a clinical center in Lublin – has launched the Expanded Access Programme. The initiative is designed for families whose children are affected by ASD (autism spectrum disorder) or CP (cerebral palsy), and aims to translate scientific progress into real clinical opportunities using patients’ own cord blood. _“We are cautiously optimistic about the growing body of evidence and continue to explore the potential of cord blood in ASD,” _said Magdalena Croscińska-Krawczyk, MD, principal investigator of the EAP programme. _“Our goal is to give children an additional chance for greater independence and to support their daily therapy.”_ Tomasz Baran, MD, Chief Medical Officer, adds: _“The cord blood journey is 40 years young. Today, we not only understand its therapeutic potential better than ever before, but we are also able to store and use it effectively even after decades. Just a few years ago, its use in neurological conditions seemed unlikely – today, it is becoming a reality. At FamiCord Group, we are committed not only to storing stem cells, but to enabling our clients to truly benefit from them. We are more than a stem cell bank – we are a partner in access to future therapies.”_ The launch of therapies under the EAP program represents a significant step in translating scientific progress into real-world patient access and highlights the growing role of personalized, regenerative medicine in addressing complex conditions such as autism. More than a banking service, FamiCord Group is committed to enabling real therapeutic use of stored biological material. The EAP reflects this mission – offering families not only long-term security, but also a tangible opportunity to benefit from the preserved stem cells when it matters most. ## About FamiCord Group FamiCord is the largest stem cell bank in Europe and the third largest worldwide. With a network of laboratories across dozens of countries, the Group has been providing cord blood banking services for over 25 years. To date, FamiCord has collected more than 930,000 stem cell samples, contributing to over 8,000 therapies worldwide. --- --- title: "Expanded Access Programme" url: "https://www.famicord.com/services-for-families/expanded-access-programme-famicord" lang: "en" type: "page" last_modified: "2026-03-25T07:56:29+00:00" translations: de: "https://www.famicord.com/services-for-families/expanded-access-programme-famicord" custom_fields: display_availability_of_our_service_section: 1 --- # Expanded Access Programme # FamiCord Expanded Access Protocol ## FamiCord Expanded Access Protocol : A Breakthrough In The Use of The Own Stem Cells FamiCord Group has launched a treatment program to help FamiCord clients to use autologous cord blood stem cells for the treatment of cerebral palsy and autism spectrum disorder. This initiative ensures that FamiCord Group clients from across Europe can access innovative stem cell therapies already being conducted in Poland. The University Children’s Hospital in Lublin is the partner of FamiCord Group in this project. ![cord-blood-for-brain-development](https://www.famicord.com/wp-content/uploads/2025/01/cord-blood-for-brain-development-1.webp) The program, known as the FamiCord Group Expanded Access Protocol for Cord Blood in Brain Development, represents a significant opportunity for children suffering from these conditions, particularly cerebral palsy, as autologous (own) cord blood infusion presents a potential path for clinical improvement. The foundation for launching the program was the results of clinical trials led by Professor Joanne Kurtzberg and conducted at the Duke University in the United States, which demonstrated clinical benefits achieved by children with cerebral palsy after receiving their own cord blood. Regarding the use of cord blood in autism spectrum disorder (ASD), there are also clinical benefits; research has shown that these benefits are more pronounced in children without intellectual disabilities. It has been also confirmed that clinical benefit was achieved when appropriate dose of cells was infused. Procedure is safe and well tolerated. The program is aimed at clients of FamiCord Group who have their own cord blood stored in the group’s laboratories and have a diagnosis of autism spectrum disorder (ASD) or cerebral palsy (CP). Additionally, the cord blood unit must meet strict qualification criteria to ensure its suitability for treatment. This targeted approach ensures that eligible patients have access to potentially life-changing therapies using their own stem cells. The primary physician responsible for the programme Is Professor Magdalena Chrościńska-Krawczyk, MD, PhD, she is a paediatric neurologist at University Children’s Hospital in Lublin. For FamiCord Group clients, who wants to use their own cord blood for treatment, FamiCord Group launched the dedicated email: [braindevelopment@pbkm.pl](mailto:braindevelopment@pbkm.pl). So, if you are one of our clients – don’t hesitate to contact us. You can access the leaflet here [https://www.famicord.com/wp-content/uploads/2025/01/eksperyment-segregator-EN-04-10-2019_prev-3.pdf](https://www.famicord.com/wp-content/uploads/2025/01/eksperyment-segregator-EN-04-10-2019_prev-3.pdf) Disclaimer: Famicord cannot guarantee that you will be accepted to participate in the programme. Famicord reserves the right to stop. --- --- title: "Eliane Gluckman Award Dinner – thank you page" url: "https://www.famicord.com/eliane-gluckman-award-dinner-typ" lang: "en" type: "page" description: "Thank You for Registering Thank you for confirming your attendance at the Eliane Gluckman Award Dinner. A confirmation email has been sent to your email address, including a map with details of the meeting point from which you will be" last_modified: "2026-02-04T09:53:35+00:00" --- # Eliane Gluckman Award Dinner – thank you page **Thank You for Registering** Thank you for confirming your attendance at the **Eliane Gluckman Award Dinner**. A confirmation email has been sent to your email address, including a map with details of the meeting point from which you will be collected after the **Welcome Ceremony**. If you have any questions, feel free to contact **Aleksandra Olearczyk** at [aleksandra.olearczyk@pbkm.pl](mailto:aleksandra.olearczyk@pbkm.pl). --- --- title: "Eliane Gluckman Award Dinner – LP" url: "https://www.famicord.com/eliane-gluckman-award-dinner" lang: "en" type: "page" description: "We’re full! Thank you so much for the huge interest in the Eliane Gluckman Award Dinner. We’re sorry to say that we’ve already reached our maximum capacity and registration is now closed We hope to see you at one of" last_modified: "2026-03-19T12:57:10+00:00" --- # Eliane Gluckman Award Dinner – LP **We’re full!** Thank you so much for the huge interest in the **Eliane Gluckman Award Dinner**. We’re sorry to say that we’ve already reached our **maximum capacity** and registration is now closed We hope to see you at one of our future events instead. Thanks for understanding! --- --- title: "FamiCord Group Recognized as Europe’s Leading Stem Cell Bank" url: "https://www.famicord.com/famicord-group-recognized-as-europes-leading-stem-cell-bank" lang: "en" type: "post" description: "FamiCord is the largest stem cell bank in Europe and the third largest in the world. The quality of its services is validated by international certifications, and the company has now been recognized as Europe’s Leading Stem Cell Bank by Life Sciences Review, highlighting its commitment to excellence, clinical reliability, and innovation in stem cell banking.FamiCord Group have been awarded as “The Europe’s Leading Stem Cell Bank” , independent experts jury underlined FamiCord has established itself as a leading provider in the field, guiding families through the collection, processing, and long-term preservation of cord blood and perinatal tissues." last_modified: "2025-11-21T11:50:40+00:00" categories: [2025] translations: de: "https://www.famicord.com/famicord-group-recognized-as-europes-leading-stem-cell-bank" --- # FamiCord Group Recognized as Europe’s Leading Stem Cell Bank ## Leadership in the European Stem Cell Banking Market **FamiCord is the largest stem cell bank in Europe and the third largest in the world. The quality of its services is validated by international certifications, and the company has now been recognized as Europe’s Leading Stem Cell Bank by Life Sciences Review, highlighting its commitment to excellence, clinical reliability, and innovation in stem cell banking. FamiCord Group have been awarded as “The Europe’s Leading Stem Cell Bank” , independent experts jury underlined FamiCord has established itself as a leading provider in the field, guiding families through the collection, processing, and long-term preservation of cord blood and perinatal tissues.** ## **Criteria Behind the Life Sciences Review Award** The “Europe’s Leading Stem Cell Bank” award is part of Life Sciences Review’s annual recognition program, which highlights companies demonstrating outstanding leadership, technological advancement, and a proven commitment to improving patient outcomes. The selection is based on life sciences expert evaluation, company track record, and the tangible impact of their work within the life sciences industry. The award reflects FamiCord’s comprehensive system that ensures the therapeutic potential of stem cells from birth, from collection and processing to storage and eventual clinical use. Nearly half of the group’s laboratories are accredited by the AABB, and all operations comply fully with national regulations while aligning with Europe’s bone marrow transplant and cell therapy community as an EBMT member- comments Tomasz Baran, Chief Medical Officer of FamiCord Group. ## Clinical Impact and Global Expansion FamiCord’s pioneering approach extends to clinical applications, with almost 2,000 patients having benefited from perinatal stem cell therapies. The company continues its global expansion, including the opening of its first laboratory in Dubai in 2024, which has also achieved AABB accreditation. ## Commitment to Innovation and Medical Collaboration FamiCord is committed not only to advancing its infrastructure but also to being a reliable and active partner for the medical community, supporting clinical practice and research by collaborations with institutions such as the Medical University of Lublin enable families to access innovative treatments for conditions like cerebral palsy and autism, following internationally recognized clinical protocols. The recognition by Life Sciences Review underscores FamiCord’s position as the most trusted stem cell bank in Europe, demonstrating that its services go beyond storage to provide real therapeutic options when needed. By maintaining rigorous standards and embracing clinical innovation, FamiCord ensures that every preserved sample has the potential to support life-saving and regenerative therapies for children and adults alike. ## About Life Sciences Review Life Sciences Review is a leading industry publication that recognizes innovation and excellence across biotechnology, pharmaceuticals, healthcare, and life sciences sectors. The magazine provides expert insights, analyses, and annual rankings of organizations setting benchmarks for quality, innovation, and clinical impact worldwide References: [https://www.lifesciencesrevieweurope.com/famicord](https://www.lifesciencesrevieweurope.com/famicord) --- --- title: "Landing page" url: "https://www.famicord.com/landing-page" lang: "en" type: "page" description: "Join our educational program dedicated to midwives and discover the latest knowledge on cord blood and its role in modern medicine. By registering, you will gain access to exclusive resources, training opportunities, and a supportive community. Together, we can shape" last_modified: "2025-10-20T12:59:40+00:00" --- # Landing page ## Shape the Future of Midwifery Join our educational program dedicated to midwives and discover the latest knowledge on cord blood and its role in modern medicine. By registering, you will gain access to exclusive resources, training opportunities, and a supportive community. Together, we can shape the future of maternity care. YES, I would like to request a visit from a FamiCord representative with starter pack for midwives. I have read the information on how my data are used and agree. FamiCord AG will not disclose my data to third parties.* Submit --- --- title: "Infantile cerebral palsy – Convincing evidence for the use of perinatal stem cells" url: "https://www.famicord.com/infantile-cerebral-palsy-convincing-evidence-for-the-use-of-perinatal-stem-cells" lang: "en" type: "post" description: "Leipzig, July 15, 2025 - Cerebral palsy (CP) continues to be one of the most common motor disabilities in childhood and is associated with permanent movement restrictions and spasticity. The therapeutic potential of stem cells from umbilical cord blood and tissue was discussed at the 37th Annual Meeting of the European Academy Of Childhood-onset Disabilities (EACD) and the 4th Meeting of the International Alliance of Academies of C hildhood Disability (IAACD) from June 24 - 28, 2025 in Heidelberg. As part of a symposium supported by FamiCord AG, international experts presented the current state of research and reported on the results from clinical practice." last_modified: "2025-08-27T09:31:50+00:00" categories: [No category] translations: de: "https://www.famicord.com/infantile-cerebral-palsy-convincing-evidence-for-the-use-of-perinatal-stem-cells" --- # Infantile cerebral palsy – Convincing evidence for the use of perinatal stem cells **Leipzig, July 15, 2025 – Cerebral palsy (CP) continues to be one of the most common motor disabilities in childhood and is associated with permanent movement restrictions and spasticity. The therapeutic potential of stem cells from umbilical cord blood and tissue was discussed at the 37th Annual Meeting of the European Academy Of Childhood-onset Disabilities (EACD) and the 4th Meeting of the International Alliance of Academies of C hildhood Disability (IAACD) from June 24 – 28, 2025 in Heidelberg. As part of a symposium supported by FamiCord AG, international experts presented the current state of research and reported on the results from clinical practice.** ## **Clear recommendation for the use of umbilical cord blood in CP** In her presentation, Prof. Iona Novak from the Faculty of Medicine and Health at the University of Sydney emphasized the heterogeneous composition of umbilical cord blood (CB). The properties, mechanisms of action and therapeutic potential of CB is correspondingly diverse – also for use in neurological disorders in children. Their systematic review of the current evidence for strategies for the prevention and treatment of CP showed a clearly positive result for the use of CB.1 Promising results were also achieved with the use of cell products from mesenchymal stem cells (MSCs), which can be obtained from umbilical cord tissue, with the anti-inflammatory effect of MSCs taking center stage.(1) “We need more studies that not only look at the motor functions of patients, but also consider the improvement of cognition, concentration and communication skills in order to further explore the potential of different stem cell populations from umbilical cord blood and tissue,” Prof. Novak concluded. ## **Monocytes from CB can stimulate healing processes in the brain** Prof. Joanne Kurtzberg from the Duke University School of Medicine in Durham, USA, then gave an overview of her diverse clinical studies on the use of perinatal tissues in various neuronal disorders – including CP, autism spectrum disorder (ASD) and hypoxic-ischemic encephalopathy (HIE). “Monocytes derived from  CB can cross the blood-brain barrier and promote healing processes through paracrine signaling,” Prof. Kurtzberg explained. a randomized placebo-controlled study of 63 patients with CP aged 1-6 years demonstrated that the administration of ≥ 2 x 107 Total Nucleated Cell Count (TNCC) 12 months after treatment can significantly improve motor function.2 The improvement of the Gross Motor Function Measure (GMFM-66) score by a median of 4.3 points was associated with a significant increase in normalized whole brain connectivity.2 ## **Treatment with autologous CB improves quality of life in CP** Prof. Magdalena Chrościńska-Krawczyk , Head of the Pediatric Neurology Clinic at the University Children’s Hospital in Lublin, Poland, presented the case showing the effect of cell therapy  from CB and umbilical cord tissue under real-world conditions.3,4 She reported the case of a 2-year-old male patient with CP who was treated with autologous CB twice at 2-month intervals (TNCC: 28.5 x 107 and 114.1 x 107) .4 The treatment was well tolerated and no adverse effects were reported during the 12-month follow-up period. As a result of the therapy, the boy’s hemiparesis symptoms improved, especially the function of the left hand, and there was better control of posture. In addition, the patient showed a significant improvement in cognitive function and a sudden increase in speech ability.(4) “The effect of treatment with autologous CB is very individual, and its influence on the quality of life of those affected and their relatives is often immense,” Prof. Chrościńska-Krawczyk emphasized in conclusion. ## **Four key factors for the effectiveness of treatment with CB** The three experts agreed that the success of therapy with CB depends largely on the age of the child, the degree of impairment and the TNCC in the CB.(2) (,3)The earlier treatment is initiated and the more cells are available, the more promising the therapy.(2,3) “Patients who are expected to learn to walk in the course of their development benefit particularly from the therapy,” added Prof. Novak. The basic prerequisite is the availability of CB. The storage of CB for autologous use can therefore be regarded as a special precautionary measure. ## **About Vita 34** Vita 34 is a brand of FamiCord AG. FamiCord AG is a Leipzig-based company founded in 1997 and is the leading stem cell bank in Europe and the third largest worldwide. Driven by the guiding principle of enabling a healthier future for all people, FamiCord AG is a full-service provider with around 800 employees worldwide, providing all services related to preventive healthcare with umbilical cord blood and tissue. FamiCord provided therapeutic cells for treatment for over 7,000 patients wordwide. **Sources:** 1. Novak I et al. Curr Neurol. Neurosci Rep. 2020;20(2):3. 2. Sun JM et al. Stem Cells Transl Med. 2017;6(12):207-2078. 3. Chrościńska-Krawczyk M et al. Stem Cell Rev Rep. 2024;20(6):1636-1649. 4. Case study presented by Chrościńska-Krawczyk M. at EACD & IAACD 2025, Heidelberg. Data ahead of publication. --- --- title: "FamiCord Group’s Dubai Laboratory Earns Prestigious AABB Accreditation" url: "https://www.famicord.com/famicord-groups-dubai-laboratory-earns-prestigious-aabb-accreditation" lang: "en" type: "post" description: "Dubai, UAE – – FamiCord Group, the largest cord blood bank in Europe, proudly announces that its state-of-the-art laboratory in Dubai has received the prestigious accreditation from the Association for the Advancement of Blood & Biotherapies (AABB) – a globally recognized standard of excellence in the field of cellular and blood banking services." last_modified: "2025-06-17T11:59:32+00:00" categories: [2025] translations: de: "https://www.famicord.com/famicord-groups-dubai-laboratory-earns-prestigious-aabb-accreditation" --- # FamiCord Group’s Dubai Laboratory Earns Prestigious AABB Accreditation **Dubai, UAE – [3.06.2025] – FamiCord Group, the largest cord blood bank in Europe, proudly announces that its state-of-the-art laboratory in Dubai has received the prestigious accreditation from the Association for the Advancement of Blood & Biotherapies (AABB) – a globally recognized standard of excellence in the field of cellular and blood banking services.** FamiCord Group’s laboratory in Dubai, officially opened one year ago, is the newest facility in the Group’s international network. Strategically located to serve the rapidly growing markets of the Middle East, the laboratory was established to meet the highest global standards in stem cell processing and storage**. **Laboratory is operated by FamiCord’s subsidiary- Smart Cells International. _“The opening of our Dubai laboratory marked a significant milestone for Smart Cells Middle East and the entire FamiCord Group – it reflects our commitment to bringing world-class stem cell services closer to families in the region,”_ said Hadeel AlKhazi, Country Manager of Smart Cells ME. Earning the accreditation after one year it’s  opening confirms that highest international standards of processing are not just marketing slogan. This accreditation confirms that FamiCord’s Dubai facility meets the highest international standards for safety in the collection, processing, testing, and storage of stem cells and other cellular products. AABB accreditation is a mark of trust and reliability, underscoring FamiCord Group’s ongoing commitment to delivering world-class services to its clients.  What does in mean for future parents? For clients banking with FamiCord, the AABB accreditation provides enhanced assurance that their biological materials are handled according to rigorous international protocols. This further strengthens the Group’s reputation as a trusted partner in the long-term preservation of stem cells for potential future therapies. _“Achieving AABB accreditation in Dubai is a major milestone for FamiCord Group. By this accreditation Dubai joins the FamiCord facilities which are AABB accredited  – located in Poland, Spain, Hungary, and Portugal . It reaffirms our commitment to  quality  in every market we serve,”_ said Tomasz Baran, Chief Medical Officer at FamiCord Group. **About AABB** AABB (Association for the Advancement of Blood and Biotherapies) is an international association of stem cell banks. Its mission is to develop and deliver standards, accreditation, and educational programs to ensure that transplantation and cell therapies are safe, accessible, and effective worldwide. More information about AABB’s cellular therapy accreditation and qualification programs can be found [here]. **About FamiCord Group** FamiCord Group is the largest stem cell banks network in Europe and the third largest in the world. Thanks to an extensive network of laboratories, umbilical cord blood banking services provided by our company are available in dozens of countries around the globe. Over more than 25 years of operation, we have collected more than 1 000 000 stem cell samples, and cellular products prepared by our laboratories have supported treatment for over 7,500 patients. ![](https://www.famicord.com/wp-content/uploads/2025/06/1930121_AABB_Certificate_91-1-1024x791.png) --- --- title: "Whistleblowing" url: "https://www.famicord.com/whistleblowing" lang: "en" type: "page" last_modified: "2025-08-22T08:53:35+00:00" translations: de: "https://www.famicord.com/whistleblowing" --- # Whistleblowing # Whistleblowing - ## Whistleblowing **Guidelines on the procedure for whistleblowers in a professional context in accordance with the Whistleblower Directive 2019/ 1937/ EU and related national regulations.** ### Preamble The objective of this guideline is to inform potential whistleblowers* of the options available at FamiCord AG (hereinafter: “FamiCord”) to report violations in the professional context and to receive adequate protection against discrimination. The FamiCord Group has set up an **internal reporting office** at FamiCord for FamiCord. Where local law requires **separate internal reporting offices** for the FamiCord subsidiaries, with at least 50 employees, will be set up. FamiCord places great value on compliance and the fight against corruption and misconduct in the Company. #### 1. Reporting offices and order of use By selecting the reporting channel, the whistleblower can decide for himself whether she/he wishes to remain anonymous or provide personal information. They are free to choose an internal or external reporting office. Confidentiality is also ensured at all times when contacting the internal reporting office. #### 2. Contact internal reporting office and staffing Internal reporting office is staffed by employees with the appropriate expertise. The respective reporting channels can be found on the website, intranet, if available, or in any other form accessible to all employees. The following reporting channels are available: Digital: for internal reports, the digital reporting system is installed, to which all employees have access. The system ensures that the anonymity of the whistleblower is guaranteed, cannot be technically traced and that all security requirements are met. [https://famicord.integrityline.app/](https://famicord.integrityline.app/) In addition, reporting channels are offered via e-mail and by post. At the request of the whistleblower, there is also the possibility of a digital or personal exchange with those responsible at the internal reporting office. Only the designated persons will have access to the internal reporting office. The internal reporting office is designed to help the whistleblower and remedy the reported violation.   #### 3. External reporting offices in Germany The Federal Office of Justice (BfJ) acts as the central external reporting office. In addition, there are further external reporting offices at the Federal Financial Supervisory Authority (BaFin) and the Federal Cartel Office. Further information on the responsibilities of the external reporting offices can be found under the following links: BfJ: [https://www.bundesjustizamt.de/DE/MeldestelledesBundes/MeldestelledesBundes_node.html](https://www.bundesjustizamt.de/DE/MeldestelledesBundes/MeldestelledesBundes_node.html) - BaFin: [https://www.bafin.de/DE/DieBaFin/Hinweisgeberstelle/hinweisgeberstelle_node.html](https://www.bafin.de/DE/DieBaFin/Hinweisgeberstelle/hinweisgeberstelle_node.html) - Bundeskartellamt: [https://www.bundeskartellamt.de/DE/Kartellverbot/Hinweise_auf_Verstoesse/Hinweise_node.html](https://www.bundeskartellamt.de/DE/Kartellverbot/Hinweise_auf_Verstoesse/Hinweise_node.html) #### 4. External reporting offices in the other countries Information on the external reporting offices and their responsibilities in the other countries is published locally on the website, on the intranet, if available, or in another form accessible to all employees. #### 5. Scope of protection for the whistleblower Persons who have obtained information about violations in connection with their professional activities or in advance are protected. This includes employees, self-employed persons, board members and also third parties who support the whistleblower or are in contact with them and have suffered reprisals in a professional context. Reports of private misconduct are not protected. The aforementioned persons are protected from reprisals. This includes all discriminatory actions or omissions, such as termination of employment or disciplinary measures (e.g. warning, denial of promotion). #### 6. Protected information facts The following reported violations are protected: - criminal offenses such as fraud, theft/embezzlement, violations of the Narcotics Act, bodily injury, physical abuse, corruption, sexual offenses, infidelity; - violations subject to fines, such as violations of occupational health and safety laws, health and safety regulations, which serve to protect employees; - data protection violations; - specifications on product safety and conformity, in particular on quality and safety standards for organs and substances of human origin such as umbilical cord blood or umbilical cord tissue. ** ** Further infringements for which information can be provided can be found in the list in Art. 2 (1) of EU Directive 2019/1937 and the national requirements. #### 7. Data protection When receiving and processing non-anonymous reports, personal data is collected, processed and stored by the internal reporting office. In this respect, the internal reporting office acts independently and without instructions as “responsible bodies within the meaning of data protection law”. The internal reporting office is obliged to comply with all data protection regulations. #### 8. Implementation of the notification procedure After receipt of the notification: - the reporting office confirms receipt of the report to the whistleblower within 7 days; - the reporting office checks whether it is a relevant and legally protected violation; - if necessary, the reporting office will obtain further relevant information from the whistleblower; - the reporting office informs the whistleblower of non-anonymous reports about the processing of their personal data. As a measure, the Reporting Office can: - have an internal investigation initiated and carried out by the responsible internal department; - refer the whistleblower to another competent body; - hand over the proceedings to a competent authority. The procedure is concluded: - by providing feedback on planned and taken measures as well as the reasons, at the latest three months after receipt of the notification or at the latest 3 months and seven days after receipt of the notification; - without feedback, if this would compromise the investigation or the rights of the persons who are the subject of the report. As a rule, the documentation is deleted three years after completion of the procedure, unless longer-term storage is necessary and proportionate due to the requirements of the EU Whistleblower Directive, related national requirements or other legal regulations.   _*__The generic masculine terms used in this text are used solely to improve readability. They explicitly include all gender identities in a gender-neutral and non-judgmental way. No offense or sexism is intended._ --- --- title: "Data Privacy" url: "https://www.famicord.com/data-privacy-statement" lang: "en" type: "page" last_modified: "2025-02-05T10:41:48+00:00" translations: de: "https://www.famicord.com/data-privacy-statement" --- # Data Privacy # Data Privacy Policy ## Data Privacy Policy FamiCord AG In the following, we would like to inform you about the collection of personal data when you use our website and establish contact via the contact form, by e-mail or telephone. Personal data are all such data that refer to you in person, e.g. name, address, e-mail addresses, and user behavior. #### I. NAME AND CONTACT DETAILS OF CONTROLLER AND DATA PROTECTION OFFICER 1. Controller pursuant to article 4, section 7 of the General Data Privacy Regulation (GDPR) is FamiCord AG, Perlickstraße 5, 04103 Leipzig, Germany;  T: +49 (0)341 48792- 5500 F: +49 (0)341 48792-20,  E-mail: info@famicord.com.de (see our [imprint](https://www.famicord.com/imprint)). 2. Our data protection officer is available for contact by e-mail: [kroesch@slk-compliance.de](mailto:kroesch@slk-compliance.de) or at the address: SLK Compliance Services GmbH, attn. Christian Krösch, Königsbrücker Straße 76, 01099 Dresden. #### II. GENERAL INFORMATION ON THE COLLECTION, TRANSFER, AND MAXIMUM STORAGE TIME OF PERSONAL DATA 1. We process your personal data in compliance with the provisions as specified in the EU GDPR, the Federal Data Protection Act (BDSGneu) and all other applicable laws (e.g. German Broadcast Media Act). 2. First and foremost, data processing serves to establish and fulfil a contractual relationship with you. When you contact us by e-mail, via a contact form or by telephone, the data you provide us with (your e-mail address, your name, your address, your phone number, and, if available, your calculated date of delivery) will be stored to answer your questions. The prior legal basis for this is article 6, section 1b) GDPR. In addition, your separate consent pursuant to article 6, section 1a GDPR may be obtained, if necessary, to comply with the requirements under data privacy law. The data obtained in this connection will be deleted, when their storage is not required anymore or restrict their processing, if record retention periods are required by law. 3. If we resort to commissioned service providers to fulfil individual functions of our offered services or want to use your data for commercial purposes, we will inform you about the respective procedures as specified below, also indicating the criteria defined for the maximum storage time. 4. Your personal data will not be passed onto third parties for other than the purposes given below. We pass your data onto third parties only, if you gave your express consent to such pursuant to article 6, section 1, clause a) GDPR, transmission is required to pursue, exercise, or defend legitimate interests pursuant to article 6, section 1, clause f) GDPR and there is no reason to assume that you have a predominantly legitimate interest in not passing your data on, in case the transmission is necessary to comply with a legal obligation pursuant to article 6, section 1, clause c) GDPR as permitted by law and if necessary to perform a contract with you pursuant to article 6, section 1, clause b) GDPR. We do not intend to pass your data onto a recipient in a third country (non-member state of EU/EEA) or an international organization. 5. We will delete your personal data, when they are not needed anymore for the intended purposes. After termination of the contract, your personal data will be stored for the period stipulated by law. This follows regularly from legal obligations to produce supporting documents and obligations to retain data specified in the German Commercial Code or the German Medicinal Products Act and other documents. Accordingly, the storage periods are up to ten years for accounting data and up to 30 years for data concerning medical findings. Personal data may be furthermore stored for the period, in which claims against us can be asserted. #### III. COLLECTION OF PERSONAL DATA ON OUR WEBSITE **1. Our website** 1.1 When you use the website for information purposes only, i.e. you do not register or submit information otherwise, we collect only those personal data that your browser transmits to our server. When you want to view our website, we collect data that are technically necessary for us to show you the website and to ensure its stability and safety. The data are also stored in the system log files. Such data will not be stored together with other personal user data. Such data include the IP address, date and time of inquiry, time zone difference to Greenwich Mean Time (GMT), content of inquiry (specific page), access status/http status code, respectively transmitted data amount, website of inquiry, browser, operating system and its surface and language as well as version of browser software. 1.2 The legal basis of storing the data and log files temporarily is article 6, section 1, clause f) GDPR. 1.3 The system needs to store the IP address temporarily to enable the delivery of the website to your browser. For this purpose, your IP address must remain stored until the end of the session. It is stored in log files to ensure that the website operates correctly. Furthermore, the data serve to optimize the website and to ensure the safety of our IT systems. These aims constitute our legitimate interest in data processing pursuant to article 6, section 1, clause f) GDPR. The data will not be analyzed for marketing purposes in this connection. 1.4 The data will be deleted, when they are not necessary anymore to fulfil the purpose of their collection. In the case of collecting the data to provide the website, this is when the respective session has ended. Log files will be deleted within seven days after you accessed the website. 1.5 Collecting data when you visit the website and storing the data in log files is compulsory to operate the website. You have therefore no right to object whatsoever. Among other data, the following will be collected: name of website, file, date, amount of data, web browser, and version of web browser, operating system, domain name of your internet provider, the so-called referrer URL (the site from which you accessed our website), and the IP address. Without these data, it would be technically impossible to some extent to provide and represent the website contents. Therefore, collecting data is compulsory. Furthermore, we use the anonymous information for statistical purposes. They help us to optimize our offer and our technology. In addition, we reserve the right to check the log files retroactively, if we suspect that our offer was used unlawfully. **2. ****Use of cookies** 2.1 When you use our website, cookies will be stored on your computer system. Cookies are text files stored on the internet browser or by the internet browser on your computer system. When you access a website, a cookie may be stored on your operating system. This cookie contains a characteristic string of characters, allowing for distinct identification of the browser when you access the website again. This website uses the following types of cookies, the scope and function of which will be explained in the following: - Transient cookies (temporary use) - Persistent cookies (unlimited use) - Third-party cookies (by third-party providers according to separate information). 2.3 Transient cookies will be deleted automatically, when you close the browser. They are usually session cookies, which store a so-called session ID in order to assign different inquiries from your browser to the joint session. Thereby, your computer can be recognized, when you return to our website. Session cookies will be deleted, when you log off or exit the browser. The legal basis of processing personal data applying transient cookies is article 6, section 1, clause f) GDPR. The purpose of applying cookies is to make using the website easier for you. Some of the website functions cannot be provided without applying cookies. They require recognition of the browser after you switched pages. These aims constitute our legitimate interest in processing personal data pursuant to article 6, section 1, clause f) GDPR. 2.4 We use persistent cookies exclusively in connection with the web analysis services we apply and only as long as the purpose requires; their lifetime is two years maximum. You can delete the cookies at any time in the safety settings of your browser. In that case, functions and user-friendliness of the website may be limited. The legal basis of processing personal data applying persistent cookies is article 6, section 1, clause f) GDPR. Analysis cookies are used to improve the quality of our website and its contents. Analysis cookies provide us with information on how the website is used and thus help us in optimizing our offer. These aims constitute our legitimate interest in processing personal data pursuant to article 6, section 1, clause f) GDPR. 2.5 Cookies, which are not technically required to provide our service, are set only with your consent, which you may withdraw at any time. You agree to the use of cookies by continuing to use the website and the respective setting in the browser settings enabled within the bounds of this data privacy statement. You can give us your consent by setting your browser accordingly, e.g. by defining that you will be informed about cookies being set and them being accepted only after you expressly agreed. You can also define that cookies will be accepted in certain cases or in general. You can configure your browser settings accordingly at your own options and e.g. control the acceptance or rejection of third-party cookies or all cookies. Please note though that you may then not be able to use all functions of this website. The legal basis of processing personal data applying cookies for analysis purposes is article 6, section 1, clause a) GDPR, if the user gives his or her consent. ** 3.** **Other functions and offers of our website** 3.1 In addition to the merely informational use of our website, we offer various services you can use, if you want to. For this purpose, you usually have to enter further personal data, which we use to provide the respective service and to which the principles of data processing as given above apply. 3.2 To some extent, we resort to third-party service providers to process your data. We chose and assigned them carefully, they are bound by our instructions and will be inspected regularly. 3.3 We may furthermore pass your personal data onto third parties, when we offer the participation in sales campaigns, competitions, conclusions of contracts, or similar services in collaboration with partners. You will be provided with further information in this regard, when you indicate your personal data or below in the description of the respective service. 3.4 If our service providers or partners are officially registered in a country outside the European Economic Area (EEA), we will inform you about the consequences of this fact in the description of the respective service. ** 4.** **Use of contact forms** 4.1 We will collect further personal data only, if you provide them of your own accord in our contact forms. In that case, we will collect the information provided in the course of establishing contact. These are in particular names and submitted contact details, date and occasion of contacting. We will use your collected personal data only to the purpose of providing you with the requested products or services (legal basis article 6, section 1 b) GDPR) or to other purposes, to which you gave your consent (legal basis article 6, section 1 a) GDPR) and which are described in the present data privacy statement. You may give your consent, e.g. to set cookies by third parties or to web tracking by those, in the corresponding technical browser settings. You have the possibility to withdraw your consent to the processing of personal data at any time. 4.2 The data will be deleted, when they are not necessary anymore to fulfil the purpose of their collection. With regard to the personal data from the input mask of the contact form, this is the case, when the respective conversation with you has ended. The conversation has ended, when we can assume from the circumstances that the concerned issue has been settled finally. If the provided data are subject to obligations to retain data under tax or commercial law, they will be stored for the defined time of retention of ten years and deleted afterwards, unless you agreed to storage exceeding such time.  **5.** **Integration of social media plug-ins** 5.1 At present, we integrate the following social media plug-ins: Facebook, Xing, LinkedIn. The social networks are operated exclusively by third parties, some of whom are officially registered outside the EU or the EEA – the data privacy level pursuant to§§ 4b, 4c BDSG may therefore possibly be inadequate. The browser plug-ins and links are identified by means of icons or other references on our website. When you visit websites containing such browser plug-ins, a connection between your device (browser) and the servers of the respective social network is established automatically, thus passing the information that you visited our website onto the social network. The visit to our website will then, if you are logged into your personal user account in the social network or log in during your visit to our website, be assigned to your account. Interacting with browser plug-ins or links, e.g. by pressing a “Like” button or leaving a comment, transmits the information to the respective social network, where they are saved. You can prevent the assignment of data to your account on the one hand by logging out of your account (in the respective social network) before you visit our website. On the other hand, you can prevent the respective plug-ins from being loaded at all by applying a browser add-on, e.g. by implementing the script blocker “NoScript” (http://noscript.net/). 5.2 For the purpose and scope of data collection by social networks as well as the further processing and use of such data and your rights in this regards as well as setting options to protect your privacy, please refer to the respective data privacy statements of the providers: Facebook: [https://www.facebook.com/policy.php** ](https://www.facebook.com/policy.php)Facebook Inc., 1601 Willow Road, Nelo Park, CA 94025, USA XING: [https://www.xing.com/privacy ](https://www.xing.com/privacy)XING AG, Dammtorstraße 29-32, 20354 Hamburg, Deutschland LinkedIn: [https://www.linkedin.com/legal/privacy-policy ](https://www.linkedin.com/legal/privacy-policy)LinkedIn Corporation, 2029 Stierlin Court, Mountain View, CA 94043, USA 5.3 On our website, we also use the “visitor action pixel” by Facebook Inc. 1601 S. California Ave, Palo Alto, CA 94304, USA (“Facebook”) This way, the user behavior is tracked, when users were forwarded to the website of the provider after clicking a Facebook ad. This method serves to analyze the effectiveness of Facebook ads for statistical and marketing purposes and may help to optimize future advertisement campaigns. The data collected are anonymous to us and do not provide us with any reference to the user identity. However, the data are stored and processed by Facebook, so that the association to the respective user profile is possible and Facebook can use the data for its own marketing purposes in accordance with the Facebook data usage policy. You can allow Facebook and its partners to place ads on and off Facebook. A cookie may also be stored on your computer for these purposes. Consent to the implementation of the visitor action pixel may be declared only by users older than 13 years. If you are younger, please ask your parents or legal guardian for permission. Click here to withdraw your consent. ** 6. **Integration of Google Maps** 6.1 On our website, we use Google Maps, a service offered by Google LLC. Thus, we are able to show you interactive maps directly on the website and allow you to conveniently use the map feature. The legal basis of using Google Maps is article 6, section 1, clause f) GDPR. 6.2 By visiting the website, Google receives the information that you have accessed the corresponding subpage of our website. In addition, the data referred to in section III. 1. of this statement will be transmitted. This happens irrespective of whether you have a Google user account, to which you are logged in, or not. When you are logged into Google, your data will be allocated directly to your account. If you do not wish to be associated with your Google profile, you have to log out before activating the button. Google stores your data in usage profiles and uses them for purposes of advertising, market research and/or tailor-made design of its website. Such analysis will be carried out in particular (even for users who are not logged in) to provide tailored advertising and to inform other users about your activities on our website. You have the right to object to the formation of such user profiles. To exercise this right, you have to contact Google. 6.3 For further information on the purpose and scope of Google’s data collection and data processing, please refer to the supplier’s privacy policy. You will also find more information about your rights in this regard and privacy settings at: http://www.google.de/intl/de/policies/privacy. Google also processes your personal data in the United States and has submitted to the EU-US Privacy Shield [www.privacyshield.gov/EU-US-Framework](https://www.privacyshield.gov/EU-US-Framework).** Opt-Out: [https://adssettings.google.com/authenticated](https://adssettings.google.com/authenticated) **7.** Use of our online shop** 7.1 If you want to order from our online shop, it is necessary for the conclusion of the contract that you enter the personal data required to process your order. Compulsory data required to process the order are marked specifically; other data are optional. The legal basis of processing such personal data is article 6, section 1, sentence 1, clause b) GDPR. 7.2 Optionally, you can set up a customer account, which we use to store your data for other future purchases. When you create an account after clicking “Register”, the data you enter will be stored. Such storage may be revoked. The legal basis of processing such personal data is article 6, section 1, sentence 1, clause b) GDPR. 7.3 Your address, payment, and order data will be stored for ten years after the contract was processed subject to obligations to retain data under tax or commercial law and deleted afterwards, unless you agreed to storage exceeding such time or further data processing is required to assert, exercise, or defend legal claims. The legal basis for the processing of personal data to the purpose of complying with the archiving and retention obligations provided by law is article 6, section 1, sentence 1, clause c) GDPR. 7.4 We will process the data you entered in order to handle your order. For this purpose, we possibly forward your data to our main bank as well as to logistics companies and the provider of payment services you chose. We are entitled to forwarding such personal data pursuant to article 6, section 1, sentence 1, clause b) GDPR. Our service providers may process and use your data only for the purpose, the fulfilment of which the data were forwarded to them for. You can access the data at any time. As far as data are passed onto external service providers, we make sure that the data privacy regulations are complied with through technical and organizational measures. 7.5 You are not obligated to provide the above given personal data. The data given are required to conclude a contract. Without providing the data, communication, conclusion of a contract, or processing of the contract may be impossible. ** 8. ****Newsletter** 8.1 By giving your consent, you may subscribe to our newsletter to inform you about our latest interesting offers. The advertised goods and services will be specified in the declaration of consent. 8.2 The registration for our newsletter follows the so-called double-opt-in procedure. That means, after the registration, we will send you an e-mail to the given e-mail address, asking you to confirm your subscription to the newsletter. If we do not receive the confirmation within 24 hours, we will block your information and delete it after one month. Furthermore, we store the IP addresses you used, the time of registration, and the time of the confirmation. The purpose of this procedure is to prove your registration and, if necessary, to be able to resolve the possible misuse of your personal data. The legal basis is article 6, sections 1 a) and c), article 7, section 1 GDPR. 8.3 The only compulsory indication we need for the delivery of the newsletter is your e-mail address. Other, separately marked data are optional and used to be able to address you personally. After your confirmation, we store your e-mail address with the purpose of sending you the newsletter. The legal basis is article 6, section 1, clause a) GDPR. The data will be deleted, when they are not necessary anymore to fulfil the purpose of their collection. Accordingly, the e-mail address of the user will be stored as long as the subscription to the newsletter is active. 8.4 You can revoke your consent to the delivery of the newsletter at any time and unsubscribe from the newsletter. You can declare the revocation by clicking the link provided in each newsletter e-mail or by sending a message to the contact details stated in the imprint. 8.5 The newsletter will be delivered by the newsletter service provider CleverReach GmbH & Co. KG, Mühlenstr. 43, 26180 Rastede, Germany. For the data privacy policy of the service provider, please refer to: [www.cleverreach.com/de/datenschutz/](https://www.cleverreach.com/de/datenschutz/). The newsletter service provider is assigned on the basis of our legitimate interests pursuant to article 6, section 1, clause f GDPR and a commissioned data processing agreement pursuant to article 28, section 3, sentence 1, clause 1 GDPR. The newsletter service provider may use the recipients’ data in pseudonymous form, i.e. without assignment to users, to optimize or improve its own services, e.g. for technical optimization of the delivery and representation of newsletters, or for statistical purposes. The newsletter service provider, however, shall not use the data of our newsletter recipients to contact them or forward the data to third parties. **9.** **Use of Google Analytics** 9.1 On our website, we use Google Analytics, a web analytics service provided by Google Inc. (”Google“). Google Analytics uses so-called “cookies”, text files saved on your computer and allowing for the analysis of your website usage. The information generated by the cookie about your usage of the website will be transmitted to and stored by Google on servers in the United States. If the IP anonymizer is active on this website, your IP address will shortened beforehand by Google in the member states of the European Union and in other contracting states of the EEA Agreement. Only in exceptional cases will the full IP address be transferred to Google servers in the USA and shortened there. By order of the website operator, Google will use this information for the purpose of evaluating your use of the website, compiling reports on website activity for website operators and providing other services relating to website activity and internet usage. 9.2 Within the scope of Google Analytics, Google will not associate your IP address submitted by your browser with any other data held by Google. 9.3 You may prevent the storage of cookies by selecting the appropriate settings in your browser software, however, please note that, when you do this you may not be able to use the full functionality of this website. You can furthermore prevent the collection of the data generated by cookies and related to your website usage (including your IP address) and them being sent to and processed by Google by downloading and installing the following browser plug-in: [http://tools.google.com/dlpage/gaoptout?hl=de](http://tools.google.com/dlpage/gaoptout?hl=de). Sie können die Erfassung durch Google Analytics verhindern, indem Sie auf folgenden Link klicken. Es wird ein Opt-Out-Cookie gesetzt, das die zukünftige Erfassung Ihrer Daten beim Besuch dieser Website verhindert: [**Google Analytics deaktivieren**](https://devstage.vita34.de/en/data-privacy/) 9.4 This website uses Google Analytics with the extension “_anonymizeIp()”.As a result, IP addresses will be further processed in shortened form, thus excluding reference to persons. If the data collected about you have a personal reference, this will be excluded promptly and the personal data deleted immediately. 9.5 5 We use Google Analytics to analyze the usage of our website and be able to improve it on a regular basis. We can improve our offer and make it more interesting for users by means of the obtained statistics. Regarding the exceptional cases, in which personal data are transmitted to the USA, Google has submitted to the EU-US Privacy Shield EU-US Privacy Shield, [www.privacyshield.gov/EU-US-Framework](https://www.privacyshield.gov/EU-US-Framework). The legal basis of using Google Analytics is article 6, section 1, clause f) GDPR. 9.6 For information on the third-party provider, please refer to: Google Dublin, Google Ireland Ltd., Gordon House, Barrow Street, Dublin 4, Ireland, Fax: +353 (1) 436 1001, terms of use: [www.google.com/analytics/terms/de.html](http://www.google.com/analytics/terms/de.html), data privacy: [www.google.com/intl/de/analytics/learn/privacy.html](http://www.google.com/intl/de/analytics/learn/privacy.html) and the data privacy policy: [www.google.de/intl/de/policies/privacy](http://www.google.de/intl/de/policies/privacy.). 9.7 The website uses Google Analytics furthermore to carry out cross-device analysis of visitor traffic via the user ID. You can disable the cross-device analysis of your usage in your customer account in “My data”, “Personal data”. ** 10. ****Online conferences, meetings, and webinars** 10.1 We use platforms and applications of other providers (hereinafter referred to as “third-party providers”) for the purpose of conducting video and audio conferences, webinars and other types of video and audio meetings. When selecting third-party providers and their services, we comply with the legal requirements. In this context, data of the communication participants are processed and stored on the servers of third-party providers, as far as they are part of communication processes with us. Such data may include, in particular, registration and contact data, visual and vocal contributions, as well as entries in chats and shared screen content. We provided the use of the third-party providers has been agreed in this context. Otherwise, the user data will be collected on the basis of our legitimate interests. In this context, please refer additionally to the information on the use of cookies in this privacy policy. - Purposes of the processing: Contractual and other services, contact requests and communication, office and organizational procedures - Legal foundation: Consent (art. 6 sec. 1 clause 1 (a) GDPR), performance of the contract and precontractual requests (art. 6 sec. 1 clause 1 (b) GDPR), legitimate interests (art. 6 sec. 1 clause 1 (f) GDPR) Services and service providers used: - Cisco WebEx: Konferenz-Software; Dienstanbieter: Webex Communications Deutschland GmbH, Hansaallee 249, c/o Cisco Systems GmbH, 40549 Düsseldorf, Mutterunternehmen: Cisco Systems, Inc. 170 West Tasman Dr., San Jose, CA 95134, USA; Website: [https://www.webex.com/de](https://www.webex.com/de); Datenschutzerklärung: [https://www.cisco.com/c/de_de/about/legal/privacy-full.html](https://www.cisco.com/c/de_de/about/legal/privacy-full.html) (Gewährleistung Datenschutzniveau bei Verarbeitung von Daten in den USA): ** 11.** **Collection, processing, and use of personal data when using and registering via our mobile apps** 11.1 If you want to make use of the services of our mobile apps via the smartphone to have one of our products available when you are on the go, such data will be collected, processed and used that are necessary to use the functions of the respective mobile app. This applies in particular to the “Our baby” mobile app, which processes personal data. Because of the sensitivity of such data, it is absolutely necessary that you protect your device from access by others and make sure that unauthorized third parties cannot take note of such data, while you use the app. 11.2 The (personal) data you enter to use the mobile app will be stored and processed at data processing centers of our provider. The provider will use the data only to provide the services. These include in particular maintenance and repair works. When such works are carried out, we cannot exclude in individual cases that provider’s or sub-contractors’ employees may take note of your (personal) data. 11.3 Please note that it is possible that exact position data will be obtained, used, and passed on, when you use our products, internet offers, and services on so-called mobile devices (smartphones, mobile phones, tablet PCs, etc.), including the geographic position of your mobile device. In addition, further data may be obtained, processed, and used as specified in the terms of use of your provider of telecommunication services. **12. ****Data security** 12.1 During visits to our website, we use the common SSL technology (Secure Socket Layer) in connection with the respectively highest encryption level supported by your browser. This is usually the 256-bit encryption. If your browser does not support 256-bit encryption, we resort to the 128-bit v3 technology. You can recognize, whether an individual page of our internet presence is transmitted in an encrypted manner, by the closed lock symbol in the status bar of your browser. 12.2 We take suitable technical and organizational safety measures to protect your data from accidental or intentional manipulation, loss in parts or in whole, destruction, and unauthorized access by third parties. We improve our safety measures continuously to keep up with the technological development. #### IV. COLLECTION OF PERSONAL DATA IN CASE OF CONTACT BY E-MAIL, MAIL, AND BY TELEPHONE **1. Collection of personal data of customers, prospective customers, and suppliers** 1.1 We collect your personal data as a customer, prospective customer, or supplier only, if you provide them of your own accord by e-mail, mail, or telephone. In that case, we will collect the information provided in the course of establishing contact. These are in particular names and submitted contact details, date and occasion of contacting. We will use your collected personal data only to the purpose of providing you with the requested products or services (legal basis article 6, section 1 b) GDPR) or to other purposes, to which you gave your consent (legal basis article 6, section 1 a) GDPR) and which are described in the present data privacy statement. You have the possibility to withdraw your consent to the processing of personal data at any time. 1.2 You are not obligated to provide the personal data given above. The data given are required to conclude a contract. Without providing the data, communication, conclusion of a contract, or processing of the contract may be impossible. 1.3 The data relevant to the individual case will be passed on in line with the provisions of the law or an agreement to public authorities, in the event that other legal provisions prevail, to external service providers or other sub-contractors, if you gave your express consent to such or the transmission is permitted for predominantly legitimate interests. We do not intend to pass your data onto a recipient in a third country (non-member state of EU/EEA) or an international organization. 1.4 The data will be deleted, when they are not necessary anymore to fulfil the purpose of their collection. With regard to the personal data provided, this is the case, when the respective conversation with you has ended. The conversation has ended, when we can assume from the circumstances that the concerned issue has been settled finally. If the provided data are subject to obligations to retain data under tax or commercial law, they will be stored for the defined time of retention of ten years and deleted afterwards, unless you agreed to storage exceeding such time or further data processing is required to assert, exercise, or defend legal claims. The legal basis of the processing of personal data to the purpose of complying with the archiving and retention obligations provided by law is article 6, section 1, sentence 1, clause c) GDPR. **2. Collection of personal data of applicants** 2.1 We collect your personal data as an applicant only, if you provide them of your own accord by e-mail, mail, or telephone. This applies to applications for job advertisements and to unsolicited applications. We will collect the data provided within the scope of the application, in particular including name, date of birth, contact details, interests, qualification details as well as details of education and career. The personal data collected will be used only to the purpose of handling the application procedure (legal basis article 6, section 1, clauses a), b), and f) GDPR, § 26 BDSG). 2.2 You are not obligated to provide the personal data given above. The data given may be required to conclude a contract after the application procedure has ended. Without providing the data, communication, handling of the application procedure or the conclusion of a contract may be impossible. 2.3 The data relevant to the individual case will be passed on in line with the provisions of the law or an agreement. The data will be passed onto employees of the human resources department, employees of the management, and the respective head of department. Your personal data will not be passed onto third parties. We do not intend to pass your data onto a recipient in a third country (non-member state of EU/EEA) or an international organization. 2.4 The data will be deleted, when they are not necessary anymore to fulfil the purpose of their collection. Therefore, we will store the data after the application procedure has ended, if you were rejected for six months after you were notified of the rejection. If you agreed to storage for a longer time, the data will be stored for two years. Then, we will either delete your data or obtain your consent to storage again. You have the possibility to withdraw your consent to the processing of personal data at any time. #### V. OBJECTION TO OR REVOCATION OF CONSENT TO DATA PROCESSING 1. If you have given consent to the processing of your personal data, you can revoke it at any time. Such revocation does not affect the lawfulness of the processing carried out on the basis of the consent given until the revocation. 2. Insofar as we base the processing of your personal data on the balance of interests, you can object to the processing. This is the case, if the processing is not required to fulfil a contract concluded with you, which we explain in the respective description of the functions. When you exercise such an objection, we ask you to explain the reasons why we should not process your personal data as we have done. In case of your justified objection, we will examine the situation and will either discontinue or adapt the data processing or explain to you our imperative legitimate grounds on which we continue the processing. 3. You may object to the processing of your personal data for advertising and data analysis purposes at any time. You can notify us about your objection to advertising through the following contact details: Famicord AG Perlickstraße 5, 04103 Leipzig Telefon: +49 (0)341 48792-0 Telefax: +49 (0)341 4879-20 E-Mail: [info@famicord.com](mailto:info@famicord.com) #### VI. YOUR RIGHTS 1. Pursuant to article 15 GDPR, you have the right to request information about your personal data processed by us. In particular, you may request information about the purposes of processing, the categories of recipients to whom we disclose or disclosed your data, the planned storage time, the existence of the right to rectification, deletion or restriction of the processing or to objection, the existence of the right to claim, the origin of the data, if they were not collected by us, as well as on the existence of automated decision-making including profiling and, if necessary, significant information on the relevant details. 2. Pursuant to article 16 GDPR, you have the right to request the prompt correction of incorrect personal data or completion of incomplete personal data that are stored by us. Pursuant to article 17 GDPR, you have the right to request deletion of your stored personal data, unless the processing is required to exercise the right to freedom of expression and information, to comply with a legal obligation, for reasons of public interest or to assert, exercise or defend legal claims. 3. Pursuant to article 18 GDPR, you have the right to restrict the processing of your personal data, if you contest the accuracy of the data, processing is unlawful, but you oppose the erasure of the data and we do no longer need the data, but you require them to assert, exercise or defend legal claims or you have objected to processing pursuant to article 21 GDPR. 4. Pursuant to article 20 GDPR, you have the right to receive your personal data that you provided to us in a structured, commonly used and machine-readable format or to request the transmission of the data to another controller. 5. Pursuant to article 7, section 3 GDPR, you have the right to withdraw your once given consent at any time. The consequence will be that we are not permitted to continue the data processing based on this consent as before. 6. Furthermore, pursuant to article 77 GDPR, you have the right to lodge a complaint concerning the processing of your personal data by us with a supervisory authority, e.g. with the competent Saxon data protection officer: Sächsischer Datenschutzbeauftragter, Bernhard-von-Lindenau-Platz 1, D-01067 Dresden, telephone: +49 (0)351 / 49 3-5401, e-mail: [saechsdsb@slt.sachsen.de](mailto:saechsdsb@slt.sachsen.de). --- --- title: "Imprint" url: "https://www.famicord.com/imprint" lang: "en" type: "page" last_modified: "2026-03-24T09:04:57+00:00" translations: de: "https://www.famicord.com/imprint" --- # Imprint # Imprint ### Editorial office and administration **FamiCord AG** Perlickstraße 5 04103 Leipzig Germany T: +49 341 487 92 – 5500 F: +49 341 487 92 – 20 info@famicord.com **Chairman of the Supervisory Board:** Dr. Peter Greiner **Management Board:** Jakub Baran (CEO), Thomas Pfaadt (CFO), Dr. Cornelia Wittke-Kothe (CCO), Tomasz Baran (CMO) Registered in the Commercial Register: HRB 20339 Amtsgericht (Local Court) Leipzig Sales tax ID: DE 239 733 620 ### Disclaimer We do not assume any liability whatsoever for the correctness, completeness, currentness, or quality of the data and information provided on this website. Any liability whatsoever for material or immaterial damages of any kind caused by the use of the provided data or by the use of incorrect or incomplete information shall be excluded, unless wilful or grossly negligent misconduct on our part is demonstrably available. We expressly reserve the right of changing the data provided on our website or our entire offer at any time without prior notice. We are also entitled to supplement or delete this website at any time or to suspend its publication temporarily or finally. ### Links If links, which are beyond our responsibility, are directly or indirectly referred to on this website, liability on our part shall come into question only if we knew about the contents and it would have been technically feasible and reasonable for us to prevent their use in case of unlawful contents. We expressly declare that we have no influence whatsoever on design and content of the linked pages. Therefore, we distance ourselves expressly from all contents on pages linked to this website. We do not adopt these contents as our own and exclude any liability whatsoever in this regard. We also declare that we do not know about any forbidden contents on the linked pages. Furthermore, the reference or non-reference of links and their order does not represent any kind of appreciation or depreciation. This shall not affect the possible liability of the provider of the linked page for its content and in particular damages resulting from the use or disuse of the provided data and information. The aforementioned restrictions shall also apply to third-party entries made in the provided guest books, forums, and mailing lists. ### Copyrights/trademark rights We shall be exclusively entitled to any rights to objects, graphics, sound recording, video sequences, and texts. It is forbidden to copy or use such objects, graphics, sound recording, video sequences, and texts in other electronic or printed publications without our express prior consent. The owners of the respective trademarks shall be solely entitled to any trademark rights to trademarks named on this website or the linked pages. ### Eligibility requirements for FamiCord customer recommendation **Eligibility requirements (valid since April 1, 2014)** A recommendation is successful, if the parents you informed conclude one of the contract variants VitaPlus or VitaPlusCord with FamiCord on the stem cell storage of a newborn. This applies only interested to persons, who are not yet registered as customer or sales lead with FamiCord. A contract that is cancelled shall not be regarded as a successful recommendation. If interested persons are recruited several times, only the person who recommended them at first (as registered with FamiCord) will get the premium. FamiCord agrees to grant the recommending party a bonus and the interested party a discount on the contract fee for VitaPlus or VitaPlusCord of 100 Euro each in case of a successful recommendation. The bonus cannot be cashed or offset against possibly arising cancellation fees. Only one premium is credited per stem cell storage. This campaign cannot be combined with other discounts/vouchers/offers. ### Picture Credits All images have been licensed on shutterstock, fotolia, iStockphoto, getty images, clip Dealer and Photocase. This does not include images of pixelio, here you will find the image detection at each side end. ### Online Dispute Resolution We participate in a dispute resolution procedure before a consumer arbitration board. The universal arbitration board of the Zentrum für Schlichtung e.V., Straßburger Straße 8, 77694 Kehl am Rhein ([https://www.verbraucher-schlichter.de](https://www.verbraucher-schlichter.de)) is responsible. --- --- title: "Other Options for Cord Blood Banking" url: "https://www.famicord.com/services-for-families/other-options-for-cord-blood-banking" lang: "en" type: "page" last_modified: "2025-04-16T12:26:17+00:00" translations: de: "https://www.famicord.com/services-for-families/other-options-for-cord-blood-banking" custom_fields: display_availability_of_our_service_section: 1 --- # Other Options for Cord Blood Banking # Stem Cells Banking for Society At FamiCord, we believe in the future of medicine and the power of stem cells. Umbilical cord blood is a natural source of specialized stem cells and offers a unique opportunity to protect a child’s health and potentially help others. That is why we offer various options for storing umbilical cord blood, tailored to the needs of families. Please note that our services may vary from country to country due to different regulatory requirements. ## Private Storage of Umbilical Cord Blood – Security for Your Child The private storage of umbilical cord blood is an investment in your child’s future health. The umbilical cord blood, along with the stem cells it contains, remains exclusively available for your child. Ownership rights belong to your child or, until they reach adulthood, to you. The specific details of our service may vary by country. For more information, please visit the pages of FamiCord partner companies in your region. [ See list of countries ](#regions) ![jonathan-borba-RWgE9_lKj_Y-unsplash](https://www.famicord.com/wp-content/uploads/2025/01/jonathan-borba-RWgE9_lKj_Y-unsplash.webp) ### Targeted Storage as a Family Donation This program supports families in which a child suffers from a severe illness that can be treated with a stem cell transplant. If the family is expecting another child, the newborn’s umbilical cord blood can be stored free of charge for the sick child.   The only costs incurred by the family are a portion of the processing fee and storage costs if the blood is preserved for an extended period. The specific details of our service (e.g., duration of free storage or the amount of the processing fee) may vary by country. For more information, please visit the pages of FamiCord partner companies in your region. [ See list of countries ](#regions) ## Public Umbilical Cord Blood Donation – Saving Lives by Sharing As a socially responsible company, we operate public umbilical cord blood banks and finance them as part of a CSR initiative. Parents who decide against private storage have the option in certain regions to donate their baby’s umbilical cord blood. The goal of this initiative is to increase the availability of stem cell donations and thus make potentially life-saving treatments more accessible to unrelated patients. ![parents-kv](https://www.famicord.com/wp-content/uploads/2024/12/parents-kv.webp) ### Hybrid Storage of Umbilical Cord Blood – Flexibility for Families Hybrid storage of umbilical cord blood combines private health care with the possibility of public donation. Parents can store their child’s umbilical cord blood for personal use while also offering others a potential treatment opportunity. The specific details of our service may vary by country. For more information, please visit the pages of FamiCord partner companies in your region. [ See list of countries ](#regions) ## Education and Responsibility – Our Mission At FamiCord, we are committed to raising awareness about the medical significance of umbilical cord blood. Our long-term goal is to educate families and the public about the life-saving potential of stem cells, enabling them to make well-informed decisions. --- --- title: "Stellenangebote" url: "https://www.famicord.com/career/career-with-famicord-germany/job-postings" lang: "en" type: "page" last_modified: "2025-02-04T09:12:15+00:00" translations: de: "https://www.famicord.com/career/career-with-famicord-germany/job-postings" --- # Stellenangebote # Stellenangebote --- --- title: "Contact" url: "https://www.famicord.com/contact" lang: "en" type: "page" last_modified: "2025-02-04T07:51:25+00:00" translations: de: "https://www.famicord.com/contact" --- # Contact # Contact # Contact us **We’re here to help and look forward to connecting with you!** #### FamiCord AG FamiCord AG Perlickstraße 5 04103 Leipzig Germany [ T:+49(0)341 48792 – 5500](tel:+49341487925500) [F:+49 (0) 34148792 – 20](tel:+493414879220) [info@famicord.com](mailto:info@famicord.com) ![Pill](https://www.famicord.com/wp-content/uploads/2025/01/Pill.webp) ![Pill](https://www.famicord.com/wp-content/uploads/2025/01/Pill.webp) I have read the [information on how my data are used](https://www.famicord.com/data-privacy-statement) and agree. FamiCord AG will not disclose my data to third parties.* The fields marked with * are obligatory. You need to fill them in before you send the form. Send now ![Pill (2)](https://www.famicord.com/wp-content/uploads/2025/01/Pill-2.webp) --- --- title: "News" url: "https://www.famicord.com/news" lang: "en" type: "page" last_modified: "2025-01-31T07:52:24+00:00" translations: de: "https://www.famicord.com/news" --- # News # FamiCord News ## FamiCord News Search: Go to section: [All](https://www.famicord.com/news) [2026](https://www.famicord.com/news/category/2026) [2025](https://www.famicord.com/news/category/2025) [2024](https://www.famicord.com/news/category/2024) [2023](https://www.famicord.com/news/category/2023) [2021](https://www.famicord.com/news/category/2021) [2020](https://www.famicord.com/news/category/2020) [2018](https://www.famicord.com/news/category/2018) [2017](https://www.famicord.com/news/category/2017) [2016](https://www.famicord.com/news/category/2016) [2015](https://www.famicord.com/news/category/2015) [2014](https://www.famicord.com/news/category/2014) [2013](https://www.famicord.com/news/category/2013) - 30 June 2026 FamiCord Advances Scientific Dialogue on Cell Therapies at EACD 2026 [ Read more ](https://www.famicord.com/famicord-advances-scientific-dialogue-on-cell-therapies-at-eacd-2026) - 06 May 2026 Cell Therapies – From Experiment to Standard of Care [ Read more ](https://www.famicord.com/cell-therapies-from-experiment-to-standard-of-care) - 02 April 2026 Autism Awareness Day: First FamiCord EAP Therapies Launched for ASD Patients [ Read more ](https://www.famicord.com/autism-awareness-day-first-famicord-eap-therapies-launched-for-asd-patients) - 17 November 2025 FamiCord Group Recognized as Europe’s Leading Stem Cell Bank FamiCord is the largest stem cell bank in Europe and the third largest in the world. The quality of its services is validated by international certifications, and the company has now been recognized as Europe’s Leading Stem Cell Bank by Life Sciences Review, highlighting its commitment to excellence, clinical reliability, and innovation in stem cell banking.FamiCord Group have been awarded as “The Europe’s Leading Stem Cell Bank” , independent experts jury underlined FamiCord has established itself as a leading provider in the field, guiding families through the collection, processing, and long-term preservation of cord blood and perinatal tissues. [ Read more ](https://www.famicord.com/famicord-group-recognized-as-europes-leading-stem-cell-bank) - 27 August 2025 Infantile cerebral palsy – Convincing evidence for the use of perinatal stem cells Leipzig, July 15, 2025 – Cerebral palsy (CP) continues to be one of the most common motor disabilities in childhood and is associated with permanent movement restrictions and spasticity. The therapeutic potential of stem cells from umbilical cord blood and tissue was discussed at the 37th Annual Meeting of the European Academy Of Childhood-onset Disabilities (EACD) and the 4th Meeting of the International Alliance of Academies of C hildhood Disability (IAACD) from June 24 – 28, 2025 in Heidelberg. As part of a symposium supported by FamiCord AG, international experts presented the current state of research and reported on the results from clinical practice. [ Read more ](https://www.famicord.com/infantile-cerebral-palsy-convincing-evidence-for-the-use-of-perinatal-stem-cells) - 03 June 2025 FamiCord Group’s Dubai Laboratory Earns Prestigious AABB Accreditation Dubai, UAE – [3.06.2025] – FamiCord Group, the largest cord blood bank in Europe, proudly announces that its state-of-the-art laboratory in Dubai has received the prestigious accreditation from the Association for the Advancement of Blood & Biotherapies (AABB) – a globally recognized standard of excellence in the field of cellular and blood banking services. [ Read more ](https://www.famicord.com/famicord-groups-dubai-laboratory-earns-prestigious-aabb-accreditation) []() [ 01 ]() [ 02 ](https://www.famicord.com/llms-full.txt/page/2) [ 03 ](https://www.famicord.com/llms-full.txt/page/3) … [ 05 ](https://www.famicord.com/llms-full.txt/page/5) [](https://www.famicord.com/llms-full.txt/page/2) --- --- title: "Sustainability (ESG)" url: "https://www.famicord.com/company/sustainability-esg" lang: "en" type: "page" last_modified: "2024-12-17T14:51:24+00:00" translations: de: "https://www.famicord.com/company/sustainability-esg" --- # Sustainability (ESG) --- --- title: "Supervisory Board" url: "https://www.famicord.com/company/supervisory-board-2" lang: "en" type: "page" last_modified: "2024-12-17T14:51:00+00:00" translations: de: "https://www.famicord.com/company/supervisory-board-2" --- # Supervisory Board --- --- title: "Supervisory Board" url: "https://www.famicord.com/company/supervisory-board" lang: "en" type: "page" last_modified: "2024-12-17T14:50:33+00:00" translations: de: "https://www.famicord.com/company/supervisory-board" --- # Supervisory Board --- --- title: "Management Board" url: "https://www.famicord.com/company/management-board" lang: "en" type: "page" last_modified: "2024-12-17T14:50:17+00:00" translations: de: "https://www.famicord.com/company/management-board" --- # Management Board --- --- title: "Financial Data" url: "https://www.famicord.com/company/financial-data" lang: "en" type: "page" last_modified: "2024-12-17T14:49:58+00:00" translations: de: "https://www.famicord.com/company/financial-data" --- # Financial Data --- --- title: "Company" url: "https://www.famicord.com/company" lang: "en" type: "page" last_modified: "2024-12-17T14:49:31+00:00" translations: de: "https://www.famicord.com/company" --- # Company --- --- title: "Career with FamiCord Germany" url: "https://www.famicord.com/career/career-with-famicord-germany" lang: "en" type: "page" last_modified: "2025-02-05T09:51:37+00:00" translations: de: "https://www.famicord.com/career/career-with-famicord-germany" --- # Career with FamiCord Germany # Career with FamiCord Germany ![join_our_team_we_are](https://www.famicord.com/wp-content/uploads/2024/12/join_our_team_we_are-1.webp) ## Career with FamiCord Germany Welcome to the careers page for Germany! We are pleased that you are interested in becoming part of our team. In Germany, we operate at three locations: At our headquarters with laboratory and sales in Leipzig, at our laboratory in Rostock and at our sales office in Munich. We are currently a team of around 130 people who are committed to enabling families to have a healthier future. ## At FamiCord, we not only offer an inspiring working environment, but also numerous benefits that support your health and well-being: ![Icon](https://www.famicord.com/wp-content/uploads/2024/12/g5564.svg) Company pension plan Save taxes and social security contributions and at the same time make provisions for the future. With the salary conversion promoted by the employer, you can e.g., save for a direct insurance policy and thus provide for your own financial future. ![Icon](https://www.famicord.com/wp-content/uploads/2024/12/arrows-up.svg) Capital-forming benefits We subsidise capital-forming benefits in the amount of 39.88 Euro per Month. These can be paid into a building savings contract, a fund or a pension plan. ![Icon](https://www.famicord.com/wp-content/uploads/2024/12/prevention.svg) Group accident insurance Various costs arising from private and occupational accidents, such as recovery costs, rehabilitation or cosmetic surgery, are covered. Surviving dependants receive support amounting to one year’s salary. ![Icon](https://www.famicord.com/wp-content/uploads/2024/12/privilege.svg) Company health insurance Enjoy the benefits of company dental insurance from the first day of your employment. ![Icon](https://www.famicord.com/wp-content/uploads/2024/12/Group.svg) Free drinks Free drinks such as coffee, water and tea. ![Icon](https://www.famicord.com/wp-content/uploads/2024/12/fruit-salad.svg) Fresh fruit Fresh fruit is offered to our employees free of charge. ![Icon](https://www.famicord.com/wp-content/uploads/2024/12/tax-free.svg) Tax-free benefits in kind After the probationary period, each employee receives a prepaid credit card to which 40 Euro per month is transferred as a tax-free benefit in kind and is therefore available on a net basis. After the probationary period, a further 40 Euro can be used for a job bike, job ticket or company pension scheme. ![Icon](https://www.famicord.com/wp-content/uploads/2024/12/Info-1.svg) If you want to help people maintain their health and ensure a healthy future, apply now and become part of our team!     [ Job advertisements ](https://famicord.com/career/employment-in-germany/job-postings) [ Contact us ](https://famicord.com/contact) --- --- title: "Career within the FamiCord Group" url: "https://www.famicord.com/career/career-within-the-famicord-group" lang: "en" type: "page" last_modified: "2025-03-07T13:42:42+00:00" translations: de: "https://www.famicord.com/career/career-within-the-famicord-group" --- # Career within the FamiCord Group # Career within the FamiCord Group ## Career within the FamiCord Group If you are interested in working with FamiCord, please select your country and contact us directly. Below you can see in which areas we are active in the respective countries. ![](https://www.famicord.com/wp-content/themes/starter-empressia/dist/images/icons/accessibility/touch-screen.webp) Country Departments Laboratory and medical Sales, marketing and customer service Administration and finance R&D and CDMO Contact Austria X [ vita.at ](https://www.vita34.at/) Czech Republic [ pupecnikovakrev.cz ](https://pupecnikovakrev.cz/) Germany X X X X [ famicord.com ](https://www.famicord.com/career/career-within-the-famicord-group) Hong-Kong X X X [ smartcells.com ](https://smartcells.com) Hungary X X X [ krio.hu ](https://krio.hu) Italy X X [ sorgente.com ](https://sorgente.com) Latvia X X [ nabassaite.lv ](https://nabassaite.lv) Poland X X X X [ pbkm.pl ](https://pbkm.pl) Portugal X X X X [ crioestaminal.pt ](https://crioestaminal.pt) Romania X X X [ biogenis.ro ](https://biogenis.ro) Slovakia [ cakam-babatko.sk ](https://cakam-babatko.sk) Spain X X X [ sevibe.es ](http://sevibe.es) Switzerland X X X [ famicord.ch ](https://famicord.ch) Turkey X X X X [ kordonkanibankasi.com ](https://kordonkanibankasi.com) United Arab Emirates X X X [ smartcells.ae ](https://smartcells.ae) United Kingdom X X X [ smartcells.com ](https://smartcells.com) --- --- title: "FamiCord Employees" url: "https://www.famicord.com/career/famicord-employees" lang: "en" type: "page" last_modified: "2025-02-20T14:20:15+00:00" translations: de: "https://www.famicord.com/career/famicord-employees" --- # FamiCord Employees # FamiCord Employees ![join_our_team_we_are](https://www.famicord.com/wp-content/uploads/2024/12/join_our_team_we_are-1.webp) ## Working at FamiCord Together for the health of tomorrow! At FamiCord, we combine scientific excellence with real passion – and have done so for more than 25 years. We are Europe’s leading stem cell bank and we work every day to make medical innovations based on stem cells accessible to families around the world. ## We are: - More than 750 employees - Thereof 78 % females - Working in 16 countries - True experts in many fields – ranging from scientists, medical doctors, marketers, customer advisors, laboratory technicians, quality managers, to accountants - Connected by our passion for cell therapies ![sayen](https://www.famicord.com/wp-content/uploads/2025/02/sayen.webp) Operations Manager Arzu Kılıç Sayın ![turkey](https://www.famicord.com/wp-content/uploads/2024/12/turkey.svg) Türkiye **Since when and in which position you are working for FamiCord? **I have been working for FamiCord as an operations manager since July 2019   With the support and leadership of my colleagues I left behind many very enjoyable and productive years. ![Roberto Gurguta](https://www.famicord.com/wp-content/uploads/2025/02/gorgute-1.webp) Field Sales Specialist Roberto Gurguta ![germany](https://www.famicord.com/wp-content/uploads/2024/12/germany.svg) Germany **Since when you have been working with us : September 2020**   Future-orientated, sustainable and an added value for society. We are a modern and transparent company that gives me the freedom to develop myself and where you are valued as a person. ![dr_michele_de_lucia](https://www.famicord.com/wp-content/uploads/2024/12/dr_michele_de_lucia-1.webp) Area Manager Southern Italy Dr. Michele De Lucia ![italy](https://www.famicord.com/wp-content/uploads/2024/12/italy.svg) Italy **Since when you have been working with us : January 2012**   The topic of conservation and the new frontiers in the field of stem cell application… The topic of conservation and the new frontiers in the field of stem cell applications represent an opportunity for life both in the present and for the future. There is the sharing of professionalism and work experiences as the fulcrum of personal and team growth. Meritocracy is recognized. Hide Read more ![noemi_n_moretti](https://www.famicord.com/wp-content/uploads/2024/12/noemi_n_moretti-1.webp) Senior Consultant and Tutor Noemi N. Moretti ![italy](https://www.famicord.com/wp-content/uploads/2024/12/italy.svg) Italy **Since when you have been working with us : October 2018**   Working at Sorgente Famicord allows me to experience unique and precious moments… Working at Sorgente Famicord allows me to experience unique and precious moments. Being present in such a delicate moment as the birth of a child, guiding families through the process of stem cell conservation, is an experience that fills me with joy and satisfaction. Every call, every question, the trust given to me is a confirmation that our work has a profound impact on people’s lives birth of a new hope, e I am honored to be part of it. Hide Read more ![sinem-akin-employees](https://www.famicord.com/wp-content/uploads/2025/01/sinem-akin-employees.webp) Quality Assurance Manager Sinem Akın ![turkey](https://www.famicord.com/wp-content/uploads/2024/12/turkey.svg) Türkiye **Since when you have been working with us : June 2018**   Working at FamiCord is both inspiring and rewarding. The collaboration with a passionate and dedicated team… Working at FamiCord is both inspiring and rewarding. The collaboration with a passionate and dedicated team motivates me to contribute to the field of cord blood banking. Being part of an international group like FamiCord not only allows us to maintain the highest standards but also encourages innovation and growth. **Why do you like working for Famicord?** I deeply value the opportunity to work in a field that positively impacts lives and transforms healthcare. FamiCord’s commitment to supporting the scientific community through advanced R&D capabilities and clinical trials is truly inspiring. Additionally, contributing to the development of regenerative medicine is both meaningful and fulfilling. The supportive environment and dedication to excellence make FamiCord a place where I can thrive and grow professionally. Hide Read more ![baris-cetin-turkiye](https://www.famicord.com/wp-content/uploads/2025/01/baris-cetin-turkiye.webp) Operations and Administrative Affairs Manager Barış Çetin ![turkey](https://www.famicord.com/wp-content/uploads/2024/12/turkey.svg) Türkiye **Since when you have been working with us : 16.07.2018**   First of all, I like the idea of helping people. Secondly I like working for a… First of all, I like the idea of helping people. Secondly I like working for a people-oriented company as Famicord. And Last but not Least I like working with people who forms the Famicord family. Hide Read more ![renata-gajewska-poland](https://www.famicord.com/wp-content/uploads/2025/01/renata-gajewska-poland.webp) Medical Consultant Renata Gajewska ![poland](https://www.famicord.com/wp-content/uploads/2024/12/poland.svg) Poland **Since when you have been working with us : August 2023**   I hold a Master’s degree in Zootechnics and I am a veterinary technician, so you could say that medical topics are “in my blood.”… I hold a Master’s degree in Zootechnics and I am a veterinary technician, so you could say that medical topics are “in my blood.” I have always sought opportunities for both mental and professional development in my work. These are the exact values I found when I joined PBKM. On a daily basis, I work with doctors, midwives, and expectant parents. This allows me to understand the problems from both the medical side and the concerns of future parents. The birth of a child, especially in today’s world, is a significant event, often eagerly awaited for a long time. Working at PBKM gives me the opportunity to experience this moment with the parents and help them secure their child’s future. For me, this is very important because I know that through my work, I may someday save someone’s life.  Hide Read more ![Eszter-Gacsádi](https://www.famicord.com/wp-content/uploads/2025/01/Eszter-Gacsadi.webp) Senior Sales Representative Eszter Gacsádi ![hungary](https://www.famicord.com/wp-content/uploads/2024/12/hungary.svg) Hungary **Working for FamiCord for 8 years**   My name is Eszter, and I have been working as a Senior Sales Representative at the KRIO Institute… My name is Eszter, and I have been working as a Senior Sales Representative at the KRIO Institute, the Hungarian member of FamiCord, for eight years. There are several reasons why I enjoy working here. Firstly, I find this field of healthcare both highly significant and intellectually stimulating. It gives me the opportunity to educate families about the importance of stem cell storage and provide them with accurate, reliable information about its potential applications. Secondly, the workplace atmosphere is outstanding. I have a great working relationship with my colleagues, and it is always a pleasure to come to work. This collaborative environment makes my role not only fulfilling but also enjoyable. Lastly, being part of a large, stable international organization like FamiCord is incredibly rewarding. It not only provides families with confidence in choosing our services but also offers employees a sense of security and belonging. I feel fortunate to contribute to such a meaningful mission while being part of a trusted global network. Hide Read more ![Anna-Hufgart](https://www.famicord.com/wp-content/uploads/2025/01/Anna-Hufgart.webp) Division Manager Anna Hufgart ![hungary](https://www.famicord.com/wp-content/uploads/2024/12/hungary.svg) Hungary **Since when you have been working with us : 2012**   My name is Anna, and I have been a part of the Krio Institute since 2012. I feel incredibly fortunate to have had the opportunity to work in various roles… I feel incredibly fortunate to have had the opportunity to work in various roles, tackling diverse and challenging tasks. Over the past few years, I have been managing the sperm banking division, an exciting and rapidly evolving field. I take pride in supporting many men and couples as they navigate the challenges of building a family. What motivates and inspires me every day is the opportunity to collaborate with my colleagues. They are highly dedicated, exceptionally talented, and driven by a passion for overcoming challenges and striving for continuous improvement. Being part of this team enables me to grow constantly, gaining new knowledge and experiences along the way. I am particularly delighted to contribute to a group project as a member of the risk management team. Over the past year and a half, this work has significantly expanded my expertise. I hope to continue adding value to the success of both the Group and Krio through my efforts. Hide Read more ![Joanna-Płaczkowska](https://www.famicord.com/wp-content/uploads/2025/01/Joanna-Placzkowska.webp) Director of Medicinal Product Manufacturing Joanna Płaczkowska ![poland](https://www.famicord.com/wp-content/uploads/2024/12/poland.svg) Poland **Since when you have been working with us : 12.04.2010**   I appreciate being able to participate in innovative projects that are shaping the future of medicine… I appreciate being able to participate in innovative projects that are shaping the future of medicine. Every day brings new challenges and opportunities to learn, and the friendly work atmosphere allows me to fully focus on achieving goals and developing my skills. Working at PBKM is not only an opportunity to pursue my interests but also to collaborate with a dedicated and fantastic team. I am surrounded by passionate, knowledgeable people who are always ready to tackle even the most difficult challenges together. Hide Read more ## Make your talent meet the future at FamiCord! We are looking for talented, committed people who want to grow with us, create new things and make a real difference. In a dynamic environment with the latest technology, team spirit and exciting development opportunities, you can actively shape your career. ## You will fit in with us if you - Love science and progress: You are passionate about modern medicine, technology and innovative solutions. - Want to take responsibility: You are ready to make a real difference to families around the world with your work. - Work with precision and quality awareness: Care and reliability are a matter of course for you. - Live team spirit: You value open, trusting collaboration and want to grow together with your colleagues. - Are curious and willing to learn: You question, develop and always want to be up to date. - Act with heart and mind: In addition to your professional expertise, you bring empathy and humanity to your work. ## Does that sound like you? Then become part of FamiCord and shape the future of medicine! [ Find your dream job with FamiCord here ](https://www.famicord.com/career/employment-in-germany/job-postings) --- --- title: "Career" url: "https://www.famicord.com/career" lang: "en" type: "page" last_modified: "2024-12-17T14:48:08+00:00" translations: de: "https://www.famicord.com/career" --- # Career --- --- title: "Our Experience" url: "https://www.famicord.com/services-for-business-partner/our-experience" lang: "en" type: "page" last_modified: "2024-12-30T08:16:17+00:00" translations: de: "https://www.famicord.com/services-for-business-partner/our-experience" --- # Our Experience # Our Experience US Biotech Allogeneic cell therapy for muscular dystrophy. Tech transfer in of their process and cGMP production / QC release. On-going collaboration since 2021. German Biotech Process development, validation, production and QC assessments. Preclinical stage for cartilage damage. Scandinavian Biotech Process development & clinical Phase II production and QC release for diabetes. Polish University Clinic Collaboration since 2017. Production and QC testing of autologous ATMP for clinical trial Phase I/II in dermatological indications. --- --- title: "Certificates and Accreditations" url: "https://www.famicord.com/services-for-business-partner/certificates-and-accreditations" lang: "en" type: "page" last_modified: "2025-06-17T11:40:09+00:00" translations: de: "https://www.famicord.com/services-for-business-partner/certificates-and-accreditations" --- # Certificates and Accreditations # Certificates and Accreditations ## Certificates and Accreditations FamiCord is dedicated to providing high-quality services of cell and tissue banking.  The way in which umbilical cord blood and tissue are collected, transported, processed, and stored directly impacts the quality of stem cells and the chances of saving a life during transplantation. Our high standards are confirmed by certificates obtained by local authorities as well global organizations. The fact that as transplantation and cellular therapy clinics used cell products from our labs confirms that the way they were prepared by our bank meet the criteria for therapy. Additionally, we are the only private cord blood bank in Europe which provides cells utilized in innovative experimental therapies and clinical research.  All our labs needs to comply with local requirements for cord blood banking set by applicable authorities in the country they are located (Germany, Poland, Spain, Hungary, Portugal, Turkey, Romania, Switzerland, UK and United Arab Emirates). - ![aabb-accreditation](https://www.famicord.com/wp-content/uploads/2024/12/aabb-accreditation.webp) Association for the Advancement of Blood and Biotherapies, AABB [formerly known as: American Association of Blood Banks) Our commitment to excellence is underscored by the Accreditation of Association for the Advancement of Blood and Biotherapies (AABB) for our laboratories, which ensures compliance with the most stringent standards set for cord blood banking procedures. This accreditation, which we have held since 2007, guarantees adherence to the strictest quality standards established in the U.S. and applicable worldwide. The FamiCord Group’s accredited laboratories are located in Cantanhede (Portugal), Dubai, Madrid, Budapest, and Warsaw. Read more - ![aabb-stemlab](https://www.famicord.com/wp-content/uploads/2024/12/aabb-stemlab.webp) Cellular Starting Material Association for the Advancement of Blood and Biotherapies For many years the only use of stored cord blood/stem cells has been standard transplantation. With evolving science and research it is more frequently used as starting material for new category of drugs – cell and gene products or therapies (CGT) . The prestigious AABB accreditation is the result of an intensive evaluation process conducted by independent, professional auditors who verify whether the facility maintains a comprehensive quality management system for cellular starting material. The assessment is based on compliance with international standards set by the AABB, as well as local guidelines. The AABB CSM accreditation confirms that the FamiCord Group is a trusted partner for companies seeking a banking partner in the provision of cellular starting material. It also enables the production of personalized cell therapies for clients banking umbilical cord blood. Among the laboratories within the FamiCord Group, the prestigious accreditation has been obtained by the facilities in Cantanhede, Girona, Madrid, and Warsaw. All banks that achieve AABB and AABB CSM accreditation must undergo re-evaluation every two years. Read more - ![jacie](https://www.famicord.com/wp-content/uploads/2024/12/jacie.webp) The Joint Accreditation Committee ISCT-EBMT (JACIE) The Joint Accreditation Committee ISCT-Europe & EBMT (JACIE) is Europe’s only official accreditation body in the field of haematopoietic cell transplantation and cellular therapy. It promotes high-quality patient care and medical and laboratory practice through a profession-led, voluntary accreditation scheme. As an accredited institution by JACIE, FamiCord adheres to global standards of quality in cellular therapy. JACIE’s accreditation encourages healthcare institutions to implement and maintain quality management systems that impact all aspects of their activities. Our accreditation not only demonstrates our commitment to continuous improvement but also ensures that we provide the highest standards in stem cell processing, translating into safety and efficacy for patients who received ATMP products from our facilities. JACIE accreditation has been given to our lab in Germany. Read more - ![main-pharmaceutical-inspector](https://www.famicord.com/wp-content/uploads/2024/12/main-pharmaceutical-inspector.webp) Consent of the Main Pharmaceutical Inspector The Consent of the Polish Chief Pharmaceutical Inspectorate is a crucial approval that enables us to manufacture Advanced Therapy Medicinal Products (ATMPs). This regulatory endorsement not only affirms our compliance with the highest standards of safety and quality but also allows us to contribute significantly to the field of clinical research and innovative experimental therapies. With this consent, we are empowered to produce ATMPs that are used in clinical trials, paving the way for groundbreaking treatments that can address unmet medical needs. Our ability to develop and provide these advanced products positions us at the forefront of medical innovation, allowing researchers and healthcare professionals to explore new therapeutic avenues. The consent of the Chief Pharmaceutical Inspectorate have been granted to the FamiCord Group laboratory in Warsaw. Read more - ![gdp-certificate](https://www.famicord.com/wp-content/uploads/2024/12/gdp-certificate.webp) Certificate of GDP compliance of a wholesale distributor The Certificate of GDP Compliance for a Wholesale Distributor is a vital accreditation that verifies our adherence to Good Distribution Practice (GDP) standards. This certification ensures that our processes for the storage and distribution of pharmaceutical products meet the highest quality and safety requirements, safeguarding the integrity of the products we handle. With this certificate, we are authorized to distribute a range of medicinal products, including Advanced Therapy Medicinal Products (ATMPs), ensuring that they are transported and stored under optimal conditions. This compliance not only reinforces our commitment to patient safety but also enhances our reputation as a trusted partner in the healthcare supply chain. The Certificate of GDP Compliance for a Wholesale Distributor has been awarded to the FamiCord Group laboratory in Cantanhede. Read more - ![infarmed](https://www.famicord.com/wp-content/uploads/2024/12/infarmed.webp) Certificate of GMP compliance of a manufacturer The Certificate of GMP Compliance for a Manufacturer is a critical accreditation that verifies our adherence to Good Distribution Practice (GDP) standards in the production of Advanced Therapy Medicinal Products (ATMPs). This certification ensures that our manufacturing processes meet the highest quality and safety requirements, crucial for safeguarding the integrity of the products we create. With this certificate, we are authorized to manufacture ATMPs, enabling us to develop innovative therapies that can significantly impact patient care. The compliance with GMP standards ensures that all aspects of our production—from sourcing raw materials to the final product—are conducted under stringent quality controls, thus enhancing the safety and efficacy of the therapies we provide. The Certificate of GMP Compliance for a Manufacturer has been awarded to the FamiCord Group laboratory in Cantanhede and Leipzig. Read more - ![iso-certificate-stemlab](https://www.famicord.com/wp-content/uploads/2024/12/iso-certificate-stemlab.webp) ISO 9001 standard for Quality Management System In 2004, FamiCord facility in Warsaw, obtained certification of the quality management system ISO 9001:2000, specific to the umbilical cord stem cell collection, storage, and freezing procedures. The audit was conducted by Lloyd Register Quality Assurance, ensuring that our practices align with internationally recognized quality standards. This certification reflects our commitment to maintaining the highest level of quality in all our processes, reinforcing our dedication to the safety and efficacy of the stem cells we handle. It also serves as a benchmark for continuous improvement and operational excellence within our organization. The certificate is still maintained, now the scope of inspection has been expanded to include collection, procurement, freezing and storage of human stem cells. Also, two laboratories from the FamiCord Group have successfully passed this audit – in Turkey and Portugal. This achievement reflects our unified approach to quality across all facilities, ensuring that we consistently deliver safe and effective cellular therapy products. By adhering to these standards, we reinforce our credibility in the industry and demonstrate our dedication to excellence in all aspects of our services. Read more - ![iso-certificate-krio](https://www.famicord.com/wp-content/uploads/2024/12/iso-certificate-krio.webp) ISO: 14001:2005 standard for Quality Management System satisfactory (QMS) In 2011, the FamiCord Group proudly achieved compliance with the MSZ EN ISO 14001:2005 standard for Environmental Management Systems (EMS), reflecting our commitment to sustainable practices and environmental stewardship. Our Budapest laboratory is specifically recognized for maintaining this certification, demonstrating our proactive approach to minimizing environmental impact across our operations. The three-year certification involves regular monitoring of our Environmental Management System, alongside our Quality Management System, ensuring that we consistently adhere to rigorous environmental standards. This auditing process is conducted by SGS Hungaria Kft., a reputable organization known for its thorough assessment practices. By prioritizing sustainability, we not only enhance our operational efficiency but also contribute positively to the communities and ecosystems we serve. The FamiCord Group remains dedicated to continuous improvement in our environmental performance, reinforcing our role as a responsible leader in the industry. Read more --- --- title: "Our Facilities" url: "https://www.famicord.com/services-for-business-partner/our-facilities" lang: "en" type: "page" last_modified: "2025-02-05T12:50:29+00:00" translations: de: "https://www.famicord.com/services-for-business-partner/our-facilities" --- # Our Facilities # Our Facilities ## Our Facilities Both CDMO facilities in Poland and Portugal are cGMP compliant for the development and production of cell therapy products for clinical trial use and commercial production. - ## Warsaw Our 1,100-square meter facility contains over 600 square meters of GMP production space. We have 16 separate production suites split into tissue-engineered and somatic cell therapy products, as well as gene modified products. We can produce treatments tailored for individual patients (autologous) or for larger groups (allogeneic) to support research and clinical trials. We also provide the necessary documentation to simplify the approval process with regulators. The GMP suite design includes class B clean rooms equipped with class A cabinets. Our facility is capable of producing a wide range of cell therapies using different types of cells, customized to meet the specific needs of our clients. ![our-facilities](https://www.famicord.com/wp-content/uploads/2025/01/our-facilities.webp) - ## Cantanhede With a total area of 900 square meters the Cantanhede facility operates as a fully integrated cell and tissue processing facility, including a GMP area for the manufacturing of investigational cell-based therapy products. The GMP area includes 3 class B rooms, and it is designed to handle multi-product manufacturing. The state-of-the-art quality control laboratory also operates under GMP compliance and the team has long track record of analytical methods development and validation for cell therapy products, including flow cytometer, molecular biology, endotoxins and microbiological analyses. The facility also includes a cryopreservation storage area compliant with both GMP and GDP (Good Distribution Practices). ![023](https://www.famicord.com/wp-content/uploads/2025/01/023-scaled.webp) --- --- title: "Scientific Publications" url: "https://www.famicord.com/services-for-business-partner/scientific-publications" lang: "en" type: "page" last_modified: "2025-01-27T13:14:07+00:00" translations: de: "https://www.famicord.com/services-for-business-partner/scientific-publications" --- # Scientific Publications # Scientific Publications ## Scientific Publications **Scientific publications in peer reviewed journals on banking, processing or clinical use of stem cells, in which a company from ** - Khrystyna Nasadiuk, Tomasz Kolanowski, Cezary Kowalewski, Katarzyna Wozniak, Tomasz Oldak, Natalia Rozwadowska. 2025. “Harnessing Mesenchymal Stromal Cells for Advanced Wound Healing: A Comprehensive Review of Mechanisms and Applications” International Journal of Molecular Sciences 26, no. 1: 199. [https://doi.org/10.3390/ijms26010199](https://doi.org/10.3390/ijms26010199) [ https://www.mdpi.com/1422-0067/26/1/199 ](https://www.mdpi.com/1422-0067/26/1/199) - Różycka-Baczyńska A.M., Stepaniec I.M., Warzycha M., Zdolińska-Malinowska I., Oldak T., Rozwadowska N., Kolanowski T.J. Development of a novel gene expression panel for the characterization of MSCs for increased biological safety. J Appl Genetics (2024). [https://doi.org/10.1007/s13353-024-00917-5](https://doi.org/10.1007/s13353-024-00917-5). [ https://link.springer.com/article/10.1007/s13353-024-00917-5#citeas ](https://link.springer.com/article/10.1007/s13353-024-00917-5#citeas) - Michał Romiszewski, Khrystyna Nasadiuk, Iwona Malinowska, Aleksandra Olearczyk, Emilian Snarski, Tomasz Ołdak, Paweł Łaguna, Abstract 18: A Case of Successful Poor Graft Function Treatment with Wharton Jelly Mesenchymal Stem Cells, Stem Cells Translational Medicine, Volume 13, Issue Supplement_1, September 2024, Page S20, [https://doi.org/10.1093/stcltm/szae062.018](https://doi.org/10.1093/stcltm/szae062.018) [ https://academic.oup.com/stcltm/article/13/Supplement_1/S 20/7738252#google_vignette ](https://academic.oup.com/stcltm/article/13/Supplement_1/S 20/7738252#google_vignette) - Felician Stancioiu, Bogdan Bulumac, Abstract 5: Decontamination of Two Umbilical Cord Blood Grafts Prior to Autologous Administration, Stem Cells Translational Medicine, Volume 13, Issue Supplement_1, September 2024, Page S6, [https://doi.org/10.1093/stcltm/szae062.005](https://doi.org/10.1093/stcltm/szae062.005) [ https://academic.oup.com/stcltm/article/13/Supplement_1/S6/7738230 ](https://academic.oup.com/stcltm/article/13/Supplement_1/S6/7738230) - Chrościńska-Krawczyk M, Zdolińska-Malinowska I, Boruczkowski D. The Impact of Umbilical Cord Mesenchymal Stem Cells on Motor Function in Children with Cerebral Palsy: Results of a Real-world, Compassionate use Study. Stem Cell Rev Rep. 2024 Jun 15. doi: 10.1007/s12015-024-10742-2. [ https://pubmed.ncbi.nlm.nih.gov/38877284/ ](https://pubmed.ncbi.nlm.nih.gov/38877284/) - Szabłowska-Gadomska I, Humięcka M, Brzezicka J, Chróścicka A, Płaczkowska J, Ołdak T, Lewandowska-Szumiel M. Microbiological Aspects of Pharmaceutical Manufacturing of Adipose-Derived Stem Cell-Based Medicinal Products. Cells. 2023 Feb 21;12(5):680. doi: 10.3390/cells12050680. [ https://pubmed.ncbi.nlm.nih.gov/36899816/ ](https://pubmed.ncbi.nlm.nih.gov/36899816/) - Dos Santos FF, Nunes L, Martins C, Smith MA, Cardoso C. Single laboratory evaluation of umbilical cord blood units processing methodologies for banking. Lab Med. 2023 Aug 11:lmad073. doi: 10.1093/labmed/lmad073. [ https://pubmed.ncbi.nlm.nih.gov/37566522/ ](https://pubmed.ncbi.nlm.nih.gov/37566522/) - Laranjeira P, Dos Santos F, Salvador MJ, Simões IN, Cardoso CMP, Silva BM, Henriques-Antunes H, Corte-Real L, Couceiro S, Monteiro F, Santos C, Santiago T, da Silva JAP, Paiva A. Umbilical-Cord-Derived Mesenchymal Stromal Cells Modulate 26 Out of 41 T Cell Subsets from Systemic Sclerosis Patients. Biomedicines. 2023 Apr 30;11(5):1329. doi: 10.3390/biomedicines11051329 [ https://www.mdpi.com/2227-9059/11/5/1329 ](https://www.mdpi.com/2227-9059/11/5/1329) - Stancioiu F, Bogdan R, Bulumac B, Ivanescu B, Dumitrescu R. Decontamination of Two Umbilical Cord Blood Grafts Prior to Autologous Administration. Maedica (Bucur). 2022 Dec;17(4):885-892. doi: 10.26574/maedica.2022.17.4.885 [ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9923064/ ](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9923064/) - Noske S, Karimov M, Hansen M, Zatula N, Ewe A, Aigner A. Non-viral siRNA transfection of primary mesenchymal stromal cells (MSCs): Assessment of tyrosine-modified PEI and PPI efficacy and biocompatibility. Int J Pharm. 2022 Jan 25;612:121359. doi: 10.1016/j.ijpharm.2021.121359. [ https://pubmed.ncbi.nlm.nih.gov/34896217/ ](https://pubmed.ncbi.nlm.nih.gov/34896217/) - Semenova E, Grudniak MP, Machaj EK, Bocian K, Chroscinska-Krawczyk M, Trochonowicz M, Stepaniec IM, Murzyn M, Zagorska KE, Boruczkowski D, Kolanowski TJ, Oldak T, Rozwadowska N. Mesenchymal Stromal Cells from Different Parts of Umbilical Cord: Approach to Comparison & Characteristics. Stem Cell Rev Rep. 2021 Oct;17(5):1780-1795. doi: 10.1007/s12015-021-10157-3. [ https://link.springer.com/article/10.1007/s12015-021-10157-3 ](https://link.springer.com/article/10.1007/s12015-021-10157-3) - Tomecka E, Lech W, Zychowicz M, Sarnowska A, Murzyn M, Oldak T, Domanska-Janik K, Buzanska L, Rozwadowska N. Assessment of the Neuroprotective and Stemness Properties of Human Wharton’s Jelly-Derived Mesenchymal Stem Cells under Variable (5% vs. 21%) Aerobic Conditions. Cells. 2021 Mar 24;10(4):717. doi: 10.3390/cells10040717. [ https://www.mdpi.com/2073-4409/10/4/717 ](https://www.mdpi.com/2073-4409/10/4/717) []() [ 01 ]() [ 02 ](https://www.famicord.com/llms-full.txt/page/2) [ 03 ](https://www.famicord.com/llms-full.txt/page/3) … [ 05 ](https://www.famicord.com/llms-full.txt/page/5) [](https://www.famicord.com/llms-full.txt/page/2) --- --- title: "Our People" url: "https://www.famicord.com/services-for-business-partner/our-people" lang: "en" type: "page" last_modified: "2025-01-22T13:08:24+00:00" translations: de: "https://www.famicord.com/services-for-business-partner/our-people" --- # Our People # Our People - ![56e80a9cc8a68cd7821538e584afe03b](https://www.famicord.com/wp-content/uploads/2025/01/56e80a9cc8a68cd7821538e584afe03b-scaled.webp) Managing Director of Famicord’s CDMO business Simon Boa Simon Boa is the Managing Director of Famicord’s CDMO business, bringing over 20… Simon Boa is the Managing Director of Famicord’s CDMO business, bringing over 20 years of leadership in the life sciences sector with a particular emphasis on commercialization, strategic market expansion, and innovative business creation. He has a proven track record of delivering above-market growth for global organizations, including Thermo Fisher Scientific, Merck, and Becton Dickinson through a strong focus on client value creation. He has a PhD in epigenetics from the Roslin Institute / Edinburgh University and an MBA from Warwick University specialising in M&A and finance. Read more Okno dialogowe Back ![56e80a9cc8a68cd7821538e584afe03b](https://www.famicord.com/wp-content/uploads/2025/01/56e80a9cc8a68cd7821538e584afe03b-scaled.webp) Managing Director of Famicord’s CDMO business Simon Boa Simon Boa is the Managing Director of Famicord’s CDMO business, bringing over 20 years of leadership in the life sciences sector with a particular emphasis on commercialization, strategic market expansion, and innovative business creation. He has a proven track record of delivering above-market growth for global organizations, including Thermo Fisher Scientific, Merck, and Becton Dickinson through a strong focus on client value creation. He has a PhD in epigenetics from the Roslin Institute / Edinburgh University and an MBA from Warwick University specialising in M&A and finance. - ![Joanna](https://www.famicord.com/wp-content/uploads/2025/01/Joanna.webp) Director of Manufacturing Joanna Płaczkowska Joanna Płaczkowska has been working at Famicord’s Warsaw facility for 15 years and… Joanna Płaczkowska has been working at Famicord’s Warsaw facility for 15 years and holds the role of Director of Manufacturing; she oversees the production and quality control of all medicinal products and is one of our Qualified Persons (QPs). With a background in clinical chemistry and a postgraduate education, she combines a strong technical expertise with an in-depth knowledge of cGMP requirements in order to effectively manage our operations and maintain our high-quality standards. Read more Okno dialogowe Back ![Joanna](https://www.famicord.com/wp-content/uploads/2025/01/Joanna.webp) Director of Manufacturing Joanna Płaczkowska Joanna Płaczkowska has been working at Famicord’s Warsaw facility for 15 years and holds the role of Director of Manufacturing; she oversees the production and quality control of all medicinal products and is one of our Qualified Persons (QPs). With a background in clinical chemistry and a postgraduate education, she combines a strong technical expertise with an in-depth knowledge of cGMP requirements in order to effectively manage our operations and maintain our high-quality standards. - ![Karolina](https://www.famicord.com/wp-content/uploads/2025/01/Karolina.webp) Global Director of Quality Karolina Zagórska Karolina Zagórska has been working at Famicord for 15 years and is our Global Direc… Karolina Zagórska has been working at Famicord for 15 years and is our Global Director of Quality. In collaboration with our sites, she is responsible for compliance with ATMP regulations and oversees risk management and change control processes. In addition, she is responsible for non-conformance management and supervision of the technical infrastructure for production. She also has significant experience in managing projects related to the design and construction of GMP facilities in Europe, Arabia and Asia, and in the preparation and submission of the relevant qualification documentation to the regulatory authorities. Read more Okno dialogowe Back ![Karolina](https://www.famicord.com/wp-content/uploads/2025/01/Karolina.webp) Global Director of Quality Karolina Zagórska Karolina Zagórska has been working at Famicord for 15 years and is our Global Director of Quality. In collaboration with our sites, she is responsible for compliance with ATMP regulations and oversees risk management and change control processes. In addition, she is responsible for non-conformance management and supervision of the technical infrastructure for production. She also has significant experience in managing projects related to the design and construction of GMP facilities in Europe, Arabia and Asia, and in the preparation and submission of the relevant qualification documentation to the regulatory authorities. - ![francisco 1 1](https://www.famicord.com/wp-content/uploads/2025/01/francisco-1-1.webp) Director of Production and Development at Famicord’s Cantanhede Francisco dos Santos Francisco dos Santos is the Director of Production and Development at Famicord’s… Francisco dos Santos is the Director of Production and Development at Famicord’s Cantanhede facility and has a background in Biological Engineering and a PhD in Biotechnology. He has been involved in the Cell and Gene Therapy field for 18 years, with the particular focus on the development and clinical translation of innovative ATMPs for unmet clinical needs, and has built an in-depth knowledge on manufacturing and analytical control of ATMPs. Read more Okno dialogowe Back ![francisco 1 1](https://www.famicord.com/wp-content/uploads/2025/01/francisco-1-1.webp) Director of Production and Development at Famicord’s Cantanhede Francisco dos Santos Francisco dos Santos is the Director of Production and Development at Famicord’s Cantanhede facility and has a background in Biological Engineering and a PhD in Biotechnology. He has been involved in the Cell and Gene Therapy field for 18 years, with the particular focus on the development and clinical translation of innovative ATMPs for unmet clinical needs, and has built an in-depth knowledge on manufacturing and analytical control of ATMPs. - ![Irina headshot](https://www.famicord.com/wp-content/uploads/2025/01/Irina-headshot-scaled.webp) Site Manager and Head of Quality Assurance of the Cell Therapy Lab Irina Neves Simões Irina Neves Simões has been working at Famicord’s Cantanhede facility for 4 years… Irina Neves Simões has been working at Famicord’s Cantanhede facility for 4 years and is Site Manager and Head of Quality Assurance of the Cell Therapy Lab (LTC). With over 10 years of experience in stem cell biology and tissue engineering and a growing knowledge in biobanking and research management as well as Quality Control and Assurance of Advanced Therapy Medicinal Products (ATMPs). Is highly involved in validation processes, mainly analytical method validation. Her background is in Biology and Biotechnology, with a PhD in Bioengineering and post-graduate work performed in cartilage tissue engineering. Read more Okno dialogowe Back ![Irina headshot](https://www.famicord.com/wp-content/uploads/2025/01/Irina-headshot-scaled.webp) Site Manager and Head of Quality Assurance of the Cell Therapy Lab Irina Neves Simões Irina Neves Simões has been working at Famicord’s Cantanhede facility for 4 years and is Site Manager and Head of Quality Assurance of the Cell Therapy Lab (LTC). With over 10 years of experience in stem cell biology and tissue engineering and a growing knowledge in biobanking and research management as well as Quality Control and Assurance of Advanced Therapy Medicinal Products (ATMPs). Is highly involved in validation processes, mainly analytical method validation. Her background is in Biology and Biotechnology, with a PhD in Bioengineering and post-graduate work performed in cartilage tissue engineering. - ![Callum-1](https://www.famicord.com/wp-content/uploads/2025/01/Callum-1.webp) Business Development Manager Callum King Callum King is the Business Development Manager at Bramble Bio… Callum King is the Business Development Manager at Bramble Bio. With over eight years of experience in the CRO/CDMO sector, and more than five of those within the Cell and Gene Therapy field, he brings extensive knowledge and client focus to his role. Callum’s responsibilities include managing client relationships and ensuring seamless support in advancing therapeutic products from concept to clinic. Read more Okno dialogowe Back ![Callum-1](https://www.famicord.com/wp-content/uploads/2025/01/Callum-1.webp) Business Development Manager Callum King Callum King is the Business Development Manager at Bramble Bio. With over eight years of experience in the CRO/CDMO sector, and more than five of those within the Cell and Gene Therapy field, he brings extensive knowledge and client focus to his role. Callum’s responsibilities include managing client relationships and ensuring seamless support in advancing therapeutic products from concept to clinic. --- --- title: "Our Quality" url: "https://www.famicord.com/services-for-business-partner/our-quality" lang: "en" type: "page" last_modified: "2025-01-22T11:06:00+00:00" translations: de: "https://www.famicord.com/services-for-business-partner/our-quality" --- # Our Quality # Our Quality # Our Quality We are a socially responsible CDMO, specializing in the manufacturing of cellular medicinal products on behalf of various entities conducting their projects and clinical trials, as well as for individual therapies prescribed to treat specific patients. Regardless of the purpose of our production, we consistently maintain the highest quality standards. Throughout our work, we remain deeply aware that the medicines we produce will ultimately be administered to patients in need. Our commitment to quality standards is guided by the legislation of the European Union, implemented in each member state and reflected in our Good Manufacturing Practice (GMP) system. The principles of GMP include all aspects related to the production of cellular therapy products: from facility design and equipment quality to infrastructure oversight, production processes, quality control, and the final release of the product for human use. #### We Are Subject to Supervision and Regularly Inspected by Competent Authorities. - ![main-pharmaceutical-inspector](https://www.famicord.com/wp-content/uploads/2024/12/main-pharmaceutical-inspector.webp) Consent of the Main Pharmaceutical Inspector In Warsaw, Poland, our main centre for ATIMP and ATMP-HE manufacturing operates under the supervision of the Polish Chief Pharmaceutical Inspectorate, affiliated with the EMA [www.gov.pl/web/chief-pharmaceutical-inspectorate](https://www.gov.pl/web/chief-pharmaceutical-inspectorate) Read more - ![infarmed](https://www.famicord.com/wp-content/uploads/2024/12/infarmed.webp) Certificate of GMP compliance of a manufacturer In Cantanhede, Portugal, our centre of excellence for advanced analytics in cell therapy applications is regulated by Infarmed—the National Authority of Medicines and Health Products (Autoridade Nacional do Medicamento e Produtos de Saúde), which is also EMA-associated. Read more When our products are intended for clinical trials, they undergo expert evaluation through the unified EU Clinical Trials Information System (CTIS). It is also worth noting that any experimental application of cellular therapy products in humans must first receive a positive opinion from an ethics committee. --- --- title: "Our Services" url: "https://www.famicord.com/services-for-business-partner/our-services" lang: "en" type: "page" last_modified: "2026-03-13T09:59:02+00:00" translations: de: "https://www.famicord.com/services-for-business-partner/our-services" --- # Our Services # Our Services ## Our Services **Bramble Bio provides a range of services to support the development of cell therapy products from preclinical through all clinical phases and into commercialisation.** ![our-services-1](https://www.famicord.com/wp-content/uploads/2025/01/our-services-1.webp) ![our-services-1](https://www.famicord.com/wp-content/uploads/2025/01/our-services-1.webp) Manufacturing More This is our core service, covering technology transfer, process development, optimization, and cGMP manufacturing for clinical and commercial applications. All of our advanced therapy medicinal products (ATIMPs and ATMPs) are produced under strict cGMP conditions for administration to patients. [ Learn more ](https://bramble.bio/services/manufacturing/) Less ![our-services-2](https://www.famicord.com/wp-content/uploads/2025/01/our-services-2.webp) ![our-services-2](https://www.famicord.com/wp-content/uploads/2025/01/our-services-2.webp) Analytics More Our site in Cantanhede, Portugal is our centre of excellence for cell therapy analytics. This involves testing and monitoring the quality, safety, and effectiveness of therapeutic cells throughout their development and manufacturing. This includes analysing cell identity, viability, potency, and purity to ensure they meet strict standards for use in patients. Advanced tools and techniques are used to assess the cells’ characteristics, detect impurities, and confirm that the therapy works. [ Learn more ](https://bramble.bio/services/analytical/) Less ![technical-assessment](https://www.famicord.com/wp-content/uploads/2026/03/technical-assessment.webp) ![technical-assessment](https://www.famicord.com/wp-content/uploads/2026/03/technical-assessment.webp) Technical assessments More Both academic and emerging biotech companies sometimes need additional guidance on the best path to take to develop their new cell therapies. We offer detailed reviews of their manufacturing process and have partners who can assess their preclinical needs and complete an economic analysis. [ Learn more ](https://www.bramble.bio/services/guidance) Less ![cell-sourcing](https://www.famicord.com/wp-content/uploads/2026/03/cell-sourcing.webp) ![cell-sourcing](https://www.famicord.com/wp-content/uploads/2026/03/cell-sourcing.webp) Cell sourcing More All cell therapies begin with cells generously donated by individuals. These donations can serve different purposes depending on the type of therapy. Some are patient-specific (autologous cell therapies), where cells are taken from and used to treat the same individual. Others are designed to treat multiple patients with the same condition (allogeneic cell therapies), using cells from a single donor. There is also a middle ground, where cells are matched as closely as possible to a specific patient to minimize adverse immune reactions, often using HLA typing or haplotyping to ensure compatibility. [ Learn more ](https://bramble.bio/services/cell-and-tissue-sourcing/) Less ![our-services-5](https://www.famicord.com/wp-content/uploads/2025/01/our-services-5.webp) ![our-services-5](https://www.famicord.com/wp-content/uploads/2025/01/our-services-5.webp) Near-to-patient logistics More For autologous cell therapies, cells must be collected from the patient, transported to a manufacturing facility (either at FamiCord or another location), processed or modified, and then returned to the hospital for re-administration to the patient. This process demands exceptional coordination, as speed is critical to ensure the cells remain viable. Additionally, the cells often need to be cryopreserved at -150°C for transit, a highly skilled and strictly regulated procedure. [ Learn more ](https://bramble.bio/services/logistics/) Less --- --- title: "Services for business partner" url: "https://www.famicord.com/services-for-business-partner" lang: "en" type: "page" last_modified: "2025-01-22T14:20:26+00:00" translations: de: "https://www.famicord.com/services-for-business-partner" --- # Services for business partner # FamiCord Services for Business Partner ## Bramble Bio Bramble Bio, a Famicord company, provides services to support pharma, biotechs, hospitals and academics to develop manufacturing processes for their novel cell therapies and manufacture them for clinical and commercial use. Find out more [here](http://www.bramble.bio). ![cell-therapy](https://www.famicord.com/wp-content/uploads/2025/01/cell-therapy.webp) #### Process Development in Cell Therapy Process development in cell therapy is about creating reliable and efficient ways to produce therapeutic cells. It involves figuring out how to grow, expand, and preserve the cells while ensuring they are safe, effective, and consistent. This process also focuses on making production scalable for larger use and meeting strict quality and safety standards required for medical treatments. ![stem-cells-therapy-2](https://www.famicord.com/wp-content/uploads/2025/01/stem-cells-therapy-2.webp) #### Manufacturing to cGMP Manufacturing to cGMP (current Good Manufacturing Practices) means making products in a way that meets strict quality and safety standards set by regulators. It involves carefully controlling the environment, equipment, and processes to ensure consistency, purity, and safety. For cell therapy, this includes using cleanrooms, sterile techniques, and rigorous testing to ensure the cells are safe and effective for use in patients. ![Icon](https://www.famicord.com/wp-content/uploads/2025/01/microscope-white.svg) ##### As a Contract Development and Manufacturing Organisation (CDMO), Bramble Bio has helped support tens of clinical trials and thousands of patients across a multitude of indications exclusively in human cell-based therapies. --- --- title: "CSR" url: "https://www.famicord.com/services-for-families/csr" lang: "en" type: "page" last_modified: "2025-02-03T15:48:43+00:00" translations: de: "https://www.famicord.com/services-for-families/csr" custom_fields: display_availability_of_our_service_section: 1 --- # CSR --- --- title: "Stem Cells Banking" url: "https://www.famicord.com/services-for-families/stem-cells-banking" lang: "en" type: "page" last_modified: "2025-02-05T07:50:08+00:00" translations: de: "https://www.famicord.com/services-for-families/stem-cells-banking" custom_fields: display_availability_of_our_service_section: 1 --- # Stem Cells Banking # Stem Cells Banking ## Umbilical Cord Blood Storage: From Collection to Clinical Application The storage of umbilical cord blood offers families a unique opportunity for future medical treatments. By collecting and storing stem cells from umbilical cord blood, access to stem cell therapies is made possible. The FamiCord Group is the leading provider in Europe, boasting unparalleled experience in supplying materials for both hematopoietic transplants and innovative experimental therapies — all while adhering to the highest quality standards. A complex process of collection, processing, and storage ensures that the stem cells remain viable for potential future use. Families can trust that their cord blood is safely preserved and represents a valuable resource when medical treatments are needed. - 1 **Information and decision** Expectant parents can gather information about the possibility of umbilical cord blood storage from various sources. These include medical professionals, prenatal courses, as well as online and print media. - 2 **Contract signing** If the parents decide to collect umbilical cord blood, they sign a contract with a cord blood bank authorized to collect cord blood at the hospital where the birth is planned. The required documents also include a medical history. The parents will receive a special collection kit that they must bring to the hospital. - 3 **Collection at birth** The collection of umbilical cord blood and other perinatal tissues is performed at the hospital by trained medical staff. The cord blood is collected after the baby is born and the umbilical cord is clamped. Typically, a sample of the mother’s blood is also taken for diagnostic testing. - 4 **Shipping to the laboratory** After collection, the umbilical cord blood and other biological materials are sent to the laboratory by courier. This must be done within 72 to a maximum of 96 hours, depending on local regulations. - 5 **Processing and testing** In a certified laboratory, the umbilical cord blood is prepared for freezing (cryopreservation), and diagnostic tests are performed to measure the key parameters. - 6 **Cryopreservation** Umbilical cord blood samples (units) and other biological materials collected at birth are stored in special cryotanks at temperatures below -180 degrees Celsius. - 7 **Release for treatment** If therapeutic use of the stored samples is required, the parents contact the FamiCord Group to organize the process of releasing the samples from the bank to the clinic. The FamiCord Group handles every aspect of umbilical cord blood storage, from collection to release for transplant clinics. Our commitment to quality and safety means that each step is carefully monitored and controlled. Additionally, the entire process is overseen by independent international and national auditors to ensure that the highest industry standards are met. Families can trust that at the FamiCord Group, everything necessary is done to securely preserve the stem cells, ensuring they are available when needed. --- --- title: "Expanded Access Programme" url: "https://www.famicord.com/services-for-families/expanded-access-programme" lang: "en" type: "page" last_modified: "2025-10-06T08:57:48+00:00" translations: de: "https://www.famicord.com/services-for-families/expanded-access-programme" custom_fields: is_unavailable_in_germany: 1 display_availability_of_our_service_section: 1 allowed_ips.0.ip: "217.7.5.50" allowed_ips.1.ip: "194.34.158.41" allowed_ips.2.ip: "94.101.33.193" --- # Expanded Access Programme # FamiCord Expanded Access Protocol ## FamiCord Expanded Access Protocol : A Breakthrough In The Use of The Own Stem Cells FamiCord Group has launched a treatment program to help FamiCord clients to use autologous cord blood stem cells for the treatment of cerebral palsy and autism spectrum disorder. This initiative ensures that FamiCord Group clients from across Europe can access innovative stem cell therapies already being conducted in Poland. The University Children’s Hospital in Lublin is the partner of FamiCord Group in this project. ![cord-blood-for-brain-development](https://www.famicord.com/wp-content/uploads/2025/01/cord-blood-for-brain-development-1.webp) The program, known as the FamiCord Group Expanded Access Protocol for Cord Blood in Brain Development, represents a significant opportunity for children suffering from these conditions, particularly cerebral palsy, as autologous (own) cord blood infusion presents a potential path for clinical improvement. The foundation for launching the program was the results of clinical trials led by Professor Joanne Kurtzberg and conducted at the Duke University in the United States, which demonstrated clinical benefits achieved by children with cerebral palsy after receiving their own cord blood. Regarding the use of cord blood in autism spectrum disorder (ASD), there are also clinical benefits; research has shown that these benefits are more pronounced in children without intellectual disabilities. It has been also confirmed that clinical benefit was achieved when appropriate dose of cells was infused. Procedure is safe and well tolerated. The program is aimed at clients of FamiCord Group who have their own cord blood stored in the group’s laboratories and have a diagnosis of autism spectrum disorder (ASD) or cerebral palsy (CP). Additionally, the cord blood unit must meet strict qualification criteria to ensure its suitability for treatment. This targeted approach ensures that eligible patients have access to potentially life-changing therapies using their own stem cells. The primary physician responsible for the programme Is Professor Magdalena Chrościńska-Krawczyk, MD, PhD, she is a paediatric neurologist at University Children’s Hospital in Lublin. For FamiCord Group clients, who wants to use their own cord blood for treatment, FamiCord Group launched the dedicated email: [braindevelopment@pbkm.pl](mailto:braindevelopment@pbkm.pl). So, if you are one of our clients – don’t hesitate to contact us. You can access the leaflet here [https://www.famicord.com/wp-content/uploads/2025/01/eksperyment-segregator-EN-04-10-2019_prev-3.pdf](https://www.famicord.com/wp-content/uploads/2025/01/eksperyment-segregator-EN-04-10-2019_prev-3.pdf) Disclaimer: Famicord cannot guarantee that you will be accepted to participate in the programme. Famicord reserves the right to stop. --- --- title: "Stem Cell Applications Stories" url: "https://www.famicord.com/services-for-families/stem-cell-applications-stories" lang: "en" type: "page" last_modified: "2025-09-30T11:13:12+00:00" translations: de: "https://www.famicord.com/services-for-families/stem-cell-applications-stories" custom_fields: is_unavailable_in_germany: 1 display_availability_of_our_service_section: 1 allowed_ips.0.ip: "217.7.5.50" allowed_ips.1.ip: "194.34.158.41" allowed_ips.2.ip: "94.101.33.193" --- # Stem Cell Applications Stories # Stories Our Patients # Our Patients Parents considering depositing cord blood often wonder if it’s worth it. The best ambassadors for the cord blood banking service are Patients who have been saved by stem cell collection during delivery. We encourage you to read selected stories of Children who are alive thanks to cord blood. ## Historie naszych pacjentów - ![antek-thumbnail](https://www.famicord.com/wp-content/uploads/2024/12/antek-thumbnail.webp) ## Antek was cured thanks to stem cells from his own cord blood At the age of 3, Antoś developed aplastic anemia.This disease involves damage to the bone marrow, resulting in reduced production of red and white blood cells and platelets leading to anemia. The salvation for patients is a stem cell transplant. At the time of Antek’s illness, his sister was 7 months old, and despite being genetically compatible with him, she could not become a bone marrow donor for her brother because she was too young.Fortunately, the boy’s parents secured his stem cells from umbilical cord blood during delivery.Despite the low leukocyte content of the biological material collected, it was sufficient for transplantation and saved Antek’s life. ![](https://www.famicord.com/wp-content/themes/starter-empressia/dist/images/patientsStories/woman-image.webp) Małgosia Mom of Antoś - ![](https://www.famicord.com/wp-content/themes/starter-empressia/dist/images/patientsStories/man-image.webp) Antek - ![ada-thumbnail](https://www.famicord.com/wp-content/uploads/2024/12/ada-thumbnail.webp) ## Using your own stem cells in cerebral palsy – Ada’s story Ada underwent a stem cell transplant from her own cord blood at the age of 2 due to cerebral palsy. The symptom that worried the Parents was the lack of grip with the right hand. After the diagnosis, it turned out that Ada had undergone a stroke and in the future would have problems with the functioning of the right side of her body. Ada’s parents secured her umbilical cord blood during delivery. In 2018, the girl had a transplant of her own stem cells at Duke University in the United States. About two days after the transplant, Ada began grasping with her right hand. ![adas-mom](https://www.famicord.com/wp-content/uploads/2024/12/adas-mom.webp) Beata Ada’s mom - ![ada](https://www.famicord.com/wp-content/uploads/2024/12/ada.webp) Ada - ![olek-thumbnail](https://www.famicord.com/wp-content/uploads/2024/12/olek-thumbnail.webp) ## Olek was cured with stem cells from his younger brother’s umbilical cord blood Learn the story of Olek, whose stem cells from cord blood taken from his younger brother saved his life. Olek suffered from chronic granulomatous disease. The disease is a rare primary immunodeficiency, and unfortunately leads to death by the age of 20-30. An urgent bone marrow transplant was needed and the search for a donor began. The younger brother was not genetically compatible with the boy, but fortunately, the parents banked the cord blood during his delivery. Umbilical cord blood requires less genetic compatibility than marrow so it could be successfully used in Olek’s treatment. ![katarzyna-mom](https://www.famicord.com/wp-content/uploads/2024/12/katarzyna-mom.webp) Katarzyna Olek’s mom - ![olek](https://www.famicord.com/wp-content/uploads/2024/12/olek.webp) Olek - ![wojtek-thumbnail](https://www.famicord.com/wp-content/uploads/2024/12/wojtek-thumbnail.webp) ## Stem cells from umbilical cord improve Wojtek’s functioning Wojtek developed normally until 2.5 years. After that time he began to limp on his leg. Unfortunately, it turned out that I suffer from Krabbe’s globoid leukodystrophy. This is a rare disease for which there is no cure. The only salvation for patients is the possibility of administering stem cells from the umbilical cord, which can improve the quality of life and lead to a slowdown in the development of the disease. After stem cell therapy, Wojtek began to swallow, became less spastic, and even went to kindergarten. ![mom-wojtek](https://www.famicord.com/wp-content/uploads/2024/12/mom-wojtek.webp) Anna Wojtek’s mom - ![wojtek](https://www.famicord.com/wp-content/uploads/2024/12/wojtek.webp) Wojtek - ![lidka-thumbnail](https://www.famicord.com/wp-content/uploads/2024/12/lidka-thumbnail.webp) ## Stem cell therapy from the umbilical cord in the treatment of Lidka Lidzia was born as a premature baby at 29 weeks gestation. In the first year of the girl’s life, she was diagnosed with spinal cerebellar ataxia and Hirschsprung’s disease…. Lidka’s parents learned about stem cell therapy from the Internet. After an initial medical evaluation, the girl was qualified for stem cell therapy from the umbilical cord. Five days after the stem cells were administered, Lidia began walking. The therapy helped her get rid of the symptoms of cerebellar ataxia, and also improved her overall condition. The painful sprains that were causing great pain to the girl disappeared. ![lidka-mom](https://www.famicord.com/wp-content/uploads/2024/12/lidka-mom.webp) Ewa Lidka’s mom - ![lidka](https://www.famicord.com/wp-content/uploads/2024/12/lidka.webp) Lidka - ![tadzio-thumbnail](https://www.famicord.com/wp-content/uploads/2024/12/tadzio-thumbnail.webp) ## Stem cell therapy from the umbilical cord – Tadzio’s story Tadeusz suffers from hypoxic-ischemic encephalopathy, probably caused by a long 24-hour labor. As a baby boy, he underwent stem cell therapy from the umbilical cord, which significantly improved his motor and cognitive abilities. Now Tadzio is able to reach for objects on his own, something he couldn’t do before. His speech has also improved significantly – it was virtually non-existent before. Thanks to the therapy, Tadzio has begun to bend his knees, put foot after foot after foot, and even try to jump and run on bent legs. ![tadzio-mom](https://www.famicord.com/wp-content/uploads/2024/12/tadzio-mom.webp) Magdalena Tadzio’s mom - ![tadzio](https://www.famicord.com/wp-content/uploads/2024/12/tadzio.webp) Tadzio - ![mateusz-thumbnail](https://www.famicord.com/wp-content/uploads/2024/12/mateusz-thumbnail.webp) ## Stem cell therapy from the umbilical cord in the treatment of Matthew Matthew was born with many defects. The boy suffers from min.Cerebral palsy.At the age of 5, Matthew was qualified for stem cell therapy from the umbilical cord. The therapy brought amazing results. Matthew became less spastic, more contactable, his focus improved. The boy began to take his first steps, as well as to speak single words. ![matthew-dad](https://www.famicord.com/wp-content/uploads/2024/12/matthew-dad.webp) Józef Matthew’s dad - ![matthew](https://www.famicord.com/wp-content/uploads/2024/12/matthew.webp) Matthew - ![kacper-thumbnail](https://www.famicord.com/wp-content/uploads/2024/12/kacper-thumbnail.webp) ## Victoria’s cord blood saves big brother’s life For more than two years, 7-year-old Kacper struggled with aplastic anemia – a severe bone marrow dysfunction.The only chance for the boy was a bone marrow transplant. Unfortunately, the parents were genetically compatible with Kacper in only half, and younger brother Nikolai in 7 out of 10 antigens. Since a 9 out of 10 match is required when transplanting marrow – family members were excluded as donors. The fight against time began. A year after the disease was diagnosed, a donor was found, and Kacper began preparing for surgery. Unfortunately, 10 days before the scheduled surgery, the donor withdrew. The rescue came in the form of a younger sister, from whom cord blood was collected and then transplanted into Kacper. This was the 9th.consecutive family stem cell transplantation from cord blood stored at PBKM. ![kacper-mom](https://www.famicord.com/wp-content/uploads/2024/12/kacper-mom.webp) Dorota Kacper’s mom - ![kacper](https://www.famicord.com/wp-content/uploads/2024/12/kacper.webp) Kacper - ![radek-thumbnail](https://www.famicord.com/wp-content/uploads/2024/12/radek-thumbnail.webp) ## The use of cells from one’s own cord blood in autism – Radek’s story Autism spectrum disorders are neurodevelopmental disorders. Symptoms that characterize the boy’s disorder include: lack of independence requiring daily support such as eating, problems communicating with the environment and hyperactivity. After the administration of his own stem cells from umbilical cord blood, Radek began to pronounce the “r” voice. Very spontaneously, instead of las my child says bór,” Radek’s mother recalls. The boy has learned to clap his hands and his need for closeness with his mother has emerged, which translates into improved overall communication. ![](https://www.famicord.com/wp-content/themes/starter-empressia/dist/images/patientsStories/woman-image.webp) Anna Radek’s mom - ![](https://www.famicord.com/wp-content/themes/starter-empressia/dist/images/patientsStories/man-image.webp) Radek ### See Also - ![milosz-thumbnail](https://www.famicord.com/wp-content/uploads/2024/12/milosz-thumbnail.webp) Milosz is alive thanks to cord blood - ![amelia-thumbnail](https://www.famicord.com/wp-content/uploads/2024/12/amelia-thumbnail.webp) Stem cells a lifesaver for Amelia - ![dominika](https://www.famicord.com/wp-content/uploads/2024/12/dominika.webp) Cord blood saved Dominika’s life - ![michael-yt](https://www.famicord.com/wp-content/uploads/2024/12/michael-yt.webp) Michael is alive thants to Antony’s cord blood - ![veronica-yt](https://www.famicord.com/wp-content/uploads/2024/12/veronica-yt.webp) Veronica overcame leukemia thanks to cord blood - ![agata-yt](https://www.famicord.com/wp-content/uploads/2024/12/agata-yt.webp) The amazing story of Agata Roczniak --- --- title: "Stem Cell Applications List" url: "https://www.famicord.com/services-for-families/stem-cell-applications-list" lang: "en" type: "page" last_modified: "2026-06-16T08:54:08+00:00" translations: de: "https://www.famicord.com/services-for-families/stem-cell-applications-list" custom_fields: is_unavailable_in_germany: 1 display_availability_of_our_service_section: 1 allowed_ips.0.ip: "217.7.5.50" allowed_ips.1.ip: "194.34.158.41" allowed_ips.2.ip: "94.101.33.193" --- # Stem Cell Applications List # Stem Cells Therapies ## Stem Cells Therapies The purpose of banking stem cells is to apply them in the therapy. For the first time cord blood was used in 1988 and since then according to publicly available statistics it has been used over 85 000 times worldwide (including statistics of China). FamiCord Group stores over 1,000,000 samples of cells of different types and has supplied stem cells for application in clinic for more than 7000 patients. We supply stem cells for standard transplantations (cord blood , bone marrow and mobilized peripheral blood) and cellular therapies. On top of that we provide cell based products in GMP standard for clinical trials. Stem cells manufactured in our premises helped patients with various diseases and therapeutic areas, including haematological, neurological, ophthalmological, orthopaedical, dermatological disorders. Check the full list of patients who received stem cell therapy derived from FamiCord labs List last update: 06.2026 ## List of patients who received stem cells from FamiCord Group laboratories ![](https://www.famicord.com/wp-content/themes/starter-empressia/dist/images/icons/accessibility/touch-screen.webp) --- --- title: "FamiCord Contribution" url: "https://www.famicord.com/services-for-families/famicord-contribution" lang: "en" type: "page" last_modified: "2025-07-08T08:35:16+00:00" translations: de: "https://www.famicord.com/services-for-families/famicord-contribution" custom_fields: display_availability_of_our_service_section: 1 --- # FamiCord Contribution # FamiCord Contribution ## FamiCord: More than a stem cell bank We believe that banking umbilical cord blood, cord tissue, and the stem cells they contain is a step toward a safer future for families. We are dedicated to the processing, storage, and provision of cell products of the highest quality to save lives or at least improve the health of our customers. Additionally, we collaborate closely with physicians worldwide who use stem cells for hematopoietic transplants. Through initiatives such as our Compassionate Use Program, we promote the use of stored umbilical cord blood for the treatment of autism spectrum disorders and cerebral palsy. Our program enables families to access treatments that can significantly impact the health and well-being of their loved ones. ![Icon](https://www.famicord.com/wp-content/uploads/2024/12/Info-1.svg) #### Important This content provides information about the applications of cord blood and other tissues. Due to local regulations in Germany, access is restricted for viewers in Germany. For more information, please visit www.vita34.de. [ See more ](#regions) [ ![family](https://www.famicord.com/wp-content/uploads/2024/12/family.webp) ![family](https://www.famicord.com/wp-content/uploads/2024/12/family.webp) List of patients who received stem cells from FamiCord Group laboratories ](https://famicord.com/index.php/services-for-families/stem-cell-applications-list/) [ ![getty-images-KXGbJmSWQzM-unsplash (1) (1) 1](https://www.famicord.com/wp-content/uploads/2025/02/getty-images-KXGbJmSWQzM-unsplash-1-1-1.webp) ![getty-images-KXGbJmSWQzM-unsplash (1) (1) 1](https://www.famicord.com/wp-content/uploads/2025/02/getty-images-KXGbJmSWQzM-unsplash-1-1-1.webp) Stem cells applications stories ](https://famicord.com/index.php/services-for-families/stem-cell-applications-stories/) [ ![af0a55523e86b0ed0521a405c74848b1](https://www.famicord.com/wp-content/uploads/2024/12/af0a55523e86b0ed0521a405c74848b1.webp) ![af0a55523e86b0ed0521a405c74848b1](https://www.famicord.com/wp-content/uploads/2024/12/af0a55523e86b0ed0521a405c74848b1.webp) Expanded Access Programme ](https://famicord.com/index.php/services-for-families/expanded-access-programme/) --- --- title: "Scientific Proof" url: "https://www.famicord.com/services-for-families/scientific-proof" lang: "en" type: "page" last_modified: "2025-04-16T12:30:19+00:00" translations: de: "https://www.famicord.com/services-for-families/scientific-proof" custom_fields: display_availability_of_our_service_section: 1 --- # Scientific Proof # Scientific Proof ## Umbilical Cord Blood in Medicine Umbilical cord blood is a valuable resource for the treatment of various blood disorders. This is due to the blood stem cells contained in umbilical cord blood. These cells can generate all types of blood cells when needed and are therefore used, for example, to restore blood formation and the immune system after severe chemotherapy or radiation therapy1. So far, umbilical cord blood has been used in the treatment of approximately 80 diseases, including various types of cancer, blood disorders, and immune system disorders2. Due to the special properties of stem cells, umbilical cord blood is also a foundation for the development of new, innovative therapies. ![Ikona](https://www.famicord.com/wp-content/uploads/2024/12/document.svg) ## Diseases for Which Umbilical Cord Blood Can Be Used2 Adrenoleukodystrophy Acute biphenotypic leukemia Acute lymphoblastic leukemia (ALL) Acute myelofibrosis Acute myeloid leukemia (AML) Acute lymphogranulomatosis Common variable immunodeficiency Severe aplastic anemia Beta-thalassemia Breast cancer Chediak-Higashi syndrome Chronic granulomatous disease (CGD) Chronic lymphocytic leukemia (CLL) Chronic myeloid leukemia (CML) Chronic myelomonocytic leukemia (CMML) DiGeorge syndrome Ewing sarcoma Familial erythrophagocytic lymphohistiocytosis Fanconi anemia Gaucher disease Glanzmann’s thrombasthenia Hemophagocytosis Histiocytic disorders Histiocytosis-X Hunter syndrome (MPS-II) Juvenile chronic myeloid leukemia (JCML) Juvenile myelomonocytic leukemia (Naegeleg leukemia) (JMML) Cartilage-hair hypoplasia Kostmann syndrome Lesch-Nyhan syndrome Leukocyte adhesion deficiency Maroteaux-Lamy syndrome (MPS-VI) Megakaryocytosis (inherited thrombocythemia) Metachromatic leukodystrophy Krabbe disease Morquio syndrome (MPS-IV) Mucolipidosis II Mucopolysaccharidoses (MPS) Multiple myeloma Myelofibrosis Neuroblastoma Neutrophil actin dysfunction Niemann-Pick disease Kidney cancer Non-Hodgkin lymphoma Omenn syndrome Osteopetrosis (marble bone disease) Paroxysmal nocturnal hemoglobinuria Plasmacytic leukemia Polycythemia vera Prolymphocytic leukemia Refractory anemia (RA) Refractory anemia with ringed sideroblasts (RARS) Refractory anemia with excess blasts (RAEB) Refractory anemia with excess blasts in transformation (RAEB-T) Pure red cell aplasia Reticular dysgenesis Sanfilippo syndrome (MPS-III) Scheie syndrome (MPS-IS) Poorly differentiated acute leukemia Severe combined immunodeficiency (SCID) SCID adenosine deaminase deficiency SCID T- and B-lymphocyte negative SCID T-lymphocyte negative and B-lymphocyte positive Sickle cell anemia Sly syndrome, beta-glucuronidase deficiency (MPS-VII) Bare lymphocyte syndrome Telangiectasia Waldenström’s macroglobulinemia Essential thrombophlebitis Wiskott-Aldrich syndrome Wolman disease X-linked lymphoproliferative disorder **PLEASE NOTE:** For the diseases listed above, umbilical cord blood has been proven to be used in treatment. However, the decision to use stored umbilical cord blood is made individually by the attending physician based on the specific disease situation and available treatment options. ## Diseases Under Research for Umbilical Cord Blood Treatment New therapies for blood formation and immune system restoration3 Immunocell therapies4 Brain damage5 Heart defects6 Lung diseases7 Autoimmune diseases8 Metabolic diseases9 COVID10 Degenerative muscle diseases11 Endometrial diseases12 Solid tumors13 ## References - Bundesärztekammer. 2019. _Dtsch Arztebl International_. doi:10.3238/arztebl.2019.rl_haematop_sz02. - Dessels C;Alessandrini M;Pepper M.S. 2018. Stem Cells Transl Med. doi:10.1002/sctm.17-0244. - ClinicalTrials.gov. NCT03441958: A Phase I-II Open-label Study of Non-myeloablative-allogeneic Transplant of ECT-001 (UM171/ Fed-batch Culture System) Expanded Cord Blood in Patients With High-risk Multiple Myeloma. https://clinicaltrials.gov/ct2/show/NCT03441958. Accessed September 10, 2024. - ClinicalTrials.gov. NCT02727803: Personalized NK Cell Therapy in Cord Blood Transplantation. https://clinicaltrials.gov/ct2/show/NCT02727803. Accessed September 27, 2024. - ClinicalTrials.gov. NCT02881970: Neonatal Hypoxic Ischemic Encephalopathy : Safety and Feasibility Study of a Curative Treatment With Autologous Cord Blood Stem Cells (NEOSTEM). https://clinicaltrials.gov/ct2/show/NCT02881970. Accessed September 27, 2024. - ClinicalTrials.gov. NCT04907526: Intramyocardial Injection of Autologous UCB-MNC During Fontan Surgery for SRV Dependent CHD. https://clinicaltrials.gov/ct2/show/NCT04907526?recrs=abdf&cond=heart&intr=cord+blood&draw=2&rank=3. Accessed September 27, 2027. - ClinicalTrials.gov. NCT01632475: Long Term Follow-Up Study of the Safety and Exploratory Efficacy of Pneumostem® in Premature Infants With Bronchopulmonary Dysplasia. https://clinicaltrials.gov/ct2/show/NCT01632475. Accessed September 27, 2024. - ClinicalTrials.gov. NCT03835312: Sequential Transplantation of Umbilical Cord Blood Stem Cells and Islet Cells in Children and Adolescents With Monogenic Immunodeficiency Type 1 Diabetes Mellitus. https://clinicaltrials.gov/ct2/show/NCT03835312. Accessed September 27, 2024. - ClinicalTrials.gov. NCT02254863: Augmentation of Umbilical Cord Blood Transplantation for Inherited Metabolic Diseases With Intrathecal Administration of Human Umbilical Cord Blood-Derived Oligodendrocyte-Like Cells. https://clinicaltrials.gov/ct2/show/NCT02254863. Accessed September 27, 2024. - ClinicalTrials.gov. NCT05682560: Human Umbilical Cord Blood (RegeneCyte) Infusion in Patients With Post-COVID Syndrome. [Phase 2, USA]. https://www.clinicaltrials.gov/study/NCT05682560. Updated August 3, 2023. Accessed September 27, 2024. - ClinicalTrials.gov. NCT05695521: Regulatory T Cells for Amyotrophic Lateral Sclerosis (REGALS). [Phase 1, USA]. https://www.clinicaltrials.gov/study/NCT05695521. Updated August 3, 2023. Accessed September 27, 2024. - ClinicalTrials.gov. NCT05095597: Umbilical Cord Plasma for Treating Endometrial Pathologies (Thin Endometrium /​ Asherman’s Syndrome/​ Endometria Atrophy) (hSCU-PRP). [Phase 2, Spanien]. https://www.clinicaltrials.gov/study/NCT05095597. Updated August 3, 2023. Accessed September 10, 2024. - ClinicalTrials.gov. NCT05303727: Allogeneic Hematopoietic Stem Cell Transplantation for 4/​M Neuroblastoma. [Phase 2, China]. https://www.clinicaltrials.gov/study/NCT05303727. Updated August 3, 2023. Accessed September 10, 2024. --- --- title: "Stem Cells" url: "https://www.famicord.com/services-for-families/stem-cells" lang: "en" type: "page" description: "Type of stem cellsCharacteristicsExamplesTotipotent cellsEach cell can develop into a new individualCells of embryo of 1-3 daysPluripotent cellsEach cell can form any cell type (over 200)Cells of blastocyst 5-14 days Multipotent cellsCell differentiate and can form a number of tissue" last_modified: "2025-02-04T15:17:40+00:00" translations: de: "https://www.famicord.com/services-for-families/stem-cells" custom_fields: display_availability_of_our_service_section: 1 --- # Stem Cells # Stem Cells ## Stem Cells – What They Are? Stem cells are primitive, non-specialized cells characterized by their limitless potential to proliferate and their unique ability to differentiate into specialized cells, which leads to the formation of tissues. These properties allow stem cells to renew or replace damaged cells. They can be harvested from various sources, including umbilical cord blood. - ![Frame 93](https://www.famicord.com/wp-content/uploads/2024/12/Frame-93.webp) - ![Frame 94](https://www.famicord.com/wp-content/uploads/2024/12/Frame-94.webp) - ![Frame 95](https://www.famicord.com/wp-content/uploads/2024/12/Frame-95.webp) - ![Frame 96](https://www.famicord.com/wp-content/uploads/2024/12/Frame-96.webp) Historically, bone marrow was the primary source of stem cells, as bone marrow transplantation involves transplanting stem cells derived from the bone marrow. However, today, umbilical cord blood stem cells are more commonly used for therapeutic purposes. Other sources of stem cells include peripheral blood drawn from donors who have undergone pharmacological mobilization. Throughout an organism’s life, new cells are systematically produced, and these cells gradually mature and differentiate into more specialized types. Eventually, these cells perish after a specific period of time, as inscribed in their genetic code. Specific stem cells are cells which directly replace the dead ones All stem cells, even those with only transient presence in the body, can be classified into four categories: totipotent, pluripotent, multipotent, and unipotent. Multipotent cells include hematopoietic stem cells and the human umbilical cord blood is a good source of such cells. ## Type of Stem Cells | Type of stem cells | Characteristics | Examples | | --- | --- | --- | | Totipotent cells | Each cell can develop into a new individual | Cells of embryo of 1-3 days | | Pluripotent cells | Each cell can form any cell type (over 200) | Cells of blastocyst 5-14 days | | Multipotent cells | Cell differentiate and can form a number of tissue types | Fetal tissue, cord blood, adult cells | Stem cells, due to their unique properties, can be used in treatment. However, it’s important to remember that not all stem cells are equal, and not every type can be used in therapy. In the FamiCord Group we focus on multipotent stem cells from perinatal tissues such as cord blood stem cells, cord tissue stem cells and placenta stem cells. Umbilical cord blood is one of the richest sources of stem cells found in nature. While cord blood stem cells are not embryonic, they are more pristine than the stem cells in adults because they are younger and have had less exposure to illness or environmental factors. The most well-known uses of stem cells include the widely recognized “bone marrow transplants,” which are essentially transplants of hematopoietic stem cells. Umbilical cord stem cells are also hematopoietic stem cells and can be used to treat over 80 severe oncological and hematological diseases. However, what are the differences between them? ##### Differences between stem cells from umbilical cord blood and bone marrow ![Ikona](https://www.famicord.com/wp-content/uploads/2024/12/Drop.svg) ## Umbilical cord blood ![Ikona](https://www.famicord.com/wp-content/uploads/2024/12/bone.svg) ## Bone marrow ### Source material collection simple, blood harvesting takes a few minutes at childbirth, non-invasive and safe time-consuming, takes at least 25-30 minutes, invasive procedure under general anesthesia ### Risk of cross contamination minimal, as the blood is taken from the placenta and the umbilical vessels higher risk, as donors could potentially be virus carriers ### Availability for transplantation cord blood is available after deposition in a transplant bank and awaits the recipient the marrow has to be harvested from a donor who, even if registered, is required to be present in order to confirm compatibility and collect the marrow, the donor must be in excellent health to allow the bone marrow harvest ### Growth potential higher cell proliferation lower cell proliferation ### Donor and recipient compatibility easy – 4 out of 6 HLA antigens must match extremely difficult – 18 out of 10 HLA antigens must match haploidentical transplants can be performed ### Potential donors can only be removed once in a lifetime (at birth) any healthy adult can be a potential donordates may prove complicated ### Potential recipients the average cord blood unit is suitable for a recipient weighing around 40 kg sufficient for recipients up to 70-80 kg in 2024, the FDA approved Omidubicel, an innovative method for expanding stem cells that allows cord blood to overcome further limitations ## Cord tissue & Placenta: promising source of stem cells The tissues of the umbilical cord and placenta are abundant sources of mesenchymal stromal cells (MSCs). The cells in the umbilical cord, known as Wharton’s jelly cells, differ slightly from umbilical cord blood cells. They are more easily differentiated into other types of cells, such as nerve cells, bone, and cartilage. Currently, MSCs are the most widely used cell type in regenerative medicine and are frequently featured in research. These cells show significant potential in treating a wide range of autoimmune disorders and injuries to muscle, bone, and organs, including heart disease and sports-related injuries. MSCs derived from neonatal sources, like the umbilical cord tissue and placenta, have a faster growth rate compared to those obtained from adult donors and are free from disease exposure. The umbilical cord can be easily harvested after delivery in a non-invasive, painless procedure for both the mother and baby. A 10–15 cm section of the umbilical cord is cut and placed into a special container by a doctor or midwife. In the laboratory, the tissue is examined, prepared, and frozen. Stem cells can also be isolated before freezing. In addition to stem cell collection from umbilical cord blood and tissue, FamiCord offers placenta tissue banking in some markets. The placenta, like the umbilical cord, is a source of mesenchymal stem cells. Due to its unique location, the stem cells in the placenta have distinct properties, which make them useful in regenerative medicine. Tissue stem cells from the umbilical cord and placenta can be used by the child, their siblings, parents, and even grandparents. --- --- title: "Services for families" url: "https://www.famicord.com/services-for-families" lang: "en" type: "page" last_modified: "2024-12-17T13:47:35+00:00" translations: de: "https://www.famicord.com/services-for-families" --- # Services for families --- --- title: "FamiCord Group" url: "https://www.famicord.com/about-us/famicord-group" lang: "en" type: "page" description: "CountryBrandWebsiteAustriaVita 34vita34.atCzech RepublicNárodní centrum pupečníkové krvepupecnikovakrev.czDenmarkVita 34vita34.dkGermanyVita 34vita34.deGermanyeticureticur.deHong-KongSmart Cellssmartcells.comHungaryKRIO Intezetkrio.huItalySorgentesorgente.comLatviaCilmes Šūnu Bankacilmessunubanka.lvLuxemburgFamiCord Suissefamicord.luPolandDiagnostica Bank Komórek Macierzystychdbkm.plPolandPolski Bank Komórek Macierzystychpbkm.plPortugalCrioestaminalcrioestaminal.ptPortugalBebéCordbebecord.ptRomaniaBiogenisbiogenis.roSlovakiaRodinná banka Slovakiacakam-babatko.skSpainVita 34secuvita.esSpainIvidabancodecordonivida.comSpainSevibesevibe.esSwitzerlandVita 34vita34.chSwitzerlandFamiCord Suissefamicord.chTurkeyFamicord-Acibadem Kordon Kanı Sağlık Hizmetlerifamicordturkiye.comTurkeyYaşam Bankası Sağlık Hizmetleri İç ve Dış Tıcaretkordonkanibankasi.comUnited Arab EmiratesSmart Cellssmartcells.aeUnited KingdomSmart Cellssmartcells.com" last_modified: "2026-04-17T06:40:47+00:00" translations: de: "https://www.famicord.com/about-us/famicord-group" custom_fields: display_availability_of_our_service_section: 1 --- # FamiCord Group # FamiCord Group FamiCord is represented in 34 countries. We offer our services under locally recognized brands. Find the FamiCord brand in your country. | Country | Brand | Website | | --- | --- | --- | | Austria | Vita 34 | vita34.at | | Czech Republic | Národní centrum pupečníkové krve | pupecnikovakrev.cz | | Denmark | Vita 34 | vita34.dk | | Germany | Vita 34 | vita34.de | | Germany | eticur | eticur.de | | Hong-Kong | Smart Cells | smartcells.com | | Hungary | KRIO Intezet | krio.hu | | Italy | Sorgente | sorgente.com | | Latvia | Cilmes Šūnu Banka | cilmessunubanka.lv | | Luxemburg | FamiCord Suisse | famicord.lu | | Poland | Diagnostica Bank Komórek Macierzystych | dbkm.pl | | Poland | Polski Bank Komórek Macierzystych | pbkm.pl | | Portugal | Crioestaminal | crioestaminal.pt | | Portugal | BebéCord | bebecord.pt | | Romania | Biogenis | biogenis.ro | | Slovakia | Rodinná banka Slovakia | cakam-babatko.sk | | Spain | Vita 34 | secuvita.es | | Spain | Ivida | bancodecordonivida.com | | Spain | Sevibe | sevibe.es | | Switzerland | Vita 34 | vita34.ch | | Switzerland | FamiCord Suisse | famicord.ch | | Turkey | Famicord-Acibadem Kordon Kanı Sağlık Hizmetleri | famicordturkiye.com | | Turkey | Yaşam Bankası Sağlık Hizmetleri İç ve Dış Tıcaret | kordonkanibankasi.com | | United Arab Emirates | Smart Cells | smartcells.ae | | United Kingdom | Smart Cells | smartcells.com | FamiCord also offers its services via business partners. Find the FamiCord partner in your country. | Country | Legal Entity | Website | | --- | --- | --- | | Albania | Bio Save Albania | biosave.al | | Bosnia & Herzegovina | Bio Save Adriatic  | bio-save.ba | | Bulgaria | Orthogyn | orthogyn.com | | Bulgaria | Cells4Good | cells4good.com | | Croatia | BioSave Croatia | biosave.hr | | Cyprus | FamiCord Cyprus | famicordcy.com/el | | Denmark | Cellaviva Denmark | cellaviva.dk | | Estonia | UAB Placenta | placenta.lt | | Italy | VitaCord | vitacord.it | | Italy | Serena Medical | serenastaminali.com | | Lebanon | CryoGene | cryogene.eu | | Lithuania | UAB Placenta | placenta.lt | | Macedonia | BioSave Macedonia | biosave.mk | | Montenegro | BioSave Montenegro | biosave.me | | Romania | Besmax Life Solution | besmax.ro | | Serbia | BioSave Serbia | biosave.rs | | Serbia | Cord iPS | cord.rs | | Slovenia | BioSave Slovenia | izvorna-celica.si | | South Africa | Next Biosciences | nextbio.co.za | | Sweden | Cellaviva Sweden | cellaviva.se | | Ukraine | Ukrainian Stem Cell Bank | ubsk.com.ua | --- --- title: "FamiCord Story" url: "https://www.famicord.com/about-us/famicord-story" lang: "en" type: "page" last_modified: "2025-02-04T15:23:52+00:00" translations: de: "https://www.famicord.com/about-us/famicord-story" custom_fields: display_availability_of_our_service_section: 1 --- # FamiCord Story # FamiCord Story # FamiCord Story Today’s FamiCord Group is the result of the gradual merger of European stem cell banks. Our roots go back to the founding of the German Vita 34 in 1997 and the Polish PBKM in 2002. 25 years of continuous development have resulted in the largest European stem cell bank. ### 2025 FamiCord becomes a corporate brand. The parent company Vita 34 AG is renamed into FamiCord AG. ### 2024 FamiCord opens its first laboratory outside Europe in Dubai. For the first time, the Group is storing more than one million umbilical cord blood units and other biological materials. ### 2023 FamiCordTx in Warsaw manufactures the first proprietary CAR-T product for cancer therapy. ### 2022 Following the merger, the Group consolidates its overlapping activities in Spain and Switzerland. ### 2021 PBKM FamiCord acquires the SmartCells Group, which operates in the UK, the Middle East and Hong Kong. Vita 34 and PBKM FamiCord merge to form the largest european stem cell bank. Vita 34 AG will become the sole owner of PBKM S.A. and PBKM shareholders receive Vita 34 shares in exchange for PBKM shares. ### 2020 AOC Health GmbH becomes the main shareholder of PBKM. FamiCordTx is founded as a PBKM spin-off to develop CAR-T therapies for the treatment of cancer. PBKM strengthens its presence in Turkey with a further acquisition and begins strategic cooperation with Acibadem, the country’s largest hospital group. PBKM acquires a stake in Sorgente, the market leader on the Italian market. ### 2019 Sevibe, the Spanish subsidiary of the PBKM FamiCord Group, acquires local competitor IVI Cordon. PBKM acts as a backup for a stem cell bank in Switzerland and transfers its stem cells safely from Belgium, Switzerland and Germany to Warsaw for storage. PBKM FamiCord launches an Expanded Access Program for the use of umbilical cord blood for brain repair. ### 2018 PBKM FamiCord’s services will also be available in the Balkans in cooperation with BioSave. PBKM acquires Stemlab, the market leader in Portugal, which also operates in Italy, Spain and Switzerland. PBKM acquires a laboratory in Switzerland. The PBKM FamiCord Group has grown to become the world’s fifth largest umbilical cord blood bank. ### 2017 Vita 34 acquires the largest German competitor Seracell and thus becomes the clear market leader. ### 2016 PBKM goes public as Polski Bank Komórek Macierzystych S.A. on the Warsaw Stock Exchange. ### 2015 Sevibe Cells’ laboratory becomes the first private stem cell bank in Spain to be accredited by the AABB. Vita 34 acquires Stemcare, the largest private umbilical cord blood bank in Denmark. Vita 34 is expanding via partnerships and minority shareholdings in the Balkans and the Baltic States. Following further acquisitions, the PBKM FamiCord Group stores 122,000 umbilical cord blood and tissue samples. ### 2014 PBKM acquires majority stakes in local competitors in Poland. ### 2013 PBKM acquires Yasam Bankasi, the oldest umbilical cord blood bank in Turkey. In Warsaw, PBKM opens the most modern site for the processing and storage of stem cells in Europe. ### 2012 PBKM acquires a blood bank in New Jersey, USA with 1,800 preparations for allogeneic applications. ### 2011 The first stem cell transplant from umbilical cord blood is performed in Hungary. The first therapy with PBKM mesenchymal stem cells is carried out in Poland. ### 2010 Enterprise Investors invests in PBKM with a venture fund. PBKM FamiCord has stored more than 35,0000 umbilical cord blood and tissue samples. ### 2009 PBKM launches FamiCord as a common brand for all European activities. PBKM founds the joint venture in Romania (Biogenis) and FamiCord Italia. ### 2008 PBKM acquires the umbilical cord blood and sperm bank Krio Intezet in Hungary. ### 2007 Vita 34 AG goes public and is listed on the regulated market of the Frankfurt Stock Exchange and at the same time in the Prime Standard sub-segment. The first stem cell application with umbilical cord blood from the PBKM laboratory is carried out. PBKM receives approval to operate a tissue and cell bank in accordance with the Polish Transplantation Act and also receives the internationally recognized AABB accreditation. PBKM makes its first international acquisition in Latvia and acquires a minority stake in an umbilical cord blood bank in Spain. ### 2006 Vita 34 receives approval for the production of blood samples for allogeneic use and can now also work as a public blood bank. PBKM secures further financing from a business angel investor and continues to expand the laboratory. ### 2005 For the first time, Vita 34 successfully uses stored umbilical cord blood to treat a sibling suffering from lymphoblastic leukemia (allogeneic application). PBKM expands its activities throughout Poland and becomes the market leader in the country. ### 2004 PBKM is audited by the Institute of Hematology and Transfusion Medicine. ### 2003 Vita 34 moves into its current company headquarters in Bio City Leipzig and opens up the “Glass Laboratory” to give customers an insight into its own work. ### 2002 In Warsaw, PBKM commences operations under the name Polski Bank Komórek Macierzystych Sp. z o.o. (Polish Stem Cell Bank) and sets up its first laboratory at the Children’s Memorial Health Institute. ### 1997 Vita 34 is founded in Leipzig as VITA 34 Gesellschaft für Zelltransplantate GmbH and opens the first private stem cell bank in Europe. The company is expanding its business in the DACH region (Germany, Austria, Switzerland). Vita 34 conducts active research and development on the preparation of stem cells from umbilical cord blood. Possible applications for umbilical cord blood transplants are being researched in cooperation with renowned research institutions. --- --- title: "About us" url: "https://www.famicord.com/about-us" lang: "en" type: "page" last_modified: "2024-12-17T13:36:49+00:00" translations: de: "https://www.famicord.com/about-us" --- # About us --- --- title: "Homepage" url: "https://www.famicord.com/" lang: "en" type: "page" last_modified: "2026-02-05T09:46:48+00:00" translations: de: "https://www.famicord.com/" --- # Homepage - [ ![famicord_slider_desktop](https://www.famicord.com/wp-content/uploads/2024/12/famicord_slider_desktop.webp) ]() - [ ![map_1](https://www.famicord.com/wp-content/uploads/2025/02/map_1.webp) ]() No. 1 Stem Cell Bank in Europe ## Who We Are FamiCord, as the first and leading European stem cell bank, has built trusted credibility over decades in the market, supported by a proven record of accomplishment in numerous clinical applications. Our core expertise lies in preserving perinatal cells and tissues, empowering families in many countries with best-in-class services that provide security and opportunities for advanced healthcare solutions. PURPOSE: We preserve cells for personalized therapies that enhance the health and quality of life for our customers. MISSION: Our mission is to empower families with personalized healthcare solutions through comprehensive cell banking services. We aim to raise awareness and make cell banking accessible and beneficial for everyone. VISION: We envision a future where cell banking and advanced cell therapies are integral to healthcare, providing accessible, life-enhancing options for all.   ![services_for_families](https://www.famicord.com/wp-content/uploads/2024/12/services_for_families.webp) ## Services for Families FamiCord offers a range of services to support families in preserving their health and future. We specialize in the collection and storage of umbilical cord blood and tissue, providing a valuable resource for potential medical treatments. Additionally, our services include personalized consultations and education, helping families make informed decisions about stem cell preservation for the well-being of their loved ones. [ More ](https://famicord.com/services-for-families/stem-cells) ![services_for_business](https://www.famicord.com/wp-content/uploads/2024/12/services_for_business.webp) ## Services for Business FamiCord provides third party companies with comprehensive solutions in the field of stem cell banking, offering reliable and secure processing, testing and long-term storage services for umbilical cord blood, cord tissue and placenta tissue. We have an extensive network of cooperating partners across Europe, Asia and Africa. Additionally, we offer a range of services for biotech companies and clinics, and we maintain partnerships with academic institutions to contribute to advancements in regenerative medicine and biotechnology. [ More ](https://famicord.com/services-for-business-partner) ![getty-images-KXGbJmSWQzM-unsplash (1) (1) 1](https://www.famicord.com/wp-content/uploads/2025/02/getty-images-KXGbJmSWQzM-unsplash-1-1-1.webp) ## FamiCord Group Contribution At FamiCord, we are working on the field of regenerative medicine, bridging the gap between scientific research and real-world solutions. From storage to clinical application, we ensure that every step of the process is meticulously managed to deliver the highest quality stem cell therapies. With our expertise and commitment, we help healthcare professionals deliver innovative therapies that improve patient outcomes worldwide. [ More ](https://famicord.com/services-for-families/stem-cell-applications-stories) ![our_areas_of_expertise](https://www.famicord.com/wp-content/uploads/2024/12/our_areas_of_expertise.webp) ## Our Areas of Expertise FamiCord operates across multiple business segments, with key areas of expertise in stem cell processing and storage and manufacturing of cell based products. Our services range from family banking for umbilical cord blood and tissue to the development of advanced cell-based therapies. With a strong focus on innovation and quality, we are committed to improve healthcare at every stage of cellular medicine, from research to clinical practice. [ More ](https://famicord.com/services-for-business-partner/our-services) ## FamiCord Accomplishments 1 000 000 Stored over 1,000,000 cord blood units and other biological materials 8 000 Provided stem cells for the treatment of over 8,000 patients 1 500 Built trustful partnerships with over 1,500 clinics around Europe 260 Enabled over 260 cord blood transplantations or infusions ## FamiCord News - 30 June 2026 FamiCord Advances Scientific Dialogue on Cell Therapies at EACD 2026 [ Read more ](https://www.famicord.com/famicord-advances-scientific-dialogue-on-cell-therapies-at-eacd-2026) - 06 May 2026 Cell Therapies – From Experiment to Standard of Care [ Read more ](https://www.famicord.com/cell-therapies-from-experiment-to-standard-of-care) [ See more ](https://famicord.com/news) --- --- title: "Blog" url: "https://www.famicord.com/blog" lang: "en" type: "page" last_modified: "2024-12-12T13:28:03+00:00" translations: de: "https://www.famicord.com/blog" --- # Blog --- --- title: "Przykładowa strona" url: "https://www.famicord.com/przykladowa-strona" lang: "en" type: "page" description: "Przykładowa strona. Strony są inne niż wpisy na blogu, ponieważ nie tylko znajdują się zawsze w jednym miejscu, ale także pojawiają się w menu witryny (w większości motywów). Większość użytkowników zaczyna od strony z informacjami o sobie, która zapozna ich" last_modified: "2024-12-12T13:27:45+00:00" translations: de: "https://www.famicord.com/przykladowa-strona" --- # Przykładowa strona Przykładowa strona. Strony są inne niż wpisy na blogu, ponieważ nie tylko znajdują się zawsze w jednym miejscu, ale także pojawiają się w menu witryny (w większości motywów). Większość użytkowników zaczyna od strony z informacjami o sobie, która zapozna ich przed odwiedzającymi witrynę. Taka strona może zawierać na przykład taką treść: > Cześć! Za dnia jestem kurierem rowerowym, nocą próbuję swoich sił w aktorstwie, a to jest moja witryna. Mieszkam w Krakowie, mam wspaniałego psa który wabi się Reks i lubię piña coladę (oraz spacery, gdy pada deszcz). …albo coś takiego: > Firma XYZ Doohickey została założona w 1971 roku i od tamtej pory dostarcza społeczeństwu dobrej jakości gadżety. Znajdująca się w Gotham City XYZ zatrudnia ponad 2000 osób i robi niesamowite rzeczy dla społeczności Gotham. Jako nowy użytkownik WordPressa, powinieneś przejść do [swojego kokpitu](https://famicord.com/wp-admin/) aby usunąć tę stronę i stworzyć nowe z własną treścią. Dobrej zabawy! --- --- title: "Dr Tomasz Baran – FamiCord Vicepresident – speaks on cord blood banking at world’s largest cord blood conference" url: "https://www.famicord.com/dr-tomasz-baran-famicord-vicepresident-speaks-on-cord-blood-banking-at-worlds-largest-cord-blood-conference" lang: "en" type: "post" description: "Tomasz Baran, MD, MBA, Vice President of FamiCord Group, recently shared his expertise on cord blood banking at the world’s largest cord blood conference..." last_modified: "2025-01-15T10:47:27+00:00" categories: [2024] translations: de: "https://www.famicord.com/dr-tomasz-baran-famicord-vicepresident-speaks-on-cord-blood-banking-at-worlds-largest-cord-blood-conference" --- # Dr Tomasz Baran – FamiCord Vicepresident – speaks on cord blood banking at world’s largest cord blood conference **Tomasz Baran, MD, MBA, Vice President of FamiCord Group, recently shared his expertise on cord blood banking at the world’s largest cord blood conference. During his presentation, Dr. Baran highlighted the latest advancements in stem cell research and discussed how it may change the current perception of cord blood banking in Europe. His insights underscore FamiCord’s commitment to innovation and leadership in the field of stem cell banking.** Cord Blood Connect is the single place where the worldwide cord blood and perinatal tissue community comes together to learn, teach, share, refresh, and reconnect. The Conference is organised each year by Cord Blood Association, the biggest association dedicated to perinatal stem cells. At Cord Blood Connect, groundbreaking results in the application of cord blood stem cells are announced, with the scientific program overseen by Dr. Joanne Kurtzberg, a pioneer in stem cell applications and the President of the Cord Blood Association. This year, Dr. Tomasz Baran took the stage on the second day of the conference, during a session dedicated to the challenges faced by the global stem cell banking sector. In his presentation, Tomasz addressed the current situation in Europe. From the perspective of FamiCord, biggest stem cell bank in Europe, a region that was once a pioneer in the field—after all, the first cord blood transplant was performed in France. Today, however, Europe is falling behind both the USA and China in terms of stem cell research and clinical applications. Dr. Baran also pointed out that the current situation in Europe is not only due to demographic challenges but is also heavily influenced by the complex legal framework that exists across the continent. These legal and regulatory barriers hinder the development and growth of the stem cell banking sector, making it difficult for European countries to catch up with more advanced markets. _“Currently, the number of applications of cord blood in Europe has drastically decreased compared to countries like China and the USA. I’m not just talking about standard hematological therapies, but also innovative applications in neurology,”_ said Dr. Baran, emphasizing the urgent need for Europe to catch up in this rapidly advancing field. FamiCord Group has been a long-standing partner of the Cord Blood Connect conference, and this year, it had the pleasure of sponsoring travel grants for six young scientists from Europe. This initiative aims to support the next generation of researchers and foster the global exchange of knowledge and ideas in the field of cord blood banking and stem cell research. --- --- title: "Expanison of cord blood stem cells as a chance for cancer patients" url: "https://www.famicord.com/expanison-of-cord-blood-stem-cells-as-a-chance-for-cancer-patients" lang: "en" type: "post" description: "Cord blood stem cells are used in medicine for treatment of over 80 different  diseases such as leukemias, lymphomas and sickle cell anaemia for over 30 years. It has also been proven that..." last_modified: "2025-01-15T10:18:21+00:00" categories: [2024] translations: de: "https://www.famicord.com/expanison-of-cord-blood-stem-cells-as-a-chance-for-cancer-patients" --- # Expanison of cord blood stem cells as a chance for cancer patients Cord blood stem cells are used in medicine for treatment of over 80 different  diseases such as leukemias, lymphomas and sickle cell anaemia for over 30 years. It has also been proven that in the field of regenerative medicine, the application of cord blood stem cells brings clinical benefit to patients. Due to its limitations, cord blood was used more often in paediatric patients than in adults. The results of new clinical trials show however that the multiplicated cord blood stem cells can be also successfully transplanted into adult patients. Cord blood stem cells are the hope of 21st century medicine. Over 3,000 studies in various fields are currently underway around the world to discover the potential of stem cells. The results of a study on the use of multiplicated cord blood stem cells in the treatment of patients with blood cancers, published last week, show that umbilical cord blood stem cells grown in the laboratory and transplanted into patients are of significant clinical benefit. Omidubicel is the name of a preparation of hematopoietic cells from a single unit of umbilical cord blood, multiplied in laboratory conditions. A clinical study investigated its effectiveness compared with standard cord blood stem cell transplantation. The study lasted between January 2015 and January 2020, and involved 125 patients aged 13 to 65 years with blood cancer. Patients who received omidubicel achieved adequate recovery of white blood cells 10 days earlier than patients undergoing standard therapy. Moreover, they had faster platelet recovery [up to 42 days vs 90 days], a lower incidence of bacterial or invasive fungal infections (37% vs 57%) and spent more time outside the hospital in the first 100 days post-transplant than control group patients. The multiplication of hematopoietic cells was the Holy Grail of haematology – an idea that, despite many attempts over decades, no one managed to implement. The results of this study show that it has reached the point where the number of cells no longer matters. What’s more – the multiplied cells from umbilical cord blood can regenerate the hematopoietic system faster after transplantation. This may mean a wider introduction of this type of methods into clinical practice – says Emilian Snarski, MD, PhD, Medical Director of the FamiCord Group. --- --- title: "New service available – Placenta banking" url: "https://www.famicord.com/new-service-available-placenta-banking" lang: "en" type: "post" description: "FamiCord Group is excited to announce the international roll-out of this innovative service to new markets. In 2024, placenta banking..." last_modified: "2025-01-15T10:26:44+00:00" categories: [2024] translations: de: "https://www.famicord.com/new-service-available-placenta-banking" --- # New service available – Placenta banking **FamiCord Group is excited to announce the international roll-out of this innovative service to new markets. In 2024, placenta banking will be launched in Poland and Romania, in addition to Switzerland, Bulgaria, and the UAE where it is available during pilot phase. Over the coming years, the service will expand to other markets within the Group, offering families the opportunity to preserve the unique regenerative properties of placenta tissue for future medical use.** Cord blood contains hematopoietic stem cells, which have been used in medicine since 1988. Due to EBMT Guidelines, they are applied to treat over 80 haematological, oncological, and metabolic diseases. The costs of these therapies are reimbursed. Placenta, on the other hand, contains non-hematopoietic (tissue) stem cells, which  are soured to produce ATMP’s- advanced medicinal products, which are used in medical therapeutic experiments to treat conditions such as cerebral palsy, amyotrophic lateral sclerosis (ALS), and cartilage damage. The use of tissue stem cells is available to the entire family, with no need to check tissue compatibility between the donor and the recipient. _“We are constantly striving to translate the latest scientific achievements into tangible benefits for our clients, and the introduction of placenta banking for our customers is a perfect example of this commitment_,” said Tomasz Baran, MD, Vice  President of FamiCord Group. “_The service was first available for clients in Switzerland and Bulgaria, recently we did tech transfer from our Swiss lab and now it will be available much broadly – starting from in Poland and Romania. In 2025 we will continue to other markets – Italy, Austria, Germany and Latvia will follow” _he added. The effectiveness of placenta-derived MSCs (mesenchymal stem cells) has been demonstrated in animal models for a variety of indications, such as myocardial infarction, type 1 diabetes, acute kidney injury, acute liver injury, liver cirrhosis, liver fibrosis, pulmonary fibrosis, ischemic stroke, Alzheimer’s disease, spinal cord injury, and bone damage due to metastatic cancer. Clinical trials are currently underway to investigate the use of placenta-derived MSCs for various indications, including graft-versus-host disease, ischemic stroke, osteoarthritis, Crohn’s disease, and erectile dysfunction. Why baningbanking a placenta stem cells is a good choice? Banking both perinatal tissues—umbilical cord and placenta, which are rich sources of MSCs (mesenchymal stem cells)—makes profound sense. First, by maximizing the number of cells, we ensure a higher yield of MSCs after fewer cell divisions. This approach provides several key benefits such as: - We obtain a larger dose, which is essential for patients with a higher body mass. - With a higher-quality product, we achieve a better expected therapeutic outcome. - We reduce the cultivation time, which is particularly critical for treating acute conditions. Second, this approach gives the flexibility to differentiate the type of cells used, depending on the therapeutic goals. This means that, based on the specific medical indication, the physician can choose MSCs from the optimal source, ensuring the most effective treatment for the patient. The introduction of new products and services is made possible because FamiCord Group is not just a bank, but also a modern biotechnology company with three dedicated R&D centres in Canthanhiede (Portugal), Warsaw (Poland), and Leipzig (Germany), where we drive continuous innovation and advancements in the field of cell therapy. FamiCord. More than a stem cell bank.  --- --- title: "Autologus cord blood in autism treatment – new clinical trial in Romania" url: "https://www.famicord.com/autologus-cord-blood-in-autism-treatment-new-clinical-trial-in-romania" lang: "en" type: "post" description: "Researchers at Bioforum Foundation have been studying whether intravenous infusions of cord blood stem cells can help young children with autism spectrum disorder (ASD)." last_modified: "2025-01-15T09:51:49+00:00" categories: [2024] translations: de: "https://www.famicord.com/autologus-cord-blood-in-autism-treatment-new-clinical-trial-in-romania" --- # Autologus cord blood in autism treatment – new clinical trial in Romania ![](https://famicord.com/wp-content/uploads/2024/03/autologus_cord_blood_in_autism_t-921x1024.webp) **Researchers at Bioforum Foundation have been studying whether intravenous infusions of cord blood stem cells can help young children with autism spectrum disorder (ASD). The leader of this research group is dr Felician Stăncioiu. Dr. Stăncioiu is the lead investigator of a registered clinical trial NCT04007224 named “CORDUS” that is using autologous umbilical cord blood to treat children that have Autism Spectrum Disorder (ASD). This therapy is being conducted at Medicover Hospital for children in Bucharest, with sponsorship from Bio-Forum Foundation.** Surprisingly, given Romania’s low birthrate, Romania is one of the most active markets in Europe for cord blood banking. There are ten different private cord blood banks participating in the market, and the two main birthing hospitals in Romania offer their own cord blood banking services. Romania does not have a public banking system to store cord blood donations. The percentage of new mothers that bank their baby’s cord blood is estimated to be 7% in Romania, second in Europe only to Portugal at 10%. By comparison, in many countries that are famous for their medical technology, such as the United States, the penetration of cord blood banking is less than 3% of births10. The presence of so many cord blood banks in Romania makes for fierce competition, but is beneficial for spreading awareness among parents about cord blood storage and therapies with cells from perinatal sources. Health care professionals in Romania play an important role in educating patients about the option to save stem cells now to protect the family’s long-term well-being. The price range among the private cord blood banks in Romania is very wide, so that parents at different income levels can afford to participate, and instalment payment plans are offered. Biogenis can offer cord blood storage either locally in their state-of-the-art laboratory in Bucharest, or at Famicord headquarters in Warsaw, Poland. The CEO of Biogenis, Bogdan Bulumac, MD MBA, says that “Biogenis offers DNA isolation and storage for the whole family, metabolic testing for the baby, extra mesenchymal cell isolation from cord tissue for multiple usage, Transplant Assistance offered by a specialized Patient Navigator, and free treatment for cerebral palsy with the Neuro Transplant package. In the near future, we plan to go beyond all this and make one step forward towards advanced genetic testing.” Nevertheless, Biogenis feels that the most important advantage of being their client is having access to new and revolutionary therapies with stem cells, when the child or relatives need it. More than 80 Romanian clients have benefited from stem cells therapies before the end of 2022, out of which 19 used samples released from the Biogenis laboratory in Bucharest. “There is no greater satisfaction of our work than seeing the gratitude of parents who acknowledge the improvement in their children who suffer from autism, cerebral palsy or developmental delays”, admits Cristina Mihăilă, Sales Director of Biogenis. Another 5 samples are expected to be released from our bank in the next two weeks. **Medical Regulations and Autism Therapy in Romania** Romania follows the EU rules governing healthcare and medical research. There are different types of cellular therapy currently available in Romania, and all of them are administered in hospitals, none are given in doctor’s offices or clinics. Stem cell transplantation is regulated and closely supervised by the Romanian National Authority in Transplantation (ANT) and is only performed by the Fundeni Institute Hospital in Bucharest and the University Hospital in Targu Mures. At the Fundeni Institute in Bucharest, under Prof. Colita’s team, more than 1000 bone marrow and peripheral blood stem cell transplants have been performed for oncological and hematological pathologies since the year 2000. These treatments are also available in Targu Mures under Prof. Benedeck’s team. Advanced cell therapies for hematologic malignancies have also come to Romania. During the year 2022, the first three patients received CAR-T therapies at the Fundeni Institute. Investigational cell therapy is available in Romania either as part of a research clinical trial or under the framework of EU compassionate care regulations. The compassionate care criteria allow for the legal administration of stem cells when a patient suffers from a condition that is chronic, debilitating, or life-threatening. This last resort framework allows patients to receive a treatment which is not currently accepted as standard-of-care, after previous treatments have failed to cure or improve the patient’s condition, and if the doctor administering the investigational treatment considers that the risk/benefit ratio of the treatment is favorable. Compassionate care exemptions for stem cell therapy in Romania have been limited; “stem cell treatments were so far performed only sporadically – less than 100 patients since 2000”, according to Felician Stăncioiu, MD, co-author of this article and a medical researcher in Romania. He says that the compassionate care framework is being used at selected hospitals to treat patients with Mesenchymal Stromal Cells derived from the patient’s own fat tissue (autologous adipose MSC). This therapy is available at the Monza Hospital and Sanador Hospital, both of which are private hospitals. The Angiomedica Hospital use to have a research program giving adipose-derived MSC for several neurological pathologies, such as stroke or ALS, but this program is currently not active. Dr. Stăncioiu is the lead investigator of a registered clinical trial NCT04007224 named “CORDUS” that is using autologous umbilical cord blood to treat children that have Autism Spectrum Disorder (ASD). This therapy is being conducted at Medicover Hospital for children in Bucharest, with sponsorship from Bio-Forum Foundation. The trial was originally launched in 2019 with the goal to test infusions of cord blood (the experimental arm of the controlled study) against a “non-invasive” therapy relying on intranasal oxytocin combined with dietary supplements ingested orally (the control arm of the study). The trial has a cross-over study design in which children that received one treatment at their first visit will receive the other treatment two months later. In this way, all children receive both therapies, and all children are followed until one year after the initial treatment. It must be cautioned that the results of this study will not be directly comparable to the well-known trials of cord blood for ASD at Duke University12, because the outcomes are measured on a different scoring system. This trial has been extended to a larger group of ASD patients ages 3 to 7 years old, due to good results so far. In the course of this study, Dr. Stăncioiu has discovered a new biomarker for ASD, and this finding will be published in the next months in the journal Experimental and Therapeutic Medicine. “Even though the Bucharest clinical study has so far treated a small number of ASD kids (around 40), it has also tested kids who were not enrolled, and has found out that blood levels of Neuron Specific Enolase (NSE) was elevated in most ASD kids. Only 1 in 20 ASD kids tested had a normal NSE value, so that NSE may be an important biomarker for ASD, and together with inflammation markers can better guide treatment strategies for ASD.” To conclude, Romania is emerging as a European destination that offers cutting edge banking and therapies with perinatal cells. References: Parent’s Guide to Cord Blood Foundation. Results from the Duke ACT Study of Cord Blood for Autism: Highlights for Parents. Published July 2020. [https://parentsguidecordblood.org/en/news/results-duke-act-study-cord-blood-autism-highlights-parents](https://parentsguidecordblood.org/en/news/results-duke-act-study-cord-blood-autism-highlights-parents) CIA World Factbook: Romania. [https://www.cia.gov/the-world-factbook/countries/romania](https://www.cia.gov/the-world-factbook/countries/romania) Wikipedia: Romania. [https://en.wikipedia.org/wiki/Romania](https://en.wikipedia.org/wiki/Romania) Cultural Atlas: Romanian Culture. [https://culturalatlas.sbs.com.au/romanian-culture/romanian-culture-core-concepts](https://culturalatlas.sbs.com.au/romanian-culture/romanian-culture-core-concepts) Romania Tourism: Count Dracula and Vlad the Impaler. [https://romaniatourism.com/dracula-legend.html#whowasvladdracula](https://romaniatourism.com/dracula-legend.html#whowasvladdracula) IMF eLibrary. Romania: Selected Issues. [https://www.elibrary.imf.org/view/journals/002/2022/311/article-A002-en.xml](https://www.elibrary.imf.org/view/journals/002/2022/311/article-A002-en.xml) Romania Institutul Naţional de Statistică. [https://insse.ro/](https://insse.ro/) Statistica. The 20 countries with the lowest fertility rates in 2021. [https://www.statista.com/statistics/268083/countries-with-the-lowest-fertility-rates/](https://www.statista.com/statistics/268083/countries-with-the-lowest-fertility-rates/) BBC News. Fertility rate: ‘Jaw-dropping’ global crash in children being born. Published 2020-07-15 [https://www.bbc.com/news/health-53409521](https://www.bbc.com/news/health-53409521) UNICEF’s Ukraine refugee response in 2022. Romania. Published 2022-12-30 [https://www.unicef.org/romania/stories/unicefs-ukraine-refugee-response-2022](https://www.unicef.org/romania/stories/unicefs-ukraine-refugee-response-2022) Verter F. Percentage of births banking cord blood by country. Published January 2020. [https://parentsguidecordblood.org/en/news/percentage-births-banking-cord-blood-country](https://parentsguidecordblood.org/en/news/percentage-births-banking-cord-blood-country) European Medicines Agency (EMA). [https://www.ema.europa.eu/](https://www.ema.europa.eu/) --- --- title: "FamiCord and Vita 34 Vice president speaks on cord blood banking at Advanced Therapies conference in London" url: "https://www.famicord.com/famicord-and-vita-34-vice-president-speaks-on-cord-blood-banking-at-advanced-therapies-conference-in-london" lang: "en" type: "post" description: "Tomasz Baran, MD, MBA, Vice President of FamiCord Group and Vita 34, shared his expertise on the evolving field of cord blood..." last_modified: "2025-01-15T10:47:01+00:00" categories: [2024] translations: de: "https://www.famicord.com/famicord-and-vita-34-vice-president-speaks-on-cord-blood-banking-at-advanced-therapies-conference-in-london" --- # FamiCord and Vita 34 Vice president speaks on cord blood banking at Advanced Therapies conference in London **Tomasz Baran, MD, MBA, Vice President of FamiCord Group and Vita 34, shared his expertise on the evolving field of cord blood banking at the prestigious Advanced Therapies Conference in London. During his presentation, Dr. Baran discussed the pivotal role of cord blood in regenerative medicine and the exciting developments in advanced therapies, highlighting FamiCord Group’s leadership in the industry in Europe. His insights emphasized how the integration of cutting-edge biotechnology and stem cell banking is shaping the future of personalized treatments and cell-based therapies.** The Advanced Therapies Congress is Europe’s largest commercial cell and gene therapy conference and exhibition. The event is for the leaders of pioneering ATMP companies and their most senior executives in charge of the latest tech and strategies that are driving the industry forward. The Advanced Therapies Congress features speakers from across the entire value chain of cell and gene therapy development; forward-thinking pharma, biotech and start-up companies, researchers, clinicians, academics, HTAs, payers and regulators.  ItT is based, each year, in ExCELL Center in London, United Kingdom. Tomasz Baran was one of speakers in a session dedicated to cord blood stem cells at the Advanced Therapies Conference in London, moderated by Professor Joanne Kurtzberg, President of the Cord Blood Association (CBA) and a pioneer in the application of cord blood stem cells from Duke University in the USA. Main topic of the speech was to present banked cord blood as viable therapeutic option. T.Baran focused on the complexities of cord blood banking, highlighting the significant differences in European legislation. He explained that while cord blood stem cells are a standard treatment in haematology across Europe, their use in neurology is classified as an Advanced Therapy Medicinal Product (ATMP), which plays a crucial role in parents’ decisions when selecting a bank for cord blood preservation. _By choosing a bank from the FamiCord Group, parents can feel confident knowing that FamiCord has two experienced CDMO manufacturing facilities under its roof, ensuring the highest production standards. If needed, FamiCord is capable of producing ATMPs for its clients, providing comprehensive support in the field of cell-based therapies- _comments T. Baran. --- --- title: "FamiCord Group Central Laboratory with prestigous AABB accrediation" url: "https://www.famicord.com/famicord-group-central-laboratory-with-prestigous-aabb-accrediation" lang: "en" type: "post" description: "The Central Laboratory of the FamiCord Group has achieved prestigious AABB accreditation for Cellular Starting Material (CSM), underscoring FamiCord's commitment to upholding the highest standards of quality and safety, as well as continuous improvement of procedures related to the preparation of co..." last_modified: "2025-01-15T09:51:11+00:00" categories: [2024] translations: de: "https://www.famicord.com/famicord-group-central-laboratory-with-prestigous-aabb-accrediation" --- # FamiCord Group Central Laboratory with prestigous AABB accrediation The Central Laboratory of the FamiCord Group has achieved prestigious AABB accreditation for Cellular Starting Material (CSM), underscoring FamiCord’s commitment to upholding the highest standards of quality and safety, as well as continuous improvement of procedures related to the preparation of cord blood stem cells. Stem cells have been used in medicine for several decades as a material for transplantation, which involves their collection, preparation, and storage. Another way to harness the therapeutic potential of cells is to use them in the production of advanced therapies (classified as Advanced Therapy Medicinal Products by the European Medicines Agency). The role of banks such as PBKM is to provide the best possible starting product (which may include cord blood). The prestigious AABB qualification is the result of an intensive evaluation process conducted by independent, professional auditors who verify whether the facility maintains a comprehensive quality management system for the cellular starting material. The assessment is based on compliance with international standards set by AABB and local guidelines. All banks that have obtained AABB CSM qualification must undergo re-evaluation every two years. The priority of the FamiCord Group is to provide high-quality cell banking services that can be used in the future to treat our clients or members of their families,” explains Dr. Tomasz Ołdak, a Member of the FamiCord Group Board responsible for laboratories and technology. _“Once again, we have proven that our quality system meets the high AABB standards for the collection, storage, and processing of cells at our Central Laboratory. We are proud of this, as AABB accreditation is synonymous with quality and excellence recognized worldwide.”_ AABB CSM accreditation confirms that the FamiCord Group is becoming a trusted partner for companies seeking a bank partner in the field of supplying initial cellular material. It also provides the opportunity to produce personalized cell therapies for clients banking cord blood. **About AABB:**  AABB (Association for the Advancement Blood and Biotherapies) is an international association of stem cell banks. Its mission is to develop and provide standards, accreditation, and educational programs to ensure that transplantation and cell therapies are safe, accessible, and effective worldwide. More information about AABB CSM qualification and accreditation can be found here. **About the FamiCord Group:**  FamiCord is part of the Vita 34 Group, the largest in Europe and the 3rd largest stem cell bank in the world. Thanks to an extensive network of laboratories, cord blood banking services in our company are available in dozens of countries worldwide. Over more than 25 years of operation, we have collected 930,000 stem cell samples, and the cell products prepared by our laboratories have helped over 6,500 patients. ![](https://famicord.com/wp-content/uploads/2024/03/145589_CSMQualificationCertifica-1024x791.webp) --- --- title: "Smart Cells International [Famicord Group] chooses Dubai as GCC hub for stem cell banking, expanding global presence" url: "https://www.famicord.com/smart-cells-international-famicord-group-chooses-dubai-as-gcc-hub-for-stem-cell-banking-expanding-global-presence" lang: "en" type: "post" description: "Dubai, Feb. 8, 2024— Smart Cells International (SCI), aleading member of FamiCord Group, proudly declares Dubai as its GCC hub for stem cell banking, solidifying its commitment to advancing healthcare solutions in the Middle East. SCI's decision to establish its state-of-the-art laboratory in Dubai..." last_modified: "2025-01-15T09:51:02+00:00" categories: [2024] translations: de: "https://www.famicord.com/smart-cells-international-famicord-group-chooses-dubai-as-gcc-hub-for-stem-cell-banking-expanding-global-presence" --- # Smart Cells International [Famicord Group] chooses Dubai as GCC hub for stem cell banking, expanding global presence ![](https://famicord.com/wp-content/uploads/2024/02/dubai-as-gcc-hub-opening3.webp) Dubai, Feb. 8, 2024— Smart Cells International (SCI), a leading member of FamiCord Group, proudly declares Dubai as its GCC hub for stem cell banking, solidifying its commitment to advancing healthcare solutions in the Middle East. SCI’s decision to establish its state-of-the-art laboratory in Dubai Healthcare City (DHCC), the enabling healthcare and wellness destination, stems from the recognition of the region’s promising growth, particularly in the United Arab Emirates and the Gulf. This strategic move positions Dubai as a central hub for stem cell banking within the Gulf Cooperation Council (GCC). The remarkable growth witnessed in the UAE and the Gulf has motivated SCI to invest significantly in the region. The demand for advanced healthcare solutions, coupled with a thriving medical landscape, aligns seamlessly with SCI’s mission to contribute to the progress of regenerative medicine. Smart Cells International, as part of FamiCord Group, is a multinational entity with a robust presence in over 35 European countries. The group’s listing on the Frankfurt Stock Market underscores its financial strength and global standing. This move to establish a GCC hub further emphasizes SCI’s commitment to being a key player in the international stem cell banking arena. Jakub Baran, Co-founder, Shareholder, and President of the Management Board of FamiCord Group, states, “Our decision to establish Dubai as the GCC hub for stem cell banking reflects our confidence in the region’s potential. We aim to contribute to the advancement of healthcare in the Gulf, and this investment marks a significant milestone in our global strategy.” Shamshad Ahmed, Founder and CEO of Smart Cells International Ltd, adds, “The Gulf region’s growth is undeniable, and we are excited to be a part of its healthcare evolution. Dubai’s strategic location and thriving healthcare ecosystem make it an ideal choice for our stem cell banking hub. We plan to invest in clinical research partnerships and educational initiatives specific to the area to advance stem cell therapies in the region and beyond.” SCI’s commitment goes beyond banking to actively contributing to the development of advanced therapies and participating in clinical trials. The establishment of the Dubai laboratory reaffirms SCI’s dedication to providing cutting-edge stem cell solutions for families in the Gulf and beyond. Smart Cells International and FamiCord Group are poised to bring their wealth of experience and expertise to the Gulf region, contributing to the transformation of healthcare through innovative stem cell solutions. The state-of-the-art Smart Cells Laboratory is located in the heart of Dubai Healthcare City, a mere 15 minutes away from Dubai International Airport. This strategic location ensures seamless transportation of samples, offering convenience and efficiency for our valued clients. The new 4000 square foot laboratory also benefits by being equipped with cutting edge technology in the field of stem cell banking, ensuring precision and prioritizing sample safety and integrity in a fully monitored, Good Manufacturing Practice (GMP) compliant clean room.  Allae Almanini, Chief Financial Officer, Dubai Healthcare City Authority (DHCA) said “We are pleased to welcome the newly established state-of-the-art laboratory at DHCC. This represents a major step forward in our commitment to enhancing healthcare delivery to meet the growing demands of the health sector. We acknowledge the dynamic needs of our expanding community and aim to enrich our offerings to contribute to the health sector in Dubai.” The Dubai Smart Cells Laboratory is proud to be licensed by both the Dubai Health Authority (DHA) and Dubai Healthcare City (DHCC), demonstrating a commitment to meeting and exceeding regulatory standards. Their expertise and commitment position the Dubai Smart Cells Laboratory as a trusted partner for parents seeking to safeguard their children’s future with advanced stem cell banking. **About FamiCord Group:** FamiCord Group is listed on the Frankfurt Stock Market, holds the title of No. 1 in Europe and No. 3 in the World for family stem cell banking. Operating 15 labs globally, the group has stored over 850,000 cord blood and tissue units to date, conducted 187 cord blood transplantations, treated over 4,500 patients with stem cells, and collaborates with over 1,500 hospitals around Europe. The extensive scale of operations underscores the group’s serious commitment to family umbilical cord blood banking, reflecting a total market capitalization of approximately EUR 249 million, based on closing prices as of 28 May 2021. To find out more about Smart Cells International, visit our website [www.smartcells.ae](http://www.smartcells.ae/) ![](https://famicord.com/wp-content/uploads/2024/02/dubai-as-gcc-hub-opening.webp) ![](https://famicord.com/wp-content/uploads/2024/02/dubai-as-gcc-hub-opening2.webp) --- --- title: "Yesterday, today and tomorrow: Umbilical cord blood can save lives World Cord Blood Day 2023" url: "https://www.famicord.com/yesterday-today-and-tomorrow-umbilical-cord-blood-can-save-lives-world-cord-blood-day-2023" lang: "en" type: "post" description: "15th November 2023, Berlin, Germany: As every year in mid-November global science community celebrates World Cord Blood Day. During that day many events, conferences and workshops take place around the world." last_modified: "2025-01-15T09:50:48+00:00" categories: [2023] translations: de: "https://www.famicord.com/yesterday-today-and-tomorrow-umbilical-cord-blood-can-save-lives-world-cord-blood-day-2023" --- # Yesterday, today and tomorrow: Umbilical cord blood can save lives World Cord Blood Day 2023 **15****th**** November 2023, Berlin, Germany: As every year in mid-November global science community celebrates World Cord Blood Day. During that day many events, conferences and workshops take place around the world. The idea of ​​the celebration is to familiarize parents who wait for the birth of their child as well as doctors with issues related to the possibilities of using umbilical cord blood. The organizer of that event is Save the Cord Foundation. In Europe, Vita34 and FamiCord take care of remembering this day, but also popularizing the benefits of storing cord blood stem cells. This year, the celebration will be very special since Matthew Farrow, the first patient who received cord blood transplant, is coming to Europe – 35 years after he was transplanted with cord blood.** Cord blood and cord blood derived stem cells have been used in treatments for over three decades. The first transplant performed by Dr. Éliane Gluckman and Dr. Hal Broxmeyer, which saved life of a 5-year-old boy from the US – Matthew Farrow. He struggled with Fanconi anemia and received a stem cell transplant from the umbilical cord blood of his newborn sister. _My little sister’s cord blood cured me from bone marrow failure caused by __Fanconi anemia__ and that allowed me to grow up and become an adult – _says Matthew. Today, he has made it his life’s work to tell his story, especially to families suffering from Fanconi anemia, in order to raise awareness and the understanding of the medical benefits of umbilical cord blood: _“I encourage families of young kids who have gone through transplants, and show them that patients can grow up, have a family, and live a normal life.“_ Since the pioneering procedure, tens of thousands transplant procedures have been performed around the world. _Stem cells from umbilical cord blood have been a recognized, proven and effective therapy in the treatment of over 80 serious diseases for 35 years. They have proven to be great in hemato-oncological therapies and no one argues with their effectiveness anymore. Currently, in some cases cord blood stem cells are source of choice, and have better outcomes than bone marrow or haploidentical transplants _– says prof. Krzysztof Kałwak, President of European Society for Blood and Marrow Transplantation (EBMT) Pediatric Diseases Working Group.  Cord blood can only be preserved once in a lifetime – during childbirth. Stem cells derived from it may in the future be used to save the health and life of not only their owner, but also his loved ones or unrelated patients. Collecting umbilical cord blood is unique opportunity in the life,  every parent should have the right to know about the pros and limitations of umbilical cord blood banking. After childbirth it may be donated for public use, family use or for research.  _Every gynecologist should inform pregnant women about the possibility that at the time of birth there is a unique opportunity to obtain the child’s young stem cells completely painlessly and risk-free- _admits prof. Prof. Dr. med. Michael Abou-Dakn, Head of Department, St Joseph’s hospital in Berlin. _As the topic of this year World Cord Blood Day: every conversation may save life._ Vita34, as the largest stem cell bank in Europe, which provides option for family, public and hybrid banking, feels responsible for raising social awareness of the importance of umbilical cord blood for health protection and access to the most modern treatment methods. Hence company is involved  in various initiatives aimed at popularizing knowledge about cord blood , stem cells and its use in hematology and regenerative medicine **About Word Cord Blood Day:** World Cord Blood Day 2023 will provide the perfect opportunity for healthcare professionals, parents, and others to learn about this vital medical resource. The central point of World Cord Blood Day is a livestream conference with global opinion leaders in the field. Cord blood use in spina bifida and cerebral palsy take center stage alongside innovative cancer treatments for glioblastoma . That online event is free, participants should register at [www.worldcordbloodday.org](http://www.worldcordbloodday.org/), and it will take place at 10 am ET (4.00 PM in Berlin) on November 15th.  **About Vita 34 & FamiCord Group.** Vita 34 & FamiCord Group is the leading stem cell bank in Europe and the third largest worldwide. The Group operates in most of markets in Europe. Driven by the principle of protecting life through the storage of stem cells from the umbilical cord, Vita 34, as a full-service provider with about 800 employees worldwide, provides all services related to the professional storage of stem cells obtained from the umbilical cord at birth. Learn more about Vita 34 on the company’s websites: [www.vita34.de](http://www.vita34.de/)   and  [www.famicord.com](http://www.famicord.com/)  --- --- title: "FamiCordTx launches first in human application of CAR-T drug candidates" url: "https://www.famicord.com/famicordtx-launches-first-in-human-application-of-car-t-drug-candidates" lang: "en" type: "post" description: "FamiCord Group, a leading cell bank in Europe and one of the largest globally, has begun enrollment in Phase I of..." last_modified: "2025-01-15T11:26:19+00:00" categories: [2023] translations: de: "https://www.famicord.com/famicordtx-launches-first-in-human-application-of-car-t-drug-candidates" --- # FamiCordTx launches first in human application of CAR-T drug candidates **FamiCord Group, a leading cell bank in Europe and one of the largest globally, has begun enrollment in Phase I of the Tarcidomgen Kimleucel clinical trial – through is majority owned company FamiCordTx. This promising drug candidate is an anti-CD19 CAR-T, a chimeric antigen receptor, and marks the first candidate in FamiCord Group’s growing Cell & Gene Therapy (CGT) portfolio.** After recent clearance by the responsible authorities and the ethics committee clereance, the start of the clinical trial under the name CARLA and the recruitment of the first patient is imminent. A total of up to ten patients are expected to be recruited for Phase I of the study, which is the usual number for this type of drug. The recruitment will take place via two clinical centres in Poland. The principal investigator of the CARLA study is Prof. Grzegorz Basak, Professor and Chairman of the Department of Haematology, Transplantation and Internal Medicine at the University Hospital of Warsaw Medical University. “We are pleased to collaborate with FamiCordTx on this project,” says Prof. G. Basak. “CAR-T therapy is one of the most promising therapies in haematology and oncology. We are currently beginning to enroll patients to receive this drug therapy.” _Tarcidomgen Kimleucel_ is being developed through FamiCordTx, a subsidiary of FamiCord that aims to develop proprietary CAR-T drug therapies. “After reaching production readiness in 2022, we have submitted the protocol for the first phase clinical trial under the name CARLA, which will target patients with various B-cell malignancies,” explains T. Kolanowski, PhD, Chief Scientific Officer of FamiCordTx. “We are very excited to enter the CAR-T market, which has immense potential to revolutionize cancer treatment. Our CAR-T drug candidate has shown promising results in preclinical studies,” said Jakub Baran, CEO of Vita 34 AG, summarizing the market potential of CAR-T cell therapy. “We are looking forward to the results of the CARLA study and the efficacy of _Tarcidomgen Kimleucel_ in the further phases of the study. We are convinced that with our expertise in cell and gene therapies in combination with our production capacities we can make an important contribution in this field.” --- --- title: "Groundbreaking: NO MORE LIMITATIONS FOR CORD BLOOD USE" url: "https://www.famicord.com/groundbreaking-no-more-limitations-for-cord-blood-use" lang: "en" type: "post" description: "On 17 April 2023, the FDA gave approval to the Gamida Cell product “Omisirge” (known also as omidubicel or NiCord)..." last_modified: "2025-01-15T10:48:27+00:00" categories: [2023] translations: de: "https://www.famicord.com/groundbreaking-no-more-limitations-for-cord-blood-use" --- # Groundbreaking: NO MORE LIMITATIONS FOR CORD BLOOD USE **On 17 April 2023, the FDA gave approval to the Gamida Cell product “Omisirge” (known also as omidubicel or NiCord)1. This is the first FDA market approval of an “expanded” cord blood product, which means that the number of stem cells in cord blood is no longer it’s limitation.** **Cord blood stem cells are used in medicine for treatment of over 80 different  diseases such as leukemias, lymphomas and sickle cell anemia for over 30 years. It has also been proven that in the field of regenerative medicine, the application of cord blood stem cells brings clinical benefit to patients. More than 60 000 patients have been treated with cord blood.** Stem cells are the hope of 21st century medicine. Over 3,000 studies in various fields are currently underway around the world to discover the potential of stem cells. Cord blood is the source of youngest, most powerful and easy to obtain stem cells. It can also be easily collected and banked at birth to be used later in life. Due to the fact that the number of stem cells isolated from umbilical cord blood is limited, critics pointed out that average cord blood unit is enough only  for patients weighing up to 40-50 kg. As result of that many people decided not to bank the cord blood – neither for family nor public use. The FDA’s groundbreaking decision for approving expanded cord blood indicates that this objection is no longer valid. The multiplication of hematopoietic cells was the Holy Grail of hematology – an idea that, despite many attempts over decades, no one managed to implement. The FDA decision shows that cord blood has reached the point where the number of cells no longer matters. What’s more – the multiplied cells from umbilical cord blood can regenerate the hematopoietic system faster after transplantation. This may mean a wider introduction of this type of methods into clinical practice – says Tomasz Baran, MD, vicepresident of FamiCord Group. What exactly is “Omisirge”2? it issubstantially modified allogeneic (donor) cord blood-based cell therapy to quicken the recovery of neutrophils (a subset of white blood cells) in the body and reduce the risk of infection. The product is intended for use in adults and pediatric patients 12 years and older with blood cancers planned for umbilical cord blood transplantation following a myeloablative conditioning regimen (treatment such as radiation and/or chemotherapy). Omisirge is intended to help patients who can’t find a suitable donor for a transplant. Currently, when transplant oncologists cannot find a fully matched bone marrow donor, they often choose a haploidentical, or half-matched, bone marrow donor over a cord blood unit. Now expanded cord blood is also an option. In the context of FDA approvals for advanced cell therapy, expanded cord blood now joins the ranks of a half dozen CAR-T products and a handful of gene therapies for inherited disorders. I hope that in the near future expanded cord blood would be approved also by EMA in Europe comments Francisco Santos,PhD, Director of Production and Development, FamiCord Group. Blood cancers are a form of cancer caused by uncontrolled growth of cells in the blood, disrupting the ability of blood cells to perform their normal functions. This abnormal cell growth often begins in the bone marrow, which is made up of stem cells that form into different types of blood cells with specific functions in the body. According to the WHO, there were around 320,000 new cases of people with blood cancer in Europe each year3. Blood cancers can be fatal, with varying survival rates based on multiple factors including the specific type of blood cancer diagnosed. This type of cancer can also cause serious and damaging effects to the body and lead to symptoms such as fatigue, bone and joint pain, night sweats, infections, weakness, weight loss and fever.  Stem cell transplantation is a common treatment for blood cancers. It involves putting healthy stem cells into the body to help restore the normal production and function of blood cells. One source of healthy stem cells is umbilical cord blood. Generally, before receiving this kind of transplant, the patient will undergo a course of treatments to remove their own stem cells and prepare the body for the new stem cells. This process may include undergoing therapies such as radiation or chemotherapy, both of which may weaken an individual’s immune system. As a result, a frequent and serious risk of this treatment is the occurrence of severe and sometimes deadly infections. **FamiCord Group** is the largest cord blood bank in Europe and 3rd largest cord blood bank in the world. We are offering services in 31 countries directly and indirectly. In our 15 laboratories, are stored more than 860 000 samples of cord blood and tissue. The quality of our service is proven by number of patients who received stem cells applications from our bank (incl. 149 cord blood transplantations). Our clients may be sure that the material entrusted to us are stored at a stable bank of international importance. 1FDA Approves Cell Therapy for Patients with Blood Cancers to Reduce Risk of Infection Following Stem Cell Transplantation, [www.fda.gov.com](http://www.fda.gov.com/) [April: 2023] 2FRANCES VERTER, Update on Omidubicel from Gamida Cell: Phase 3 Trial Outcomes. Parent’s Guide to Cord Blood Foundation News published 2021-03  [April: 2023] 3SUSAN LANGTHORP, Blood cancer diagnosis: when mission impossible became possible, Horizon: Europe Research&Development Magazine, [www.ec.europa.eu](http://www.ec.europa.eu/) [April: 2023] --- --- title: "FamiCord enters United Kingdom and expands outside Europe" url: "https://www.famicord.com/famicord-enters-united-kingdom-and-expands-outside-europe" lang: "en" type: "post" description: "Polski Bank Komórek Macierzystych S.A. (PBKM), which leads the international FamiCord Group, Europe's largest stem cell bank, signed a transaction agreement with..." last_modified: "2025-01-15T11:02:43+00:00" categories: [2021] translations: de: "https://www.famicord.com/famicord-enters-united-kingdom-and-expands-outside-europe" --- # FamiCord enters United Kingdom and expands outside Europe **Polski Bank Komórek Macierzystych S.A. (PBKM), which leads the international FamiCord Group, Europe’s largest stem cell bank, signed a transaction agreement with shareholders of Smart Cells Holdings Limited, based in London UK, to acquire a majority stake in the stem cell bank operating in Great Britain, Middle East (United Arab Emirates, Lebanon, Oman, Bahrain, Kuwait and others) and Hong Kong.** The transaction was closed on August 4th, 2021. FamiCord acquired 84.2 percent of shares in Smart Cells Holdings Limited. The transaction was financed from PBKM’s own funds. _We are very pleased to welcome another well-organized and highly efficient stem cell bank to the FamiCord Group. This is another step in our strategy towards consolidation of the European family cord blood banking market which itself attracts multiple takeover targets we are interested in. By making this move we also entered new markets, substantially strengthen our position in Europe and our global presence on the markets in Middle East (United Arab Emirates, Lebanon, Oman, Bahrain , Kuwait and others) and Hong Kong, where Smart Cells Holdings operates. We’re going to focus on strengthening Smart Cells UK and UAE markets with the goal to reach number one position within the next two years. We believe with our diverse product range, scientific expertise across many countries and financial strength, we will be the strongest service provider for stem cells and related healthcare products. I wish to add that we are continuing to seek further acquisitions from the European and other markets_ – says Jakub Baran, the co-founder,  shareholder and the President of the Management Board of PBKM S.A (the leading entity for the international FamiCord Group). Shamshad Ahmed – Founder and CEO , Smart Cells International Ltd says: I _am delighted that Smart Cells has become a part of the FamiCord family of businesses. We are confident that bringing together our excellent customer care and world class storage facilities with PBKM’s global reach and research capabilities will provide existing and new customers with unrivalled product offerings to protect their family’s health. Our vision has always been for Smart Cells to be a global enterprise empowering people to store their children’s stem cells with a company that is based on excellent science and integrity. I am so proud of what Smart Cells have accomplished together, and now with scale and presence, we are even closer to inspiring many more to take charge of their family’s health and wellbeing._ Smart Cells Holdings Limited was founded in 2001. It is the first private UK stem cell storage company to have released stored stem cell units for the use in the treatment of children with life-threatening or debilitating illnesses. Since its establishment, Smart Cells have released the greatest number of samples for use in transplants from a private UK bank for use in transplants in the UK and other countries (21 releases to 6 countries) from some of its 40,000 clients. The Company operates in the UK, Italy, Albania, Middle East, South Africa, Kenya, Pakistan, and Hong Kong. After the collection at the site of birth, biological materials are transported for storage to the Company’s laboratory in the UK. Polski Bank Komórek Macierzystych leads the international FamiCord Group, which manages stem cell banks located in Europe. After the transaction FamiCord Group will store 610.000 samples belonging to over 450,000 families. FamiCord’s core business is the procurement, processing and long-term storage of stem cells from umbilical-cord blood and other post-foetal tissues on behalf of parents (family banking). The purpose of this banking is to provide security for the family in the event of a serious illness which requires a stem cell transplant in the donor or his/her immediate family members. --- --- title: "Completion of the 1st phase inventory check of biological material samples stored originally by former service provider" url: "https://www.famicord.com/completion-of-the-1st-phase-inventory-check-of-biological-material-samples-stored-originally-by-former-service-provider" lang: "en" type: "post" description: "This information is addressed to the customers of former service provider in connection with which we have been authorized as a contact point for the customers of former service provider..." last_modified: "2025-01-15T11:17:23+00:00" categories: [2020] translations: de: "https://www.famicord.com/completion-of-the-1st-phase-inventory-check-of-biological-material-samples-stored-originally-by-former-service-provider" --- # Completion of the 1st phase inventory check of biological material samples stored originally by former service provider This information is addressed to the customers of former service provider in connection with which we have been authorized as a contact point for the customers of former service provider. PBKM S.A.- parent company of FamiCord Group (“FamiCord”) is the largest family stem cells bank in Europe. Samples of almost all families being customers of former service provider were transferred in accordance with technical and medical requirements in year 2019 and 2020 from various European locations to the state-of-the-art facility in Warsaw. In order to ensure the most accurate information concerning the samples we have initiated manual checking of all inventory. This process started in May  2019 and was completed in July 2020. Overall we have checked the biological material located in 58 storage containers (out of which 55 were provided by former service provider). It is important to mention that the biological material collected from one child could have been divided into up to 8 different cryopreserved parts (subunits). Each of those subunits could be of different type of package, size and located in different storage containers. Each sample had to be scanned and matched with the customers’ records in our database. All of that made our work extremely difficult and time consuming. It was the largest project of its kind in the world. After checking over 800.000 subunits, we can confirm with certain reservation the overall acceptable condition of the inventory. We have found however some issues with less than 0,3% of subunits. Most of the issues which have been identified are the following: traces of the biological material on outers surface of the package, signs of mechanical damage of the package, lack of testing aliquots with the main sample. All of these issues are pretty typical results of not fully proper quality control and/or cryopreservation methods used by former service provider. The whole inventory was accumulated for almost 20 years of activity of former service provider and during that period different methodologies of freezing, coding and labelling were used by the company. The quality of electronic records and samples-related information provided by former service provider was very poor. Nevertheless we managed to correct most of these errors manually. We have found over 150.000 data (coding) errors which we thoroughly checked. The errors we identified include among others: the code of the subunit in the data was different from the code scanned from the subunit, the wrong location of subunits, additional numbers/signs or missing numbers/signs in the code, typos. Those electronic errors, however, had not affected the storage conditions of the samples but the may have hindered finding and use of the samples when needed In order to perform the process of verification timely and accurately we have created dedicated teams led by lab professionals. In total over 100 people were involved not mentioning dedicated call center and IT staff. The whole process was supervised by quality control specialists and was video recorded. **In conclusion, we are able to answer the families with much bigger confidence than a year ago whether and where we have their samples stored. We are also able to release the sample for transplantation when it is needed.** In order to check whether your biological material is stored in FamiCord Group laboratory in Warsaw, Poland, please see: [**https://famicordcryobank.ch/contact-for-clients-of-the-former-service-provider/check-your-sample**](https://famicordcryobank.ch/contact-for-clients-of-the-former-service-provider/check-your-sample) and wait for the confirmation from FamiCord. A certain number of samples remain with unconfirmed status. If customers have filled out the form, please be patient. At the same time, we also see the need to continue the inventory checking process, this time in a way that allows the more accurate determination of the status of the samples, which have not been confirmed yet. This process (named “2nd phase inventory check”) will be focused on additional verification of the codes with our documentation or scanned versions of it and can take additional time not less than several months. --- --- title: "The FamiCord Group strengthens its position in Turkey" url: "https://www.famicord.com/the-famicord-group-strengthens-its-position-in-turkey" lang: "en" type: "post" description: "The FamiCord Group strengthens its position in Turkey by investing in a stem cell bank belonging to the Acıbadem Healthcare Group..." last_modified: "2025-01-15T09:50:30+00:00" categories: [2020] translations: de: "https://www.famicord.com/the-famicord-group-strengthens-its-position-in-turkey" --- # The FamiCord Group strengthens its position in Turkey ![](https://famicord.com/wp-content/uploads/2025/01/izolacja_komorek_sznura.webp) FamiCord Group has concluded an investment agreement regarding the purchase of shares in the Turkish stem cell bank which has operated so far within the structure of the Acıbadem Healthcare Group. FamiCord group has now 70% of shares in the newly created Famicord – Acibadem company. The company was formed from a separate part of the enterprise with the Acıbadem Healthcare Group, to which the scope of activities including processing, testing and storage of cord blood was transferred. The remaining 30% of shares will be owned by the Acıbadem Healthcare Group. The purchase is  financed from the resources acquired within a private subscription of PBKM shares which took place last year. --- --- title: "Letter of intent between Medical University of Warsaw (WUM) and FamiCordTx signed" url: "https://www.famicord.com/letter-of-intent-between-medical-university-of-warsaw-wum-and-famicordtx-signed" lang: "en" type: "post" description: "Rector of the Medical University of Warsaw prof. Mirosław Wielgoś and representatives of the FamiCordTx company: Dr Tomasz Baran - President of the Management Board and Dr Tomasz Ołdak - Member of the Management Board - signed aletter of intent regarding cooperation in the field of development and i..." last_modified: "2025-01-15T09:50:22+00:00" categories: [2020] translations: de: "https://www.famicord.com/letter-of-intent-between-medical-university-of-warsaw-wum-and-famicordtx-signed" --- # Letter of intent between Medical University of Warsaw (WUM) and FamiCordTx signed ![](https://famicord.com/wp-content/uploads/2020/02/izolacja_komorek_sznura.webp) Rector of the Medical University of Warsaw prof. Mirosław Wielgoś and representatives of the FamiCordTx company: Dr Tomasz Baran – President of the Management Board and Dr Tomasz Ołdak – Member of the Management Board – signed a letter of intent regarding cooperation in the field of development and implementation of immunotherapy as an innovative cancer treatment strategy. The purpose of signing the letter is to strengthen cooperation between the Clinic of Hematology, Oncology and Internal Diseases (WUM), the Department of Regenerative Medicine (WUM) and FamiCordTx in the field of CAR-T development – the most advanced and personalized technology used in hematooncological treatment, in which a drug for each patient is based on his own lymphocytes. **As prof. Mirosław Wielgoś emphasized during the meeting:** “CAR-T therapy – the greatest discovery and hope in oncology of recent years, can be used only in certified health care centers, therefore, by implementing it at the Medical University of Warsaw, we will become a reference center for FamiCordTx in the development of this technology in Europe. This is undoubtedly one of the most innovative and promising directions in medicine. WUM as a leading medical university and research center in Poland, employs highly qualified academic teachers and research workers, carries out specialized research and has clinical experience and appropriate conditions that allow the implementation of this technology. “ **Tomasz Baran – President of the Management Board of FamiCordTx noted:** “The introduction of CAR-T in treatment is a breakthrough in the approach to treatment and opens a new category of cancer therapies – cancer immunotherapy. The essence of CAR-T technology is to equip the patient’s own T lymphocytes with a molecule that will recognize the protein on the cancer cell. This process is taking place in a special cell engineering laboratory. Then specially modified T-cells – CAR-T – go back to the patient. In the patient’s body CAR-T in a targeted manner destroys the patient’s cancer cells. It is highly effective even after a single administration. “ **Prof. Grzegorz Basak – Head of the Department and Clinic of Hematology, Oncology and Internal Medicine of the Medical University of Warsaw said:** “The Clinic of Hematology, Oncology and Internal Diseases of the Medical University of Warsaw, as a leading center in the country will be the first place in Poland for the clinical implementation of this state-of-the-art therapy in the World – genetically modified lymphocyte therapy. This is a unique opportunity for patients to increase access to breakthrough treatment. I hope that the first phases of clinical trials will give an access to an effective therapy for a large group of patients who would otherwise have little chance of success. “ **Dr Tomasz Ołdak – Member of the Management Board of FamiCordTx emphasized:** “FamiCordTx has the exclusive license to develop and commercialize CAR-T technology in Europe. As a daughter company of Polish Stem Cell Bank, it is the first Polish company with the appropriate technological facilities, knowledge and experience necessary for the production of CAR-T therapy. Currently CAR-T therapies are manufactured by global pharmaceutical companies, and the cost is about EUR 400,000 per patient. The Medical University of Warsaw and FamiCordTx will cooperate in optimizing CAR-T technology and reducing treatment costs using CAR-T to increase their availability for Polish patients. “ --- --- title: "FamiCord is number 1 in Europe and number 5 in the World" url: "https://www.famicord.com/famicord-is-number-1-in-europe-and-number-5-in-the-world" lang: "en" type: "post" description: "According to recent publication by Parents Guide Cord Blood Foundation - FamiCord Group, founded by Polski Bank Komórek Macierzystych (PBKM), proudly stands as..." last_modified: "2025-01-15T10:39:14+00:00" categories: [2018] translations: de: "https://www.famicord.com/famicord-is-number-1-in-europe-and-number-5-in-the-world" --- # FamiCord is number 1 in Europe and number 5 in the World According to recent publication by Parents Guide Cord Blood Foundation – FamiCord Group, founded by Polski Bank Komórek Macierzystych (PBKM), proudly stands as the leading cord blood banking network in Europe. Recognized globally, FamiCord has been acknowledged by international databases as a top player in the field, securing its position among the world’s top 10 cord blood banks. This recognition underscores the trust placed in FamiCord’s services by families across Europe and beyond. Operating in most European markets, FamiCord’s extensive network ensures accessibility to life-saving stem cell banking services for countless families. With multiple laboratories strategically located across Europe, FamiCord provides unparalleled flexibility and efficiency in processing and storing cord blood and tissue. This robust infrastructure allows the group to meet the diverse needs of families while maintaining the highest standards of safety and quality. Globally, FamiCord shares this prestigious ranking with other notable leaders in cord blood banking. In North America, companies like CBR (Cord Blood Registry) and ViaCord dominate the private banking market. In Asia, Cryo-Save India and Cordlife represent major players, reflecting the global reach and importance of stem cell banking. In the southern hemisphere, Cryosite in Australia ensures families in Oceania have access to these critical medical resources. With over 4 million privately banked cord blood and tissue units worldwide, the industry is transforming the way families prepare for potential medical needs. FamiCord continues to play a critical role in this evolution, setting benchmarks for quality and reliability. By collaborating with hospitals, healthcare providers, and researchers, FamiCord ensures that its services remain at the forefront of stem cell therapy advancements. The group also supports initiatives to raise awareness about the life-saving potential of cord blood banking, helping more families make informed decisions about their healthcare options. As FamiCord expands its presence and services across Europe and beyond, it remains dedicated to its founding mission: empowering families with cutting-edge medical solutions and ensuring access to advanced regenerative medicine. This recognition as a European leader highlights not only the group’s achievements but also its ongoing commitment to shaping the future of healthcare worldwide. --- --- title: "Acquisition of BioCell Lugano, Switzerland" url: "https://www.famicord.com/acquisition-of-biocell-lugano-switzerland" lang: "en" type: "post" description: "FamiCord Group acquired BioCell Lugano, which includes a modern laboratory in Switzerland. This is another important step..." last_modified: "2025-01-15T10:09:14+00:00" categories: [2018] translations: de: "https://www.famicord.com/acquisition-of-biocell-lugano-switzerland" --- # Acquisition of BioCell Lugano, Switzerland FamiCord Group acquired BioCell Lugano, which includes a modern laboratory in Switzerland. This is another important step towards expanding the scope of activities in western Europe, further enhancing FamiCord’s ability to offer innovative stem cell banking and regenerative medicine solutions across the continent. The laboratory developed and started to commercialize technology of banking perinatal tissues such as placental villi and amniotic fluid cells. FamiCord plans to further expand BioCell Lugano laboratory capabilities, which currently serves B2B clients in Italy and Egypt. Company plans to expand this activity to offer cord blood banking which currently is not in the scope of BioCell services. --- --- title: "Expansion of FamiCord activity to Balkans" url: "https://www.famicord.com/expansion-of-famicord-activity-to-balkans" lang: "en" type: "post" description: "Recently FamiCord established new partnership with leading company from\nthe sector in Balkan countries - BioSave Group. Based on..." last_modified: "2025-01-15T10:05:20+00:00" categories: [2018] translations: de: "https://www.famicord.com/expansion-of-famicord-activity-to-balkans" --- # Expansion of FamiCord activity to Balkans FamiCord Group offers its services to families mostly in a B2C model where FamiCord subsidiary has direct contractual relationships with family to collect and store cord blood stem cells. The other model which is present in the market is B2B partnership, where 3 rd Party subcontracts FamiCord to perform the services. In such situation Partner contractual responsibility to the client is to collect cord blood and organize logistic to FamiCord to do processing, testing and storage of stem cells. Recently FamiCord established new partnership with leading company from the sector in Balkan countries – BioSave Group. Based on that partnership – cord blood banking services provided by FamiCord will be offered to BioSave clients in Serbia, Montenegro, Bosnia&Herzegovina, Slovenia and Macedonia as well as other markets in the region. --- --- title: "PBKM granted 13.7 mln PLN funds from NCBiR to develop stem cell therapy for ALS" url: "https://www.famicord.com/pbkm-granted-13-7-mln-pln-funds-from-ncbir-to-develop-stem-cell-therapy-for-als" lang: "en" type: "post" description: "The National Center for Research and Development (NCBiR) in Poland has approved the request of PBKM (Polski Bank Komórek Macierzystych) for co-financing the project titled \"Development of..." last_modified: "2025-01-15T10:03:33+00:00" categories: [2017] translations: de: "https://www.famicord.com/pbkm-granted-13-7-mln-pln-funds-from-ncbir-to-develop-stem-cell-therapy-for-als" --- # PBKM granted 13.7 mln PLN funds from NCBiR to develop stem cell therapy for ALS The National Center for Research and Development (NCBiR) in Poland has approved the request of PBKM (Polski Bank Komórek Macierzystych) for co-financing the project titled “Development of an Innovative Advanced Therapy Medicinal Product Based on Mesenchymal Stem Cells Derived from Wharton’s Jelly for the Treatment of Amyotrophic Lateral Sclerosis (ALS).” This funding, amounting to approximately 13.7 million PLN, will support the project’s total estimated cost of around 23.9 million PLN. The project represents a significant milestone in the advancement of cell-based therapies, focusing on the potential use of mesenchymal stem cells (MSCs) derived from the Wharton’s jelly of the umbilical cord in treating ALS, a progressive and currently incurable neurodegenerative disease. The financial support from NCBiR not only underscores the importance of this innovative research but also reflects Poland’s commitment to supporting cutting-edge biomedical advancements. This research project is an important step towards developing a novel therapeutic approach for ALS patients, leveraging the regenerative properties of stem cells. With this co-financing, PBKM aims to accelerate the development of this promising treatment, which could have a transformative impact on the lives of individuals suffering from ALS, offering hope for a future breakthrough in neurodegenerative disease therapies. The funding was part of InnoNeuroPharm program, initiated by Poland’s NCBiR, aimed to enhance the competitiveness and innovation of the Polish pharmaceutical sector, particularly in neuromedicine. In its first competition, NCBiR allocated approximately 160 million PLN to support research and development projects in this field. Program funded projects focusing on: - Innovative medicinal products - Advanced manufacturing technologies - Novel diagnostic methods and biomarkers in neuromedicine - Innovative rehabilitation methods for neurological patients - Development of tools supporting research on medicinal products --- --- title: "Vita 34 AG: Vita 34 concludes purchase agreement for the entire acquisition of its competitor Seracell Pharma AG" url: "https://www.famicord.com/vita-34-ag-vita-34-concludes-purchase-agreement-for-the-entire-acquisition-of-its-competitor-seracell-pharma-ag" lang: "en" type: "post" description: "Vita 34 AG intends to fully acquire all shares of Seracell Pharma AG, the second largest supplier of..." last_modified: "2025-01-15T11:13:13+00:00" categories: [2017] translations: de: "https://www.famicord.com/vita-34-ag-vita-34-concludes-purchase-agreement-for-the-entire-acquisition-of-its-competitor-seracell-pharma-ag" --- # Vita 34 AG: Vita 34 concludes purchase agreement for the entire acquisition of its competitor Seracell Pharma AG **Vita 34 AG intends to fully acquire all shares of Seracell Pharma AG, the second largest supplier of umbilical cord blood on the German market after Vita 34. The completion of the acquisition is planned for the middle of this year and is conditional upon, among other things, a successful company review of Seracell Pharma AG (due diligence).** Vita 34 AG, a leading stem cell bank in Europe, has finalized the purchase agreement for the entire acquisition of Seracell Pharma AG, a company specializing in cell-based therapies and regenerative medicine. This strategic acquisition significantly strengthens Vita 34’s position in the biotechnology and stem cell sectors, expanding its portfolio and capabilities in advanced therapies. Seracell Pharma AG, based in Germany, is recognized for its innovative approaches in the development of stem cell therapies and its expertise in manufacturing cell-based products. Through this acquisition, Vita 34 gains access to Seracell’s cutting-edge technologies, which will complement its existing offerings and contribute to the development of new, advanced therapies aimed at addressing a wide range of medical conditions. The integration of Seracell Pharma AG is in line with Vita 34’s long-term growth strategy, which focuses on becoming a leading player in the global biotechnology market. With the acquisition, Vita 34 strengthens its research and development capabilities, enhancing its ability to deliver next-generation treatments, particularly in the areas of regenerative medicine and advanced therapy medicinal products (ATMPs).  This acquisition not only expands Vita 34’s technological and therapeutic portfolio but also provides new opportunities for collaboration and synergies in the field of cell-based therapies. By integrating Seracell’s expertise, Vita 34 aims to accelerate the development of innovative treatments, ultimately improving patient outcomes and advancing the field of regenerative medicine.  Through this acquisition, Vita 34 further solidifies its commitment to providing innovative, high-quality cell therapies and expanding its presence as a leader in the global biotech industry. --- --- title: "PBKM becomes a member of EBMT" url: "https://www.famicord.com/pbkm-becomes-a-member-of-ebmt" lang: "en" type: "post" description: "We are very proud to report that Polski Bank Komórek Macierzystych has become a member of EBMT – European Society for Blood and Marrow Transplantation. It is the biggest..." last_modified: "2025-01-15T09:50:04+00:00" categories: [2016] translations: de: "https://www.famicord.com/pbkm-becomes-a-member-of-ebmt" --- # PBKM becomes a member of EBMT ![](https://famicord.com/wp-content/uploads/2025/01/Katarzyna-Zielinska-Kazmierska.webp) We are very proud to report that Polski Bank Komórek Macierzystych has become a member of EBMT – European Society for Blood and Marrow Transplantation. It is the biggest non-profit organization in the world which brings together scientists, doctors and nurses engaged in research on clinical use of stem cells from different sources, including cells from umbilical cord blood and from umbilical cord itself. To become a member of EBMT it is necessary to be active in the field of transplantation or stem cell based therapy. We are the only bank in Poland and one of very few in Europe to belong to EBMT. This membership is significant because it is a guarantee for our customers that their umbilical cord blood can be used by any health centre in Europe. _It is another milestone in the development of Polski Bank Komórek Macierzystych_ says Jakub Baran, the President of Polski Bank Komórek Macierzystych. _I would like to point out that EBTM is a top class international organization and by granting us a membership it appreciated our activities and commitment in the range of using stem cells for transplantations. It is an incredible honour for PBKM’s activity and in my opinion for the whole Poland as well. I am very proud of it because we have been working for this recognition for many years._ For over 30 years EBMT has been one of the most important organizations which deals with research, education, standardization, quality control and accreditation of transplantation procedures. Its mission, similarly to the mission of PBKM is a constant development of knowledge about the potential of stem cells and their use in treatment. Additionally, it is extremely important for us – a family and public bank – to increase the number of stored portions of stem cells all the time due to the fact that a bigger amount of biological material stored in the bank means higher chances to treat more patients in the future. PBKM provides services of the highest quality to its customers – both those who have their biological material stored for the future and those who have stem cells prepared for a transplantation by PBKM. Till the end of October 2016 we issued biological material to save life and health of more than 500 patients all over the world. Thanks to this fact since last year we have been the leader in the number of issued portions of biological material in Europe. --- --- title: "Sevibe Cells – the only bank in Spain accredited with AABB" url: "https://www.famicord.com/sevibe-cells-the-only-bank-in-spain-accredited-with-aabb" lang: "en" type: "post" description: "In October 2015 Sevibe Cells became the first bank in Spain accredited by the American Association of Blood Banks (AABB) - internationally recognized symbol of quality of products and services in the filed of cord blood banking. Being accredited by AABB means that all Clients ofSevibe Cells can be s..." last_modified: "2025-01-15T09:49:55+00:00" categories: [2015] translations: de: "https://www.famicord.com/sevibe-cells-the-only-bank-in-spain-accredited-with-aabb" --- # Sevibe Cells – the only bank in Spain accredited with AABB ![](https://famicord.com/wp-content/uploads/2025/01/SEVIBE_A_FAMICORD_COMPANY_2019-1024x273.webp) In October 2015 Sevibe Cells became the first bank in Spain accredited by the American Association of Blood Banks (AABB) – internationally recognized symbol of quality of products and services in the filed of cord blood banking. Being accredited by AABB means that all Clients of  Sevibe Cells can be sure that we meet the highest standards in  several different fields  from quality management system essentials  to technical requirements. In order to achieve this accreditations any cord blood bank has to  present the highest  level of safety of collecting, processing, testing, distributing and administering of the precious product. There are 117 cord blood banks in Europe, only 5 ( 3 of them belong to Famicord Group) received this prestigious accreditation. “It’s a very demanding accreditation,” says Eloi Palà, General Manager of Sevibe Cells, which also requires a permanent effort to continuously improve and control processes to ensure greater safety in a case of eventual transplant. The American Associaton of Blood Banks carries out periodic audits to verify the implementation of the quality systems implemented, guaranteeing the safety of the samples to be released in case of clinical use. In addition, all accredited banks must take on a continuous improvement plan, obligatory to renew accreditation”. --- --- title: "Vita 34 Takes Over Danish StemCare Group" url: "https://www.famicord.com/vita-34-takes-over-danish-stemcare-group" lang: "en" type: "post" description: "Vita 34 AG, one of Europe’s leading stem cell banks, has successfully completed the acquisition of the\nDanish StemCare Group, a prominent player in the field..." last_modified: "2025-01-15T09:49:48+00:00" categories: [2015] translations: de: "https://www.famicord.com/vita-34-takes-over-danish-stemcare-group" --- # Vita 34 Takes Over Danish StemCare Group Vita 34 AG, one of Europe’s leading stem cell banks, has successfully completed the acquisition of the Danish StemCare Group, a prominent player in the field of stem cell storage and regenerative medicine. This strategic acquisition marks another important step in Vita 34’s ongoing expansion into key European markets and strengthens its position in the growing regenerative medicine sector. StemCare Group, based in Denmark, is known for its expertise in the storage and processing of stem cells, as well as its contributions to the development of advanced therapies. The acquisition of StemCare will enable Vita 34 to expand its portfolio of services, particularly in the areas of stem cell banking and the emerging field of regenerative medicine. The integration of StemCare Group’s operations will enhance Vita 34’s ability to offer innovative therapies and services, making them more accessible to patients across Scandinavia and beyond. The acquisition of StemCare also aligns with Vita 34’s long-term strategy to broaden its customer base and increase its market share in Europe. By joining forces with StemCare, Vita 34 gains access to advanced technologies and expertise in stem cell processing, which will further enhance the company’s research and development efforts. This move will also improve Vita 34’s ability to provide personalized and cutting-edge treatments, such as cell-based therapies and advanced therapy medicinal products (ATMPs), to address a range of medical conditions. Furthermore, this acquisition strengthens Vita 34’s international network, positioning the company as a key player in the global biotechnology and cell therapy markets. The company aims to lead the industry by continuously expanding its capabilities and advancing the use of stem cells in medical treatments. The integration of StemCare Group’s established infrastructure and customer base will play a vital role in achieving this goal. With this acquisition, Vita 34 continues to build its reputation as a leading provider of stem cell solutions, offering high-quality services for both private individuals and healthcare institutions. The company is committed to advancing the science of regenerative medicine and making these life- changing therapies available to a growing number of patients around the world. --- --- title: "FamiCord Group continues international expansion" url: "https://www.famicord.com/famicord-group-continues-international-expansion" lang: "en" type: "post" description: "Yasam is the oldest Turkish stem cell bank and has been operating for over 10 years. Yasam, like all FamiCord Group banks, has the highest quality standards. By 2013, it had provided on 4 occasions deposited umbilical cord blood to treat children. Yasam has its own specialized laboratory, providing..." last_modified: "2025-01-15T09:49:36+00:00" categories: [2014] translations: de: "https://www.famicord.com/famicord-group-continues-international-expansion" --- # FamiCord Group continues international expansion ![](https://famicord.com/wp-content/uploads/2025/01/praca-w-lab-1024x683.webp) Yasam is the oldest Turkish stem cell bank and has been operating for over 10 years. Yasam, like all FamiCord Group banks, has the highest quality standards. By 2013, it had provided on 4 occasions deposited umbilical cord blood to treat children. Yasam has its own specialized laboratory, providing the highest standards of quality class GMP laboratory located in Ankara. Turkey is one of the 20 largest and fastest-growing economies in the world. Turkish society is very young, the average age is 29.7 years. Turkey also boasts a high birth rate, in 2010 it was reported to be 2.08. More than three-quarters of Turkish citizens are living in rapidly developing cities, five of which (Istanbul, Ankara, Izmir, Bursa, Adana) have more than two million inhabitants. Turkey is currently in the dynamic phase of growth. “With this transaction, the Group FamiCord strengthens its position as European leader. What’s more – we see great potential for development of the Turkish company, which, from the beginning of its activity, has gained a large share of the Turkish market. The company currently occupies 3rd position among stem cell banks operating in Turkey. We believe that with our support it will be able to accelerate the pace of development.” – said Jakub Baran, CEO of FamiCord Group, justifying the bank’s decision. “The key to success is a management team which has a vision” – he added. The company will focus on business development, and building awareness of the family cord blood banking in Turkey. --- --- title: "FamiCord Group opened a new laboratory in Budapest" url: "https://www.famicord.com/famicord-group-opened-a-new-laboratory-in-budapest" lang: "en" type: "post" description: "KRIO Institute in Hungary opened anew laboratory to enable the stem cell bank to process samples manually. Manual technology allows for the correction of errors that may occur during collection and separation of blood, thus samples made available for afuture therapy are especially rich in cells. Ma..." last_modified: "2025-01-15T09:48:35+00:00" categories: [2013] translations: de: "https://www.famicord.com/famicord-group-opened-a-new-laboratory-in-budapest" --- # FamiCord Group opened a new laboratory in Budapest ![](https://famicord.com/wp-content/uploads/2025/01/stem-cells.webp) **KRIO Institute in Hungary opened a new laboratory to enable the stem cell bank to process samples manually. Manual technology allows for the correction of errors that may occur during collection and separation of blood, thus samples made available for a future therapy are especially rich in cells.** Manual procedure Cord blood must be processed within 36 hours after it has been collected. Some part of it is taken for a microbiological blood culture test. All samples are kept in quarantine until sterility tests have been completed. Following this, stem cells are isolated in umbilical cord blood, in the process of which most of the red blood cells and plasma are removed. Some stem cell banks freeze the entire substance of umbilical cord blood, however, in this case the chance of survival for stem cells is lower due to red blood cells disintegrating during thawing. Therefore, processing umbilical cord blood before freezing is a basic requirement in Europe, the USA and Japan. Separation starts with a plasma squeeze in a special solution, then the sample is placed in a centrifuge. This procedure – as the entire process of manual technology – is carried out under strict control, and is interrupted at any stage of the process, if necessary, to correct errors in order to ensure the highest recovery rate of total nucleated cells (TNC). Manual technology can be compared to manual assembly in car making, which is, in many respects, still more precise than automatized assembly carried out by robots. The outcome of the process is a cell preparation rich in cells separated from the plasma. This goes into a freezing bag with a so called cryoprotectant solution added to it. The added liquid protects the cells from damage that freezing may cause. Four ampoules of 1.5 ml capacity are also filled with the sample, prepared for deep freezing and stored separately. If the sample was used later, these ampoules provide substance for an examination prior to transplantation, thus the whole sample does not need to be thawed. Such an examination is typically performed, if the stored sample is not used by the child, but it is to be transplanted into one of his or her close relatives’ (sibling, parent and grandparent) or a non-relative’s body, thus HLA matching needs to be analysed. --- --- title: "DIRECT SALES, EVENT & HCP CONSULTANT / PHARMAREFERENT (M/W/D)" url: "https://www.famicord.com/career/employment-in-germany/job-postings/direct-sales-event-hcp-consultant-pharmareferent-m-w-d" lang: "en" type: "job_offers" description: "EINSATZGEBIETE:METROPOLREGION MÜNCHEN MIT HOHER REISEBEREITSCHAFT FÜR NATIONALE EINSÄTZEMETROPOLREGION LEIPZIG MIT HOHER REISEBEREITSCHAFT FÜR NATIONALE EINSÄTZE Die FamiCord Gruppe ist der Pionier und Marktführer im Zellbanking in Europa. Wir nutzen das therapeutische Potenzial von Stammzellen und Immunzellen um die Gesundheit von" last_modified: "2026-06-25T06:20:25+00:00" custom_fields: job_offer.additional_text_under_title: "Wir suchen ab sofort für die Regionen Leipzig und München" job_offer.specification.0.key: "Standort" job_offer.specification.0.value: "Region Leipzig oder München" job_offer.specification.1.key: "Unternehmen" job_offer.specification.1.value: "FamiCord AG" job_offer.specification.2.key: "Abteilung" job_offer.specification.2.value: "Direct Sales" job_offer.sidebar_description.title: "Interesse geweckt?" job_offer.sidebar_description.text: "Wenn wir Ihr Interesse geweckt haben, dann sollten wir uns kennenlernen! Wir freuen uns über Ihre aussagekräftige Bewerbung unter Angabe Ihrer Gehaltsvorstellung und des möglichen Eintrittstermins bevorzugt über unser Online-Portal ." job_offer.offer_contact.guardians_name: "Gisela Noack" job_offer.offer_contact.description: "FamiCord AG\nPerlickstraße 5\n04103 Leipzig" --- # DIRECT SALES, EVENT & HCP CONSULTANT / PHARMAREFERENT (M/W/D) EINSATZGEBIETE: METROPOLREGION MÜNCHEN MIT HOHER REISEBEREITSCHAFT FÜR NATIONALE EINSÄTZE METROPOLREGION LEIPZIG MIT HOHER REISEBEREITSCHAFT FÜR NATIONALE EINSÄTZE ## Über uns Die FamiCord Gruppe ist der Pionier und Marktführer im Zellbanking in Europa. Wir nutzen das therapeutische Potenzial von Stammzellen und Immunzellen um die Gesundheit von Menschen zu erhalten und wiederherzustellen. Mit rund 750 Mitarbeitern sind wir in mehr als 30 Ländern tätig und erwirtschaften einen Jahresumsatz von über EUR 80 Mio. ## Ihre Zukunft bei FamiCord In über 25 Jahren Unternehmensgeschichte haben wir über eine Million Zellpräparate eingelagert und die Therapie von über 7.000 Menschen unterstützt. Die FamiCord Group befindet sich auf einer spannenden Reise, auf der wir mehrere kleinere europäische Unternehmen mit jahrzehntelanger Tradition und etablierten lokalen Marktpositionen in eine starke internationale Gruppe integrieren. Wir wollen unser Wachstum in den nächsten Jahren fortführen, indem wir unser Kerngeschäft der Stammzelleneinlagerung aus Nabelschnurblut, Nabelschnurgewebe und Plazenta ausbauen und in neue Bereiche wie Zelltherapien expandieren. Wir suchen für unser Außendienstteam **Direct Sales & Event Consultants (m/w/d)** jeweils einen Mitarbeiter für die Metropolregion München und die Metropolregion Leipzig. ## Ihre Mission Sie bauen unsere Präsenz im Direktkontakt mit werdenden Eltern aus und entwickeln lokale Formate, Partnerschaften und Veranstaltungen, die Aufklärung, Reichweite und qualifizierte Leads messbar steigern. Ihr Fokus liegt auf B2C-Events, Community-Aufbau, Kooperationsmarketing und Follow-up und auf der fachlichen Beratung von medizinischen Fachkreisen. ## Das erwartet Sie - Sie konzipieren, organisieren und betreuen eigene Elternveranstaltungen rund um Schwangerschaft und die Geburt - Sie entwickeln lokale Eventformate weiter und sorgen dafür, dass aus guten Ideen regelmäßige, gut besuchte Veranstaltungsserien werden - Sie bauen Kooperationen mit nicht-medizinischen Partnern auf, zum Beispiel mit Schwangerschaftsyogastudios, Familienzentren, Babyfotografen, Elterncoaches, Doula-Netzwerken oder Anbietern für Erstausstattung - Sie verhandeln und koordinieren Raumüberlassungen, Hosting-Pauschalen, Eventankündigungen, Social-Media-Postings, Newsletter-Platzierungen und lokale Veranstaltungskooperationen - Sie repräsentieren unser Unternehmen auf regionalen Messen, Babyevents, Family Days, Klinik-Infotagen und lokalen Community-Veranstaltungen - Sie sprechen mit werdenden Eltern vor Ort, beantworten allgemeine Fragen und überführen Kontakte strukturiert in Follow-up-Gespräche, Beratungstermine, Telefonate und E-Mail-Kommunikation - Sie arbeiten eng mit internen Schnittstellen wie Marketing, CRM, Events und der zentralen Pharmareferentin zusammen ## Das bringen Sie mit - Erfahrung im Direktvertrieb, Eventmanagement, Community-Aufbau oder im Vertrieb erklärungsbedürftiger Dienstleistungen - Hohe Umsetzungsstärke und Freude an lokaler Netzwerkarbeit - Strukturierte und eigenverantwortliche Arbeitsweise - Sicheres Auftreten im direkten Kontakt mit werdenden Eltern - Erfahrung in den Bereichen Healthcare, Family, Wellness, Events oder Premium Services ist von Vorteil - Wohnsitz in der jeweiligen Zielregion - Führerschein Klasse B sowie Reisebereitschaft ## Wichtig für die Rolle - Diese Rolle ist keine klassische medizinisch-fachliche Außendienstrolle. - Sie übernehmen keine fachliche HCP-Beratung zu arzneimittelbezogenen Themen noch die Beratung der werdenden Eltern. - Die Rolle fokussiert sich auf Organisation, Netzwerk, HCP-Beratung, und Elternevents. ## Warum die Rolle besonders ist Sie gestalten ein neues, modernes Modell des Außendienstes im Pharmabereich mit: nicht als klassische Pharmareferent im Außendienst, sondern als vertrauensvoller Netzwerker, Community Builder und Veranstaltungsmanager, der das Thema im Markt strukturiert sichtbarer macht und den Dialog mit HCPs und Eltern aktiv aufbaut. ## Unser Angebot - Mitarbeit in einem wachsenden internationalen Unternehmen der Biotechnologiebranche - Ein hohes Maß an Eigenverantwortung und Freiraum, um eigene Ideen einzubringen - Spannende, herausfordernde und abwechslungsreiche Aufgaben - Ein begeistertes, kompetentes, kooperatives und unterstützendes Team - 30 Urlaubstage + 1 Sonderurlaub für Geburtstag - Firmenwagen mit privater Nutzung - Zuschuss zu betrieblicher Altersvorsorge, Gruppenunfallversicherung und abgabefreier Sachbezug - Zuschuss für JobRad Leasing oder Jobticket - Regelmäßige Team- und Firmenevents --- --- title: "DIRECT SALES & EVENT CONSULTANT UND HEBAMMEN COMMUNITY MANAGER (M/W/D)" url: "https://www.famicord.com/career/employment-in-germany/job-postings/direct-sales-event-consultant-und-hebammen-community-manager-m-w-d-2" lang: "en" type: "job_offers" description: "EINSATZGEBIETE:METROPOLREGION MÜNCHEN MIT HOHER REISEBEREITSCHAFT FÜR NATIONALE EINSÄTZEMETROPOLREGION LEIPZIG MIT HOHER REISEBEREITSCHAFT FÜR NATIONALE EINSÄTZE Die FamiCord Gruppe ist der Pionier und Marktführer im Zellbanking in Europa. Wir nutzen das therapeutische Potenzial von Stammzellen und Immunzellen um die Gesundheit von" last_modified: "2026-06-25T06:11:25+00:00" custom_fields: job_offer.additional_text_under_title: "Wir suchen ab sofort für die Regionen Leipzig und München" job_offer.specification.0.key: "Standort" job_offer.specification.0.value: "Region Leipzig oder München" job_offer.specification.1.key: "Unternehmen" job_offer.specification.1.value: "FamiCord AG" job_offer.specification.2.key: "Abteilung" job_offer.specification.2.value: "Direct Sales" job_offer.sidebar_description.title: "Interesse geweckt?" job_offer.sidebar_description.text: "Wenn wir Ihr Interesse geweckt haben, dann sollten wir uns kennenlernen! Wir freuen uns über Ihre aussagekräftige Bewerbung unter Angabe Ihrer Gehaltsvorstellung und des möglichen Eintrittstermins bevorzugt über unser Online-Portal ." job_offer.offer_contact.guardians_name: "Gisela Noack" job_offer.offer_contact.description: "FamiCord AG\nPerlickstraße 5\n04103 Leipzig" --- # DIRECT SALES & EVENT CONSULTANT UND HEBAMMEN COMMUNITY MANAGER (M/W/D) EINSATZGEBIETE: METROPOLREGION MÜNCHEN MIT HOHER REISEBEREITSCHAFT FÜR NATIONALE EINSÄTZE METROPOLREGION LEIPZIG MIT HOHER REISEBEREITSCHAFT FÜR NATIONALE EINSÄTZE ## Über uns Die FamiCord Gruppe ist der Pionier und Marktführer im Zellbanking in Europa. Wir nutzen das therapeutische Potenzial von Stammzellen und Immunzellen um die Gesundheit von Menschen zu erhalten und wiederherzustellen. Mit rund 750 Mitarbeitern sind wir in mehr als 30 Ländern tätig und erwirtschaften einen Jahresumsatz von über EUR 80 Mio. ## Ihre Zukunft bei FamiCord In über 25 Jahren Unternehmensgeschichte haben wir über eine Million Zellpräparate eingelagert und die Therapie von über 7.000 Menschen unterstützt. Die FamiCord Group befindet sich auf einer spannenden Reise, auf der wir mehrere kleinere europäische Unternehmen mit jahrzehntelanger Tradition und etablierten lokalen Marktpositionen in eine starke internationale Gruppe integrieren. Wir wollen unser Wachstum in den nächsten Jahren fortführen, indem wir unser Kerngeschäft der Stammzelleneinlagerung aus Nabelschnurblut, Nabelschnurgewebe und Plazenta ausbauen und in neue Bereiche wie Zelltherapien expandieren. Wir suchen für unser Außendienstteam **Direct Sales & Event Consultants (m/w/d)** jeweils einen Mitarbeiter für die Metropolregion München und die Metropolregion Leipzig. ## Ihre Mission Sie verbinden Direktvertrieb, Eventaufbau und Community-Management mit einem gezielten Ausbau unseres Netzwerks im Hebammenumfeld. Als Hebamme kennen Sie die Bedürfnisse, Arbeitsrealität und Sprache der Zielgruppe und bauen Brücken zwischen unserem Unternehmen, Hebammen, Hebammenverbänden, Hebammenschulen und werdenden Eltern. Ihr Schwerpunkt liegt auf Community-Aufbau, Netzwerkpflege, Veranstaltungsorganisation, Verbandsarbeit, Schulkooperationen, Marktforschung und Elternveranstaltungen. - Sie bauen eine aktive Hebammen-Community auf und pflegen diese langfristig und strukturiert - Sie entwickeln und betreuen Beziehungen zu Hebammenverbänden, regionalen Hebammennetzwerken, Hebammenhäusern, freiberuflichen Hebammen und weiteren Multiplikatorinnen im Hebammenumfeld - Sie identifizieren, entwickeln und begleiten Kontakte zu Hebammenschulen, Ausbildungsstätten und Fortbildungsumfeldern, um Sichtbarkeit, Austausch und Awareness für das Thema systematisch auszubauen - Sie organisieren Hebammenveranstaltungen, Netzwerkabende, Round Tables, regionale Austauschformate und digitale Formate für Hebammen - Sie koordinieren, dass bei fachlich ausgerichteten Hebammenveranstaltungen die zentrale Pharmareferentin den medizinisch-fachlichen Teil übernimmt - Sie planen, bewerben und betreuen Elternveranstaltungen und bauen regionale Veranstaltungsformate mit werdenden Eltern aus - Sie sprechen mit werdenden Eltern vor Ort, beantworten allgemeine Fragen im zulässigen Rahmen und Überführen Kontakte strukturiert in Follow-up-Gespräche, Beratungstermine, Telefonate und E-Mail-Kommunikation - Sie organisieren unabhängige Infopunkte außerhalb von Hebammenkursen oder in Praxis-/Veranstaltungsflächen, ohne dass im Kurs selbst eine vertriebliche Nennung erfolgt. - Sie setzen Kooperationsmarketing-Maßnahmen mit geeigneten Partnern rund um Schwangerschaft, Geburt und frühe Elternschaft um - Sie koordinieren Marktforschungsprojekte mit Hebammen, einschließlich Ausgabe neutraler Marktforschungsbögen, Rücklaufmanagement und Dokumentation - Sie sammeln typische Fragen, Stimmungen und Marktfeedback aus der Hebammen-Community und spiegeln diese strukturiert an Marketing, Medical und Sales zurück - Sie arbeiten eng mit internen Schnittstellen zusammen, um aus Kontakten, Netzwerken und Veranstaltungen nachhaltige regionale Strukturen aufzubauen ## Das bringen Sie mit - Sie sind ausgebildete Hebamme - Sie verfügen idealerweise über Berufserfahrung als Hebamme und kennen die Arbeitsrealität im außerklinischen und/oder klinischen Umfeld - Sie bringen starke Kommunikationsfähigkeit, sicheres Auftreten und ein gutes Gespür für Beziehungsmanagement mit - Sie haben Freude daran, Netzwerke aufzubauen, Communities zu entwickeln und Veranstaltungen mit Wirkung umzusetzen - Sie arbeiten strukturiert, eigenverantwortlich und verbindlich - Sie denken unternehmerisch und erkennen Chancen für Kooperationen, Veranstaltungen und Reichweitenaufbau - Erfahrung in Eventmanagement, Community-Management, Netzwerkmanagement oder Vertrieb ist ein Plus - Hohe Reisebereitschaft und Führerschein Klasse B ## Wichtig für die Rolle - Diese Rolle ist keine klassische medizinisch-fachliche Außendienstrolle. - Sie übernehmen keine fachliche HCP-Beratung zu arzneimittelbezogenen Themen. - Fachliche Informationen an Hebammen oder andere medizinische Fachkreise erfolgen ausschließlich durch die zentrale sachkundige Pharmareferentin. - Die Rolle fokussiert sich auf Organisation, Netzwerk, Verbandsarbeit, Schulkontakte, Community-Aufbau, Marktforschung und Elternevents. ## Warum die Rolle besonders ist Sie gestalten ein neues, modernes Modell der Zusammenarbeit im Hebammenumfeld mit: nicht als klassischer Außendienst, sondern als vertrauensvolle Netzwerkerin, Community Builderin und Veranstaltungsmanagerin, die das Thema im Markt strukturiert sichtbarer macht und den Dialog mit Hebammen, Verbänden, Schulen und Eltern aktiv aufbaut. ## Unser Angebot - Mitarbeit in einem wachsenden internationalen Unternehmen der Biotechnologiebranche - Ein hohes Maß an Eigenverantwortung und Freiraum, um eigene Ideen einzubringen - Spannende, herausfordernde und abwechslungsreiche Aufgaben - Ein begeistertes, kompetentes, kooperatives und unterstützendes Team - 30 Urlaubstage + 1 Sonderurlaub für Geburtstag - Firmenwagen mit privater Nutzung - Zuschuss zu betrieblicher Altersvorsorge, Gruppenunfallversicherung und abgabefreier Sachbezug - Zuschuss für JobRad Leasing oder Jobticket - Regelmäßige Team- und Firmenevents ---